{"matching_results": 26646, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1470, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1169}, {"key": "negative", "matching_results": 293}, {"key": "neutral", "matching_results": 8}]}]}, {"key": "tickerreport.com", "matching_results": 933, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 775}, {"key": "negative", "matching_results": 157}]}]}, {"key": "watchlistnews.com", "matching_results": 906, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 639}, {"key": "negative", "matching_results": 266}]}]}, {"key": "wkrb13.com", "matching_results": 900, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 739}, {"key": "negative", "matching_results": 161}]}]}, {"key": "dailypolitical.com", "matching_results": 873, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 708}, {"key": "negative", "matching_results": 163}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 871, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 627}, {"key": "negative", "matching_results": 243}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "freelancer.com.co", "matching_results": 829, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 772}, {"key": "negative", "matching_results": 57}]}]}, {"key": "thelincolnianonline.com", "matching_results": 505, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 376}, {"key": "negative", "matching_results": 129}]}]}, {"key": "theolympiareport.com", "matching_results": 367, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 250}, {"key": "negative", "matching_results": 117}]}]}, {"key": "ecommerce.matrix-e.com", "matching_results": 279, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 209}, {"key": "negative", "matching_results": 70}]}]}]}], "results": [{"id": "eMx1tM8_E24YvdYtGGZU1rzYIYyo4bWxph8ZH6SmcPBIT49Qr3fS1LHm6lpNm4Iv", "result_metadata": {"score": 35.263474}, "author": "Zacks.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.529181, "label": "positive"}, "text": "Seattle", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}], "sentiment": {"document": {"score": 0.727959, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Seattle Genetics' Adcetris", "keywords": [{"text": "Seattle Genetics"}, {"text": "Adcetris"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "object": {"text": "Breakthrough Therapy Status", "keywords": [{"text": "Therapy Status"}]}, "action": {"verb": {"text": "Gets", "tense": "present"}, "text": "Gets", "normalized": "Gets"}}], "concepts": [{"text": "Rock music", "relevance": 0.859886, "dbpedia_resource": "http://dbpedia.org/resource/Rock_music"}], "categories": [{"score": 0.999999, "label": "/health and fitness/therapy"}, {"score": 0.999998, "label": "/science/medicine/genetics"}], "relations": [{"type": "partOf", "sentence": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "score": 0.478864, "arguments": [{"text": "Adcetris", "location": [18, 26], "entities": [{"type": "Organization", "text": "Adcetris", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Seattle Genetics", "location": [0, 16], "entities": [{"type": "Organization", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "sentiment": {"score": 0.727959, "label": "positive"}, "relevance": 0.5, "count": 1}]}, "crawl_date": "2018-11-16T20:54:01Z", "url": "https://www.nasdaq.com/article/seattle-genetics-adcetris-gets-breakthrough-therapy-status-cm1057100", "host": "nasdaq.com", "text": "Seattle Genetics has an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris.", "main_image_url": "https://www.nasdaq.com/images/dreamit.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T07:59:00-06:00", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": 0.348412, "label": "positive"}, "text": "Seattle Genetics", "relevance": 0.87299, "type": "PrintMedia"}, {"count": 3, "sentiment": {"score": -0.42452, "label": "negative"}, "text": "large cell lymphoma", "relevance": 0.397987, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"count": 3, "sentiment": {"score": -0.275959, "label": "negative"}, "text": "classical Hodgkin lymphoma", "relevance": 0.343369, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "peripheral T-cell lymphoma", "relevance": 0.337887, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Peripheral T-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_T-cell_lymphoma"}}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc", "relevance": 0.316121, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.496147, "label": "positive"}, "text": "Eli Lilly", "relevance": 0.315651, "type": "Person", "disambiguation": {"subtype": [], "name": "Eli Lilly (industrialist)", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_(industrialist)"}}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adcetris", "relevance": 0.307035, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "lymphoma", "relevance": 0.288989, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.276124, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.272579, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.698028, "label": "negative"}, "text": "Breakthrough Therapy", "relevance": 0.262422, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.251432, "label": "negative"}, "text": "United States", "relevance": 0.252448, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seattle", "relevance": 0.247788, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "PTCL", "relevance": 0.247446, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.235119, "type": "Organization"}, {"count": 2, "sentiment": {"score": -0.293198, "label": "negative"}, "text": "Merck", "relevance": 0.216511, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "cHL", "relevance": 0.209644, "type": "Organization", "disambiguation": {"subtype": ["SportsAssociation"], "name": "Central Hockey League (1963\u20131984)", "dbpedia_resource": "http://dbpedia.org/resource/Central_Hockey_League_(1963\u20131984)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SGEN", "relevance": 0.193918, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.192714, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Society of Hematology", "relevance": 0.185911, "type": "Organization", "disambiguation": {"subtype": [], "name": "American Society of Hematology", "dbpedia_resource": "http://dbpedia.org/resource/American_Society_of_Hematology"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.177751, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "cyclophosphamide", "relevance": 0.176278, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.251432, "label": "negative"}, "text": "Europe", "relevance": 0.173378, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.496147, "label": "positive"}, "text": "Company LLY", "relevance": 0.173158, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "prednisone", "relevance": 0.166505, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRK", "relevance": 0.165227, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SGEN", "relevance": 0.164143, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "doxorubicin", "relevance": 0.15519, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.152861, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRK Keytruda", "relevance": 0.148105, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.146878, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BMY Opdivo", "relevance": 0.140191, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.132729, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "four quarters", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "30 Days", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "60 days", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10.03%", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "104.9%", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "109.3%", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "115.0%", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.42", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.54", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.65", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.80", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20.6%", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "21.9%", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "32.9%", "relevance": 0.132729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "67.1%", "relevance": 0.132729, "type": "Quantity"}], "sentiment": {"document": {"score": 0.461717, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "SGEN", "keywords": [{"text": "SGEN"}], "entities": [{"type": "Company", "text": "SGEN"}]}, "sentence": " SGEN announced that the FDA has granted Breakthrough Therapy designation to Adcetrisfor the frontline treatment of certain lymphoma subtypes.", "object": {"text": "that the FDA has granted Breakthrough Therapy designation to Adcetrisfor the frontline treatment of certain lymphoma subtypes", "keywords": [{"text": "certain lymphoma subtypes"}, {"text": "Breakthrough Therapy designation"}, {"text": "frontline treatment"}, {"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA"}, {"type": "JobTitle", "text": "Breakthrough Therapy"}, {"type": "HealthCondition", "text": "lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The designation", "keywords": [{"text": "designation"}]}, "sentence": " The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "object": {"text": "granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide", "keywords": [{"text": "peripheral T-cell lymphomas"}, {"text": "angioimmunoblastic T-cell lymphoma"}, {"text": "large cell lymphoma"}, {"text": "cyclophosphamide"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"type": "Organization", "text": "PTCL", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"type": "Drug", "text": "cyclophosphamide"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "object": {"text": "with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL", "keywords": [{"text": "peripheral T-cell lymphomas"}, {"text": "angioimmunoblastic T-cell lymphoma"}, {"text": "large cell lymphoma"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"type": "Organization", "text": "PTCL", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "is granted to treat", "normalized": "be grant to treat"}}, {"subject": {"text": "angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone)", "keywords": [{"text": "angioimmunoblastic T-cell lymphoma"}, {"text": "cyclophosphamide"}, {"text": "prednisone"}, {"text": "CHP"}], "entities": [{"type": "Drug", "text": "cyclophosphamide"}, {"type": "Drug", "text": "doxorubicin"}, {"type": "Drug", "text": "prednisone"}]}, "sentence": " The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "object": {"text": "PTCL)", "keywords": [{"text": "PTCL"}], "entities": [{"type": "Organization", "text": "PTCL", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The Breakthrough Therapy designation", "keywords": [{"text": "Breakthrough Therapy designation"}], "entities": [{"type": "JobTitle", "text": "Breakthrough Therapy"}]}, "sentence": " The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life-threatening conditions.", "object": {"text": "granted to speed up the development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Breakthrough Therapy designation", "keywords": [{"text": "Breakthrough Therapy designation"}], "entities": [{"type": "JobTitle", "text": "Breakthrough Therapy"}]}, "sentence": " The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life-threatening conditions.", "object": {"text": "the development and review of drugs that target serious or life-threatening conditions", "keywords": [{"text": "drugs"}, {"text": "development"}, {"text": "review"}, {"text": "conditions"}]}, "action": {"verb": {"text": "speed", "tense": "future"}, "text": "is granted to speed", "normalized": "be grant to speed"}}, {"subject": {"text": "The FDA's decision", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " The FDA's decision was based on results from the phase III ECHELON-2 study, and the updated results will be presented at the American Society of Hematology Annual Meeting in December this year.", "object": {"text": "on results from the phase III ECHELON-2 study", "keywords": [{"text": "phase III ECHELON-2"}, {"text": "study"}, {"text": "results"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "was based", "normalized": "be base"}}, {"subject": {"text": "the updated results", "keywords": [{"text": "results"}]}, "sentence": " The FDA's decision was based on results from the phase III ECHELON-2 study, and the updated results will be presented at the American Society of Hematology Annual Meeting in December this year.", "object": {"text": "presented"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the updated results", "keywords": [{"text": "results"}]}, "sentence": " The FDA's decision was based on results from the phase III ECHELON-2 study, and the updated results will be presented at the American Society of Hematology Annual Meeting in December this year.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "Seattle Genetics along with Takeda", "keywords": [{"text": "Takeda"}, {"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Person", "text": "Takeda"}]}, "sentence": " Seattle Genetics along with Takeda announced that the phase III ECHELON-2 study on Adcetris has met its primary endpoint as well as all key secondary endpoints.", "object": {"text": "that the phase III ECHELON-2 study on Adcetris has met its primary endpoint as well as all key secondary endpoints", "keywords": [{"text": "key secondary endpoints"}, {"text": "primary endpoint"}, {"text": "phase III ECHELON-2"}, {"text": "study"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Adcetris combined with chemotherapy", "keywords": [{"text": "chemotherapy"}, {"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": " Adcetris combined with chemotherapy demonstrated a statistically significant improvement in progression-free survival as compared to the control arm.", "object": {"text": "a statistically significant improvement in progression-free survival", "keywords": [{"text": "statistically significant improvement"}, {"text": "progression-free survival"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "The study", "keywords": [{"text": "study"}]}, "sentence": " The study also achieved all key secondary endpoints and improved the overall survival in front-line CD30-expressing peripheral T-cell lymphoma (PTCL).", "object": {"text": "the overall survival", "keywords": [{"text": "overall survival"}]}, "action": {"verb": {"text": "improve", "tense": "past"}, "text": "improved", "normalized": "improve"}}, {"subject": {"text": "The drug", "keywords": [{"text": "drug"}]}, "sentence": " The drug is not currently approved for use in case of frontline PTCL.", "action": {"verb": {"text": "approve", "tense": "past", "negated": true}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Seattle Genetics' shares", "keywords": [{"text": "Seattle Genetics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics' shares have returned 1.7% so far this year against the industry 's decline of 20.6%.", "object": {"text": "1.7%", "entities": [{"type": "Quantity", "text": "1.7"}]}, "action": {"verb": {"text": "return", "tense": "past"}, "text": "have returned", "normalized": "have return"}}, {"subject": {"text": "Adcetris", "keywords": [{"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": " Adcetris is the only marketed product of Seattle Genetics.", "object": {"text": "the only marketed product of Seattle Genetics", "keywords": [{"text": "marketed product"}, {"text": "Seattle Genetics"}], "entities": [{"type": "Person", "text": "Adcetris"}, {"type": "PrintMedia", "text": "Seattle Genetics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The drug", "keywords": [{"text": "drug"}]}, "sentence": " The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "object": {"text": "approved for relapsed Hodgkin lymphoma", "keywords": [{"text": "Hodgkin lymphoma"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The drug", "keywords": [{"text": "drug"}]}, "sentence": " The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "object": {"text": "Hodgkin lymphoma", "keywords": [{"text": "Hodgkin lymphoma"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "relapse", "tense": "past"}, "text": "relapsed", "normalized": "relapse"}}, {"subject": {"text": "systemic anaplastic large cell lymphoma", "keywords": [{"text": "anaplastic large cell"}, {"text": "lymphoma"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}]}, "sentence": " The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "action": {"verb": {"text": "relapse", "tense": "past"}, "text": "relapsed", "normalized": "relapse"}}, {"subject": {"text": "It"}, "sentence": " It is also approved in the United States and Europe for the treatment of patients suffering from classical Hodgkin lymphoma (cHL) with no prior treatment and who are at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.", "object": {"text": "for the treatment of patients suffering from classical Hodgkin lymphoma (cHL) with no prior treatment and who are at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "post-autologous hematopoietic stem"}, {"text": ") consolidation"}, {"text": "prior treatment"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"type": "Organization", "text": "cHL", "disambiguation": {"subtype": ["SportsAssociation"], "name": "Central Hockey League (1963\u20131984)", "dbpedia_resource": "http://dbpedia.org/resource/Central_Hockey_League_(1963\u20131984)"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is also approved", "normalized": "be also approve"}}, {"subject": {"text": "It"}, "sentence": " It is also approved in combination with chemotherapy for the treatment of stage III or IV classical Hodgkin lymphoma (cHL) in patients with no previous treatment history.", "object": {"text": "with chemotherapy for the treatment of stage III or IV classical Hodgkin lymphoma (cHL) in patients with no previous treatment history", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "previous treatment history"}, {"text": "chemotherapy"}, {"text": "cHL"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"type": "Organization", "text": "cHL", "disambiguation": {"subtype": ["SportsAssociation"], "name": "Central Hockey League (1963\u20131984)", "dbpedia_resource": "http://dbpedia.org/resource/Central_Hockey_League_(1963\u20131984)"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is also approved", "normalized": "be also approve"}}, {"subject": {"text": "It"}, "sentence": " It is also approved for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States.", "object": {"text": "for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States", "keywords": [{"text": "CD30-expressing mycosis fungoides"}, {"text": "anaplastic large cell"}, {"text": "United States"}, {"text": "MF"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is also approved", "normalized": "be also approve"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics has an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris.", "object": {"text": "an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "commercialization"}, {"text": "agreement"}, {"text": "Ltd."}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Location", "text": "Adcetris", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "object": {"text": "all rights to sell Adcetris in the United States and Canada", "keywords": [{"text": "United States"}, {"text": "rights"}, {"text": "Adcetris"}, {"text": "Canada"}], "entities": [{"type": "Company", "text": "Adcetris"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "action": {"verb": {"text": "retain", "tense": "present"}, "text": "retains", "normalized": "retain"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "object": {"text": "Adcetris", "keywords": [{"text": "Adcetris"}], "entities": [{"type": "Company", "text": "Adcetris"}]}, "action": {"verb": {"text": "sell", "tense": "future"}, "text": "to sell", "normalized": "to sell"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "object": {"text": "commercial rights to the drug in the rest of the world", "keywords": [{"text": "commercial rights"}, {"text": "rest"}, {"text": "drug"}, {"text": "world"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the drug", "keywords": [{"text": "drug"}]}, "sentence": " However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "object": {"text": "several competitors", "keywords": [{"text": "competitors"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "refractory cHL"}, {"text": "BMY Opdivo"}, {"text": "MRK Keytruda"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "BMY Opdivo"}, {"type": "Company", "text": "Merck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "MRK Keytruda"}]}, "sentence": " However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "object": {"text": "several competitors", "keywords": [{"text": "competitors"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "Merck"}, {"text": "BMY Opdivo"}, {"text": "MRK Keytruda"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "BMY Opdivo"}, {"type": "Company", "text": "Merck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "MRK Keytruda"}]}, "sentence": " However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "object": {"text": "approved for relapsed or refractory cHL", "keywords": [{"text": "refractory cHL"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics currently carries a Zacks Rank #3 (Hold).", "object": {"text": "a Zacks Rank #3 (Hold)", "keywords": [{"text": "Rank  (Hold)"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carries", "normalized": "carry"}}, {"subject": {"text": "A better-ranked stock worth considering", "keywords": [{"text": "better-ranked stock"}]}, "sentence": " A better-ranked stock worth considering is Eli Lilly and Company LLY , carrying a Zacks Rank #2 (Buy).", "object": {"text": "Eli Lilly and Company LLY", "keywords": [{"text": "Eli Lilly"}, {"text": "Company"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["Person"], "name": "Eli Lilly (industrialist)", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_(industrialist)"}}, {"type": "Company", "text": "Company LLY"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Eli Lilly and Company LLY", "keywords": [{"text": "Eli Lilly"}, {"text": "Company"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["Person"], "name": "Eli Lilly (industrialist)", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_(industrialist)"}}, {"type": "Company", "text": "Company LLY"}]}, "sentence": " A better-ranked stock worth considering is Eli Lilly and Company LLY , carrying a Zacks Rank #2 (Buy).", "object": {"text": "a Zacks Rank #2 (Buy)", "keywords": [{"text": "Zacks Rank"}, {"text": "Buy"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carrying", "normalized": "carry"}}, {"subject": {"text": "You"}, "sentence": " You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .", "object": {"text": "the complete list of today's Zacks #1 Rank (Strong Buy) stocks here", "keywords": [{"text": "Zacks  Rank"}, {"text": "Strong Buy"}, {"text": "complete list"}, {"text": "stocks"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "can see", "normalized": "can see"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 10.03%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": " Shares of the company have increased 32.9% year to date.", "object": {"text": "increased 32.9% year", "entities": [{"type": "Quantity", "text": "32.9"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": " Shares of the company have increased 32.9% year to date.", "object": {"text": "32.9% year", "entities": [{"type": "Quantity", "text": "32.9"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "have increased", "normalized": "have increase"}}, {"subject": {"text": "It"}, "sentence": " It's hard to believe, even for us at Zacks.", "object": {"text": "to believe"}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.", "object": {"text": "+21.9%", "entities": [{"type": "Quantity", "text": "21.9"}]}, "action": {"verb": {"text": "gain", "tense": "past"}, "text": "gained", "normalized": "gain"}}, {"subject": {"text": "our top stock-picking screens", "keywords": [{"text": "stock-picking screens"}]}, "sentence": " But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.", "object": {"text": "+115.0%", "entities": [{"type": "Quantity", "text": "115.0"}]}, "action": {"verb": {"text": "return", "tense": "past"}, "text": "have returned", "normalized": "have return"}}, {"subject": {"text": "this outperformance", "keywords": [{"text": "outperformance"}]}, "sentence": " And this outperformance has not just been a recent phenomenon.", "object": {"text": "not just been a recent phenomenon", "keywords": [{"text": "recent phenomenon"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "this outperformance", "keywords": [{"text": "outperformance"}]}, "sentence": " And this outperformance has not just been a recent phenomenon.", "object": {"text": "a recent phenomenon", "keywords": [{"text": "recent phenomenon"}]}, "action": {"verb": {"text": "be", "tense": "past", "negated": true}, "text": "been", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Over the years it has been remarkably consistent.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "the composite yearly average gain for these strategies", "keywords": [{"text": "yearly average gain"}, {"text": "strategies"}]}, "sentence": " From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over.", "object": {"text": "beaten the market more than 19X over", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the composite yearly average gain for these strategies", "keywords": [{"text": "yearly average gain"}, {"text": "strategies"}]}, "sentence": " From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "beat", "tense": "past"}, "text": "has beaten", "normalized": "have beat"}}, {"subject": {"text": "even more remarkable"}, "sentence": " Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.", "object": {"text": "the fact that we're willing to share their latest stocks", "keywords": [{"text": "latest stocks"}, {"text": "fact"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.", "object": {"text": "their latest stocks", "keywords": [{"text": "latest stocks"}]}, "action": {"verb": {"text": "share", "tense": "future"}, "text": "to share", "normalized": "to share"}}, {"subject": {"text": "you"}, "sentence": " Today, you can download 7 Best Stocks for the Next 30 Days.", "object": {"text": "7 Best Stocks", "keywords": [{"text": "Best Stocks"}]}, "action": {"verb": {"text": "download", "tense": "future"}, "text": "can download", "normalized": "can download"}}, {"subject": {"text": "this"}, "sentence": " Click to get this free report", "object": {"text": "free report", "keywords": [{"text": "free report"}]}, "action": {"verb": {"text": "get", "tense": "future"}, "text": "to get", "normalized": "to get"}}, {"subject": {"text": "this article", "keywords": [{"text": "article"}]}, "sentence": " To read this article on Zacks.com click here.", "action": {"verb": {"text": "read", "tense": "future"}, "text": "To read", "normalized": "To read"}}, {"subject": {"text": "The views and opinions expressed herein", "keywords": [{"text": "views"}, {"text": "opinions"}]}, "sentence": " The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.", "object": {"text": "the views", "keywords": [{"text": "views"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "those of Nasdaq, Inc", "keywords": [{"text": "Nasdaq"}], "entities": [{"type": "Company", "text": "Inc"}]}, "sentence": " The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.", "object": {"text": "The views and opinions", "keywords": [{"text": "views"}, {"text": "opinions"}]}, "action": {"verb": {"text": "reflect", "tense": "present", "negated": true}, "text": "reflect", "normalized": "reflect"}}], "concepts": [{"text": "Lymphoma", "relevance": 0.969436, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Bristol-Myers Squibb", "relevance": 0.82214, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Anaplastic large cell lymphoma", "relevance": 0.698047, "dbpedia_resource": "http://dbpedia.org/resource/Anaplastic_large_cell_lymphoma"}, {"text": "Non-Hodgkin lymphoma", "relevance": 0.696624, "dbpedia_resource": "http://dbpedia.org/resource/Non-Hodgkin_lymphoma"}, {"text": "Hodgkin's lymphoma", "relevance": 0.649597, "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}, {"text": "Hematology", "relevance": 0.624288, "dbpedia_resource": "http://dbpedia.org/resource/Hematology"}, {"text": "Clopidogrel", "relevance": 0.522556, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Types of cancer", "relevance": 0.516611, "dbpedia_resource": "http://dbpedia.org/resource/Types_of_cancer"}, {"text": "Paclitaxel", "relevance": 0.505761, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Chemotherapy", "relevance": 0.5051, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.439575, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "T-cell lymphoma", "relevance": 0.437035, "dbpedia_resource": "http://dbpedia.org/resource/T-cell_lymphoma"}], "categories": [{"score": 0.974381, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.944609, "label": "/health and fitness/therapy"}, {"score": 0.572914, "label": "/health and fitness/disorders"}], "relations": [{"type": "agentOf", "sentence": "Shutterstock photo Seattle Genetics, Inc. SGEN announced that the FDA has granted Breakthrough Therapy designation to Adcetrisfor the frontline treatment of certain lymphoma subtypes.", "score": 0.973353, "arguments": [{"text": "Inc. SGEN", "location": [37, 46], "entities": [{"type": "Organization", "text": "Inc. SGEN", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [47, 56], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "score": 0.495082, "arguments": [{"text": "Adcetris", "location": [2478, 2486], "entities": [{"type": "Person", "text": "Adcetris"}]}, {"text": "United States", "location": [2494, 2507], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "score": 0.60372, "arguments": [{"text": "drug", "location": [2562, 2566], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "world", "location": [2586, 2591], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.675861, "arguments": [{"text": "Bristol-Myers Squibb", "location": [2646, 2666], "entities": [{"type": "Organization", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [2623, 2634], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.873588, "arguments": [{"text": "BMY Opdivo", "location": [2669, 2679], "entities": [{"type": "Organization", "text": "BMY Opdivo", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [2623, 2634], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.88474, "arguments": [{"text": "Merck", "location": [2684, 2689], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [2623, 2634], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.572428, "arguments": [{"text": "MRK Keytruda", "location": [2692, 2704], "entities": [{"type": "Organization", "text": "MRK Keytruda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [2623, 2634], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.801105, "arguments": [{"text": "BMY Opdivo", "location": [2669, 2679], "entities": [{"type": "Organization", "text": "BMY Opdivo", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Bristol-Myers Squibb", "location": [2646, 2666], "entities": [{"type": "Organization", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "However, the drug has several competitors, including Bristol-Myers Squibb's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.642354, "arguments": [{"text": "MRK Keytruda", "location": [2692, 2704], "entities": [{"type": "Organization", "text": "MRK Keytruda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merck", "location": [2684, 2689], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "A better-ranked stock worth considering is Eli Lilly and Company LLY , carrying a Zacks Rank #2 (Buy).", "score": 0.524749, "arguments": [{"text": "Zacks Rank #2", "location": [3019, 3032], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "Buy", "location": [3034, 3037], "entities": [{"type": "Organization", "text": "Strong Buy", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Lilly's earnings per share estimates have increased from $5.42 to $5.54 for 2018 and from $5.65 to $5.80 for 2019 over the past 60 days.", "score": 0.569526, "arguments": [{"text": "Lilly", "location": [3122, 3127], "entities": [{"type": "Organization", "text": "Lilly", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$5.42", "location": [3179, 3184], "entities": [{"type": "Money", "text": "$5.42"}]}]}, {"type": "agentOf", "sentence": "The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "score": 0.968879, "arguments": [{"text": "CD30", "location": [304, 308], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "expressing", "location": [309, 319], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "hasAttribute", "sentence": "Lilly's earnings per share estimates have increased from $5.42 to $5.54 for 2018 and from $5.65 to $5.80 for 2019 over the past 60 days.", "score": 0.644751, "arguments": [{"text": "Lilly", "location": [3122, 3127], "entities": [{"type": "Organization", "text": "Lilly", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$5.54", "location": [3188, 3193], "entities": [{"type": "Money", "text": "$5.54"}]}]}, {"type": "partOfMany", "sentence": "Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks.", "score": 0.647365, "arguments": [{"text": "Zacks", "location": [3511, 3516], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "us", "location": [3505, 3507], "entities": [{"type": "Person", "text": "us"}]}]}, {"type": "employedBy", "sentence": "See Them Free>> Want the latest recommendations from Zacks Investment Research?", "score": 0.50589, "arguments": [{"text": "See Them Free>>", "location": [4005, 4020], "entities": [{"type": "Person", "text": "See Them Free>>"}]}, {"text": "Zacks Investment Research", "location": [4058, 4083], "entities": [{"type": "Organization", "text": "Zacks Investment Research", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "awardedTo", "sentence": "Today, you can download 7 Best Stocks for the Next 30 Days.", "score": 0.909052, "arguments": [{"text": "Best Stocks", "location": [4111, 4122], "entities": [{"type": "EntertainmentAward", "text": "Best Stocks"}]}, {"text": "you", "location": [4092, 4095], "entities": [{"type": "Person", "text": "you"}]}]}, {"type": "agentOf", "sentence": "Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here.", "score": 0.568488, "arguments": [{"text": "SGEN", "location": [4370, 4374], "entities": [{"type": "Organization", "text": "Seattle Genetics, Inc. Price\nSeattle Genetics, Inc. Price", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [4397, 4403], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here.", "score": 0.766168, "arguments": [{"text": "Zacks.com", "location": [4428, 4437], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "Report", "location": [4397, 4403], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Seattle Genetics along with Takeda announced that the phase III ECHELON-2 study on Adcetris has met its primary endpoint as well as all key secondary endpoints.", "score": 0.937162, "arguments": [{"text": "Takeda", "location": [878, 884], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "announced", "location": [885, 894], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "The study also achieved all key secondary endpoints and improved the overall survival in front-line CD30-expressing peripheral T-cell lymphoma (PTCL).", "score": 0.520951, "arguments": [{"text": "CD30", "location": [1261, 1265], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "expressing", "location": [1266, 1276], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "employedBy", "sentence": "Adcetris is the only marketed product of Seattle Genetics.", "score": 0.601607, "arguments": [{"text": "Adcetris", "location": [1485, 1493], "entities": [{"type": "Person", "text": "Adcetris"}]}, {"text": "Seattle Genetics", "location": [1526, 1542], "entities": [{"type": "Organization", "text": "Seattle Genetics, Inc. Price\nSeattle Genetics, Inc. Price", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "score": 0.438182, "arguments": [{"text": "lymphoma", "location": [1639, 1647], "entities": [{"type": "Person", "text": "lymphoma subtypes"}]}, {"text": "United States", "location": [1663, 1676], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "It is also approved for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States.", "score": 0.658092, "arguments": [{"text": "CD30", "location": [2240, 2244], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "lymphoma", "location": [2218, 2226], "entities": [{"type": "Person", "text": "lymphoma subtypes"}]}]}, {"type": "agentOf", "sentence": "It is also approved for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States.", "score": 0.875053, "arguments": [{"text": "CD30", "location": [2240, 2244], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "expressing", "location": [2245, 2255], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "employedBy", "sentence": "Seattle Genetics has an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris.", "score": 0.77111, "arguments": [{"text": "Takeda Pharmaceutical", "location": [2340, 2361], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "Company Ltd.", "location": [2362, 2374], "entities": [{"type": "Organization", "text": "Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Seattle Genetics", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.862117, "count": 6}, {"text": "Seattle Genetics' shares", "sentiment": {"score": -0.890144, "label": "negative"}, "relevance": 0.701057, "count": 1}, {"text": "Inc. SGEN", "sentiment": {"score": 0.866417, "label": "positive"}, "relevance": 0.647297, "count": 1}, {"text": "product of Seattle Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636223, "count": 1}, {"text": "Breakthrough Therapy designation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613711, "count": 2}, {"text": "phase III ECHELON-2 study", "sentiment": {"score": 0.630847, "label": "positive"}, "relevance": 0.608007, "count": 2}, {"text": "frontline treatment of certain lymphoma subtypes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.588658, "count": 1}, {"text": "Inc. Price", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.58549, "count": 1}, {"text": "systemic anaplastic large cell lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.584551, "count": 2}, {"text": "United States", "sentiment": {"score": -0.734681, "label": "negative"}, "relevance": 0.579183, "count": 4}, {"text": "Adcetris", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.578784, "count": 4}, {"text": "review of drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571461, "count": 1}, {"text": "FDA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554409, "count": 1}, {"text": "drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552742, "count": 4}, {"text": "market", "sentiment": {"score": 0.896403, "label": "positive"}, "relevance": 0.551167, "count": 2}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549278, "count": 1}, {"text": "peripheral T-cell lymphomas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54869, "count": 1}, {"text": "progression-free survival", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.544106, "count": 1}, {"text": "Hodgkin lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541709, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54006, "count": 2}, {"text": "views", "sentiment": {"score": 0.890908, "label": "positive"}, "relevance": 0.539685, "count": 2}, {"text": "commercial rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537361, "count": 1}, {"text": "designation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535642, "count": 1}, {"text": "Merck's MRK Keytruda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535235, "count": 1}, {"text": "opinions", "sentiment": {"score": 0.890908, "label": "positive"}, "relevance": 0.534383, "count": 1}, {"text": "complete list of today", "sentiment": {"score": -0.246317, "label": "negative"}, "relevance": 0.530171, "count": 1}, {"text": "FDA's decision", "sentiment": {"score": 0.630847, "label": "positive"}, "relevance": 0.529821, "count": 1}, {"text": "Stock", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.52945, "count": 1}, {"text": "stock", "sentiment": {"score": 0.717051, "label": "positive"}, "relevance": 0.52945, "count": 1}, {"text": "development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527557, "count": 1}, {"text": "rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526563, "count": 1}, {"text": "commercialization of Adcetris", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526099, "count": 1}, {"text": "study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525643, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524963, "count": 1}, {"text": "overall survival", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524611, "count": 1}, {"text": "results", "sentiment": {"score": 0.630847, "label": "positive"}, "relevance": 0.523179, "count": 2}, {"text": "Inc. Quote", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.522289, "count": 1}, {"text": "significant improvement", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.520774, "count": 1}, {"text": "stocks", "sentiment": {"score": -0.753246, "label": "negative"}, "relevance": 0.519646, "count": 1}, {"text": "competitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519575, "count": 1}, {"text": "Canada", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518313, "count": 1}, {"text": "patients", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518137, "count": 2}, {"text": "Zacks Rank", "sentiment": {"score": 0.435402, "mixed": "1", "label": "positive"}, "relevance": 0.517762, "count": 3}, {"text": "chemotherapy", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.517561, "count": 2}, {"text": "Today", "sentiment": {"score": 0.758467, "label": "positive"}, "relevance": 0.516857, "count": 1}, {"text": "Eli Lilly", "sentiment": {"score": 0.717051, "label": "positive"}, "relevance": 0.516509, "count": 1}, {"text": "combination", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516314, "count": 2}, {"text": "high risk of relapse", "sentiment": {"score": -0.734681, "label": "negative"}, "relevance": 0.515569, "count": 1}, {"text": "angioimmunoblastic T-cell lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51533, "count": 1}, {"text": "Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514986, "count": 1}]}, "extracted_metadata": {"sha1": "030b79344988c71012839aec33adf7e742a725eb", "filename": "1542401641620.zip-e3ab49d00da2fb2a869d21f7e90a8c67.xml", "file_type": "json"}, "external_links": ["http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=MRK&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=SGEN&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "https://www.zacks.com/stocks/industry-rank/industry/medical-biomedical-and-genetics-105", "https://www.zacks.com/stock/chart/SGEN/fundamental/price", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=BMY&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link", "https://www.zacks.com/registration/rw/welcome/eoffer/38a7?site=ZCOM_RW_ANALYSTBLOG_IND_HOTSTRAT_111618&icid=EOAC-ANALYSTBLOG-tx-RW111618", "http://www.zacks.com/", "https://www.zacks.com/stock/quote/SGEN", "http://www.zacks.com/stock/news/337948/seattle-genetics-adcetris-gets-breakthrough-therapy-status?cid=CS-NASDAQ-FT-337948", "http://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=LLY&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948"], "title": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "forum_title": "Bristol-Myers Squibb Company (BMY) News Headlines - NASDAQ.com"}, {"id": "xjKeR4UGbh4pD7mnMP1KfQVNJwVlBNWmxgLkxDmVQx0twcSRt4tD74sGrfY8xKRo", "result_metadata": {"score": 35.2287}, "author": "Tammy Falkenburg", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.297971, "label": "positive"}, "text": "Seattle", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.780836, "label": "/science/biology"}, {"score": 0.761799, "label": "/science/biology/molecular biology"}, {"score": 0.635456, "label": "/science/biology/cytology"}], "relations": [{"type": "employedBy", "sentence": "Head to Head Contrast: Seattle Genetics (SGEN) & Arsanis (ASNS)", "score": 0.629983, "arguments": [{"text": "Head", "location": [8, 12], "entities": [{"type": "Person", "text": "Head"}]}, {"text": "Seattle Genetics", "location": [23, 39], "entities": [{"type": "Organization", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Sports"]}}]}]}, {"type": "hasAttribute", "sentence": "Head to Head Contrast: Seattle Genetics (SGEN) & Arsanis (ASNS)", "score": 0.69061, "arguments": [{"text": "Seattle Genetics", "location": [23, 39], "entities": [{"type": "Organization", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Sports"]}}]}, {"text": "SGEN", "location": [41, 45], "entities": [{"type": "Ticker", "text": "SGEN"}]}]}], "keywords": [{"text": "Head", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999992, "count": 1}, {"text": "Head Contrast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999398, "count": 1}, {"text": "Seattle Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.067607, "count": 1}, {"text": "SGEN", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.018844, "count": 1}, {"text": "Arsanis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.017372, "count": 1}, {"text": "ASNS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.016244, "count": 1}]}, "crawl_date": "2018-11-17T10:48:23Z", "url": "https://zolmax.com/investing/head-to-head-contrast-seattle-genetics-sgen-arsanis-asns/2696737.html", "host": "zolmax.com", "text": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with", "main_image_url": "https://www.marketbeat.com/logos/arsanis-inc-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-17T10:24:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0.409942, "label": "positive"}, "text": "Seattle", "relevance": 0.777469, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "classical Hodgkin lymphoma", "relevance": 0.450863, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Arsanis, Inc.", "relevance": 0.356162, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.430104, "label": "negative"}, "text": "large cell lymphoma", "relevance": 0.351899, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"count": 2, "sentiment": {"score": -0.613982, "label": "negative"}, "text": "solid tumors", "relevance": 0.323504, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADCETRIS", "relevance": 0.320295, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.295463, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.430104, "label": "negative"}, "text": "Hodgkin", "relevance": 0.289667, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "enfortumab vedotin", "relevance": 0.288345, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.406588, "label": "positive"}, "text": "Agensys, Inc", "relevance": 0.272259, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PSMA Development Company LLC", "relevance": 0.270721, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Waltham", "relevance": 0.253979, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Waltham, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Waltham,_Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bothell", "relevance": 0.244921, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Bothell, Washington", "dbpedia_resource": "http://dbpedia.org/resource/Bothell,_Washington"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Massachusetts", "relevance": 0.244109, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Biotechnology Ltd.", "relevance": 0.242806, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genmab A/S", "relevance": 0.241635, "type": "Company", "disambiguation": {"subtype": [], "name": "Genmab", "dbpedia_resource": "http://dbpedia.org/resource/Genmab"}}, {"count": 1, "sentiment": {"score": 0.522869, "label": "positive"}, "text": "MarketBeat.com", "relevance": 0.227246, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Unum Therapeutics, Inc.", "relevance": 0.221326, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celldex Therapeutics, Inc.", "relevance": 0.212186, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer Pharma AG", "relevance": 0.2116, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Washington", "relevance": 0.209702, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline LLC", "relevance": 0.201252, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech, Inc.", "relevance": 0.189679, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.188194, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "70.75%", "relevance": 0.188194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33.8%", "relevance": 0.188194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "50.9%", "relevance": 0.188194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "69.1%", "relevance": 0.188194, "type": "Quantity"}], "sentiment": {"document": {"score": 0.2885, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "69.1% of Arsanis shares", "keywords": [{"text": "Arsanis shares"}], "entities": [{"type": "Quantity", "text": "69.1"}]}, "sentence": " 69.1% of Arsanis shares are held by institutional investors.", "object": {"text": "held by institutional investors", "keywords": [{"text": "institutional investors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " 69.1% of Arsanis shares are held by institutional investors.", "object": {"text": "69.1% of Arsanis shares", "keywords": [{"text": "Arsanis shares"}], "entities": [{"type": "Quantity", "text": "69.1"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "by company insiders", "keywords": [{"text": "company insiders"}]}, "sentence": " 33.8% of Seattle Genetics shares are held by company insiders.", "object": {"text": "33.8% of Seattle Genetics shares", "keywords": [{"text": "Seattle Genetics shares"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Quantity", "text": "33.8"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "by company insiders", "keywords": [{"text": "company insiders"}]}, "sentence": " Comparatively, 50.9% of Arsanis shares are held by company insiders.", "object": {"text": "50.9% of Arsanis shares", "keywords": [{"text": "Arsanis shares"}], "entities": [{"type": "Quantity", "text": "50.9"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "Strong institutional ownership", "keywords": [{"text": "Strong institutional ownership"}]}, "sentence": " Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.", "object": {"text": "an indication that endowments, large money managers", "keywords": [{"text": "large money managers"}, {"text": "endowments"}, {"text": "indication"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "large money managers and hedge funds", "keywords": [{"text": "hedge funds"}, {"text": "large money managers"}], "entities": []}, "sentence": " Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.", "object": {"text": "a stock will outperform the market over the long term", "keywords": [{"text": "long term"}, {"text": "stock"}, {"text": "market"}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believe", "normalized": "believe"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics beats Arsanis on 6 of the 11 factors compared between the two stocks.", "object": {"text": "Arsanis", "keywords": [{"text": "Arsanis"}]}, "action": {"verb": {"text": "beat", "tense": "present"}, "text": "beats", "normalized": "beat"}}, {"subject": {"text": "the 11 factors", "keywords": [{"text": "factors"}]}, "sentence": " Seattle Genetics beats Arsanis on 6 of the 11 factors compared between the two stocks.", "object": {"text": "between the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "It"}, "sentence": " It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.", "object": {"text": "ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma", "keywords": [{"text": "Hodgkin lymphoma"}, {"text": "antibody-drug conjugate"}, {"text": "ADCETRIS"}, {"text": "treatment"}], "entities": [{"type": "Company", "text": "ADCETRIS"}, {"type": "HealthCondition", "text": "Hodgkin"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "markets", "normalized": "market"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer", "keywords": [{"text": "Nectin-4-positive solid tumors"}, {"text": "bladder cancer"}, {"text": "enfortumab vedotin"}, {"text": "clinical trial"}], "entities": [{"type": "Person", "text": "enfortumab vedotin"}, {"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "enfortumab vedotin", "keywords": [{"text": "enfortumab vedotin"}], "entities": [{"type": "Person", "text": "enfortumab vedotin"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "in Phase 1 clinical trial", "keywords": [{"text": "Phase"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "tisotumab vedotin that", "keywords": [{"text": "tisotumab vedotin"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "in Phase II clinical trial for patients with cervical cancer and solid tumors", "keywords": [{"text": "cervical cancer"}, {"text": "solid tumors"}, {"text": "clinical trial"}, {"text": "Phase"}], "entities": [{"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma.", "object": {"text": "phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "stage classical Hodgkin"}, {"text": "clinical trials"}, {"text": "CD30-expressing MTCL"}], "entities": [{"type": "Company", "text": "ADCETRIS"}, {"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "conducts", "normalized": "conduct"}}, {"subject": {"text": "ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "sentence": " In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma.", "object": {"text": "3 clinical trials of ADCETRIS", "keywords": [{"text": "clinical trials"}, {"text": "ADCETRIS"}], "entities": [{"type": "Company", "text": "ADCETRIS"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF", "keywords": [{"text": "ADC programs"}, {"text": "ladiratuzumab vedotin"}, {"text": "denintuzumab mafodotin"}, {"text": "immuno-oncology agents"}]}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "the company's earlier stage clinical pipeline", "keywords": [{"text": "stage clinical pipeline"}, {"text": "company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "six other ADC programs", "keywords": [{"text": "ADC programs"}]}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A,", "keywords": [{"text": "ladiratuzumab vedotin"}, {"text": "denintuzumab mafodotin"}, {"text": "SGN-CD19B"}, {"text": "SGN-CD123A"}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consisting", "normalized": "consist"}}, {"subject": {"text": "SEA-CD40 and SGN-2FF"}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "two immuno-oncology agents", "keywords": [{"text": "immuno-oncology agents"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "It"}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG", "keywords": [{"text": "Bayer Pharma AG"}, {"text": "AbbVie Biotechnology Ltd."}, {"text": "various biotechnology"}, {"text": "ADC technology"}], "entities": [{"type": "Company", "text": "AbbVie Biotechnology Ltd."}, {"type": "Company", "text": "Bayer Pharma AG"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "AbbVie Biotechnology Ltd.; Bayer Pharma AG", "keywords": [{"text": "Bayer Pharma AG"}, {"text": "AbbVie Biotechnology Ltd."}], "entities": [{"type": "Company", "text": "AbbVie Biotechnology Ltd."}, {"type": "Company", "text": "Bayer Pharma AG"}]}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "various biotechnology and pharmaceutical companies", "keywords": [{"text": "various biotechnology"}, {"text": "pharmaceutical companies"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S", "keywords": [{"text": "PSMA Development Company"}, {"text": "Unum Therapeutics"}, {"text": "Genmab A/S"}, {"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "PSMA Development Company LLC"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Unum Therapeutics, Inc."}, {"type": "Company", "text": "Genmab A/S", "disambiguation": {"subtype": ["Company"], "name": "Genmab", "dbpedia_resource": "http://dbpedia.org/resource/Genmab"}}]}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "co-development agreement with Agensys, Inc", "keywords": [{"text": "co-development agreement"}, {"text": "Agensys"}], "entities": [{"type": "Company", "text": "Agensys, Inc"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Seattle Genetics, Inc.", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "object": {"text": "founded in 1998"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "object": {"text": "headquartered in Bothell, Washington", "keywords": [{"text": "Bothell"}, {"text": "Washington"}], "entities": [{"type": "Location", "text": "Bothell", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Bothell, Washington", "dbpedia_resource": "http://dbpedia.org/resource/Bothell,_Washington"}}, {"type": "Location", "text": "Washington", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics, Inc.", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Arsanis, Inc., a clinical-stage biopharmaceutical company,", "keywords": [{"text": "clinical-stage biopharmaceutical company"}, {"text": "Arsanis"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases.", "object": {"text": "monoclonal antibody (mAb) immunotherapies", "keywords": [{"text": ") immunotherapies"}, {"text": "monoclonal antibody"}]}, "action": {"verb": {"text": "apply", "tense": "future"}, "text": "applying", "normalized": "apply"}}, {"subject": {"text": "monoclonal antibody (mAb)", "keywords": [{"text": "monoclonal antibody"}, {"text": "mAb"}]}, "sentence": " Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases.", "object": {"text": "infectious diseases", "keywords": [{"text": "infectious diseases"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "immunotherapies to address", "normalized": "immunotherapies to address"}}, {"subject": {"text": "Its lead product candidate", "keywords": [{"text": "lead product candidate"}]}, "sentence": " Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "object": {"text": "ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia", "keywords": [{"text": "staphylococcus aureus pneumonia"}, {"text": "clinical development"}, {"text": "mAb"}, {"text": "Phase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "mAbs", "keywords": [{"text": "mAbs"}]}, "sentence": " The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.", "object": {"text": "various bacterial and viral pathogens", "keywords": [{"text": "viral pathogens"}]}, "action": {"verb": {"text": "target", "tense": "present"}, "text": "targeting", "normalized": "target"}}, {"subject": {"text": "respiratory syncytial virus", "keywords": [{"text": "respiratory syncytial virus"}], "entities": []}, "sentence": " The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.", "object": {"text": "various bacterial and viral pathogens", "keywords": [{"text": "viral pathogens"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "object": {"text": "founded in 2010"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "object": {"text": "headquartered in Waltham, Massachusetts", "keywords": [{"text": "Waltham"}, {"text": "Massachusetts"}], "entities": [{"type": "Location", "text": "Waltham", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Waltham, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Waltham,_Massachusetts"}}, {"type": "Location", "text": "Massachusetts", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "News & Ratings for Seattle Genetics Daily -", "keywords": [{"text": "Seattle Genetics Daily"}, {"text": "Ratings"}, {"text": "News"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter .", "object": {"text": "your email address", "keywords": [{"text": "email address"}]}, "action": {"verb": {"text": "Enter", "tense": "present"}, "text": "Enter", "normalized": "Enter"}}], "concepts": [{"text": "Clinical trial", "relevance": 0.952499, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Pharmaceutical industry", "relevance": 0.872982, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pharmacology", "relevance": 0.760692, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pre-clinical development", "relevance": 0.713042, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Biotechnology", "relevance": 0.680997, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Drug discovery", "relevance": 0.615419, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Drug development", "relevance": 0.611992, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Anaplastic large cell lymphoma", "relevance": 0.567672, "dbpedia_resource": "http://dbpedia.org/resource/Anaplastic_large_cell_lymphoma"}, {"text": "The Canon of Medicine", "relevance": 0.545264, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Lymphoma", "relevance": 0.533014, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Cancer", "relevance": 0.532765, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Hodgkin's lymphoma", "relevance": 0.514677, "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}, {"text": "Clinical research", "relevance": 0.482087, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Clinical trial protocol", "relevance": 0.480234, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial_protocol"}, {"text": "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use", "relevance": 0.478492, "dbpedia_resource": "http://dbpedia.org/resource/International_Conference_on_Harmonisation_of_Technical_Requirements_for_Registration_of_Pharmaceuticals_for_Human_Use"}, {"text": "Monoclonal antibodies", "relevance": 0.473389, "dbpedia_resource": "http://dbpedia.org/resource/Monoclonal_antibodies"}, {"text": "Good clinical practice", "relevance": 0.451203, "dbpedia_resource": "http://dbpedia.org/resource/Good_clinical_practice"}, {"text": "Informed consent", "relevance": 0.450896, "dbpedia_resource": "http://dbpedia.org/resource/Informed_consent"}, {"text": "Staphylococcus aureus", "relevance": 0.442991, "dbpedia_resource": "http://dbpedia.org/resource/Staphylococcus_aureus"}], "categories": [{"score": 0.875195, "label": "/health and fitness/disease/cancer"}, {"score": 0.835145, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.823753, "label": "/health and fitness/therapy"}], "relations": [{"type": "employedBy", "sentence": "33.8% of Seattle Genetics shares are held by company insiders.", "score": 0.662994, "arguments": [{"text": "insiders", "location": [156, 164], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "company", "location": [148, 155], "entities": [{"type": "Organization", "text": "Institutional Ownership"}]}]}, {"type": "employedBy", "sentence": "Comparatively, 50.9% of Arsanis shares are held by company insiders.", "score": 0.662994, "arguments": [{"text": "insiders", "location": [225, 233], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "company", "location": [217, 224], "entities": [{"type": "Organization", "text": "Institutional Ownership"}]}]}, {"type": "locatedAt", "sentence": "Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "score": 0.990399, "arguments": [{"text": "Waltham", "location": [2742, 2749], "entities": [{"type": "GeopoliticalEntity", "text": "Waltham"}]}, {"text": "Massachusetts", "location": [2751, 2764], "entities": [{"type": "GeopoliticalEntity", "text": "Massachusetts"}]}]}, {"type": "partOf", "sentence": "Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter .", "score": 0.557419, "arguments": [{"text": "companies", "location": [2958, 2967], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Seattle Genetics", "location": [2929, 2945], "entities": [{"type": "Organization", "text": "Seattle Genetics\nSeattle Genetics, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "score": 0.813646, "arguments": [{"text": "patients", "location": [1030, 1038], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cervical cancer", "location": [1044, 1059], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "partOfMany", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.586522, "arguments": [{"text": "AbbVie Biotechnology Ltd.", "location": [1818, 1843], "entities": [{"type": "Organization", "text": "AbbVie Biotechnology Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [1782, 1806], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.621299, "arguments": [{"text": "Bayer Pharma AG", "location": [1845, 1860], "entities": [{"type": "Organization", "text": "Bayer Pharma AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [1782, 1806], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.985491, "arguments": [{"text": "Bothell", "location": [2178, 2185], "entities": [{"type": "GeopoliticalEntity", "text": "Bothell"}]}, {"text": "Washington", "location": [2187, 2197], "entities": [{"type": "GeopoliticalEntity", "text": "Washington"}]}]}, {"type": "employedBy", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.401099, "arguments": [{"text": "candidate", "location": [2383, 2392], "entities": [{"type": "Person", "text": "ASN100"}]}, {"text": "Its", "location": [2366, 2369], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "hasAttribute", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.950221, "arguments": [{"text": "ASN100", "location": [2396, 2402], "entities": [{"type": "Person", "text": "ASN100"}]}, {"text": "pneumonia", "location": [2499, 2508], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "hasAttribute", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.845239, "arguments": [{"text": "patients", "location": [2536, 2544], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "pneumonia", "location": [2499, 2508], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "foundedOn", "sentence": "Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "score": 0.72754, "arguments": [{"text": "Arsanis, Inc.", "location": [2684, 2697], "entities": [{"type": "Organization", "text": "Arsanis\nArsanis, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "2010", "location": [2713, 2717], "entities": [{"type": "Date", "text": "2010", "disambiguation": {"subtype": ["Starting"]}}]}]}], "keywords": [{"text": "company insiders", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.758306, "count": 2}, {"text": "Seattle Genetics shares", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.749845, "count": 1}, {"text": "clinical trial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.640618, "count": 2}, {"text": "Inc. Seattle Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613764, "count": 1}, {"text": "concise daily summary of the latest news", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.602247, "count": 1}, {"text": "email address", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.600705, "count": 1}, {"text": "biotechnology company", "sentiment": {"score": -0.551027, "label": "negative"}, "relevance": 0.596025, "count": 1}, {"text": "Inc.", "sentiment": {"score": -0.551027, "label": "negative"}, "relevance": 0.585001, "count": 8}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.584355, "count": 1}, {"text": "advanced stage", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.57883, "count": 1}, {"text": "SGN-CD123A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578172, "count": 1}, {"text": "development agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571624, "count": 1}, {"text": "pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568227, "count": 1}, {"text": "development", "sentiment": {"score": -0.551027, "label": "negative"}, "relevance": 0.56201, "count": 1}, {"text": "Arsanis shares", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.561958, "count": 2}, {"text": "CD30", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.559149, "count": 1}, {"text": "News", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.558733, "count": 1}, {"text": "Seattle Genetics", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.55426, "count": 2}, {"text": "Hodgkin lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553342, "count": 1}, {"text": "antibody-drug conjugate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550641, "count": 1}, {"text": "Ratings", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.550493, "count": 1}, {"text": "SGN-CD19B", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549929, "count": 1}, {"text": "related companies", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.547633, "count": 1}, {"text": "PSMA Development Company LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542606, "count": 1}, {"text": "Phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542585, "count": 3}, {"text": "Celldex Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538656, "count": 1}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538259, "count": 1}, {"text": "monoclonal antibody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537887, "count": 1}, {"text": "solid tumors", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.536955, "count": 2}, {"text": "hedge funds", "sentiment": {"score": 0.957984, "label": "positive"}, "relevance": 0.536597, "count": 1}, {"text": "patients", "sentiment": {"score": -0.562563, "label": "negative"}, "relevance": 0.535852, "count": 5}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535098, "count": 1}, {"text": "GlaxoSmithKline LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534518, "count": 1}, {"text": "lead product candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533854, "count": 1}, {"text": "bladder cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531605, "count": 1}, {"text": "company's earlier stage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529328, "count": 1}, {"text": "phase", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.528429, "count": 1}, {"text": "analysts' ratings", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.52401, "count": 1}, {"text": "addition", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.523974, "count": 1}, {"text": "mAb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523855, "count": 2}, {"text": "institutional investors", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.52222, "count": 1}, {"text": "Genentech", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521253, "count": 1}, {"text": "Bayer Pharma AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520876, "count": 1}, {"text": "collaborations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520833, "count": 1}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520471, "count": 1}, {"text": "various biotechnology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519961, "count": 1}, {"text": "cervical cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519763, "count": 1}, {"text": "SGN-CD33A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51764, "count": 1}, {"text": "market", "sentiment": {"score": 0.957984, "label": "positive"}, "relevance": 0.517267, "count": 1}, {"text": "respiratory syncytial virus", "sentiment": {"score": -0.480858, "label": "negative"}, "relevance": 0.516971, "count": 1}]}, "extracted_metadata": {"sha1": "d6f9ea10bc4c40cdcbe715c3521d82001b5f321a", "filename": "1542451703401.zip-9eb4ca00336181aa5143964dedb02e28.xml", "file_type": "json"}, "title": "Head to Head Contrast: Seattle Genetics (SGEN) & Arsanis (ASNS)", "forum_title": "Zolmax"}, {"id": "cDEnZW3vaIWyUhF1zeNxat71V1ZC-WgJnSvBNmgA2Tn3ZrEq1Ma6LBTemHA9-5yv", "result_metadata": {"score": 35.2287}, "author": "Jim Brewer", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seattle", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 1, "label": "/science/medicine/genetics"}], "relations": [{"type": "hasAttribute", "sentence": "Reviewing Seattle Genetics (SGEN) & Arsanis (ASNS)", "score": 0.795787, "arguments": [{"text": "Seattle Genetics", "location": [10, 26], "entities": [{"type": "Organization", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Sports"]}}]}, {"text": "SGEN", "location": [28, 32], "entities": [{"type": "Ticker", "text": "SGEN"}]}]}], "keywords": [{"text": "Seattle Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.990201, "count": 1}, {"text": "SGEN", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.221144, "count": 1}, {"text": "Arsanis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.17424, "count": 1}, {"text": "ASNS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.141766, "count": 1}]}, "crawl_date": "2018-11-17T12:08:24Z", "url": "https://www.wkrb13.com/2018/11/17/reviewing-seattle-genetics-sgen-arsanis-asns.html", "host": "wkrb13.com", "text": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with", "main_image_url": "https://www.marketbeat.com/logos/arsanis-inc-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-17T10:24:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0.409942, "label": "positive"}, "text": "Seattle", "relevance": 0.777469, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "classical Hodgkin lymphoma", "relevance": 0.450863, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Arsanis, Inc.", "relevance": 0.356162, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.430104, "label": "negative"}, "text": "large cell lymphoma", "relevance": 0.351899, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"count": 2, "sentiment": {"score": -0.613982, "label": "negative"}, "text": "solid tumors", "relevance": 0.323504, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADCETRIS", "relevance": 0.320295, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.304237, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.430104, "label": "negative"}, "text": "Hodgkin", "relevance": 0.289667, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "enfortumab vedotin", "relevance": 0.288345, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PSMA Development Company LLC", "relevance": 0.278587, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.406588, "label": "positive"}, "text": "Agensys, Inc", "relevance": 0.272259, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Waltham", "relevance": 0.253979, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Waltham, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Waltham,_Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bothell", "relevance": 0.244921, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Bothell, Washington", "dbpedia_resource": "http://dbpedia.org/resource/Bothell,_Washington"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Massachusetts", "relevance": 0.244109, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Biotechnology Ltd.", "relevance": 0.242806, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genmab A/S", "relevance": 0.241635, "type": "Company", "disambiguation": {"subtype": [], "name": "Genmab", "dbpedia_resource": "http://dbpedia.org/resource/Genmab"}}, {"count": 1, "sentiment": {"score": 0.522869, "label": "positive"}, "text": "MarketBeat.com", "relevance": 0.227246, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Unum Therapeutics, Inc.", "relevance": 0.221326, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celldex Therapeutics, Inc.", "relevance": 0.212186, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer Pharma AG", "relevance": 0.2116, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Washington", "relevance": 0.209702, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline LLC", "relevance": 0.201252, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech, Inc.", "relevance": 0.189679, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.188194, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "70.75%", "relevance": 0.188194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33.8%", "relevance": 0.188194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "50.9%", "relevance": 0.188194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "69.1%", "relevance": 0.188194, "type": "Quantity"}], "sentiment": {"document": {"score": 0.289429, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "69.1% of Arsanis shares", "keywords": [{"text": "Arsanis shares"}], "entities": [{"type": "Quantity", "text": "69.1"}]}, "sentence": " 69.1% of Arsanis shares are held by institutional investors.", "object": {"text": "held by institutional investors", "keywords": [{"text": "institutional investors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " 69.1% of Arsanis shares are held by institutional investors.", "object": {"text": "69.1% of Arsanis shares", "keywords": [{"text": "Arsanis shares"}], "entities": [{"type": "Quantity", "text": "69.1"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "by company insiders", "keywords": [{"text": "company insiders"}]}, "sentence": " 33.8% of Seattle Genetics shares are held by company insiders.", "object": {"text": "33.8% of Seattle Genetics shares", "keywords": [{"text": "Seattle Genetics shares"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Quantity", "text": "33.8"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "by company insiders", "keywords": [{"text": "company insiders"}]}, "sentence": " Comparatively, 50.9% of Arsanis shares are held by company insiders.", "object": {"text": "50.9% of Arsanis shares", "keywords": [{"text": "Arsanis shares"}], "entities": [{"type": "Quantity", "text": "50.9"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "Strong institutional ownership", "keywords": [{"text": "Strong institutional ownership"}]}, "sentence": " Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.", "object": {"text": "an indication that endowments, large money managers", "keywords": [{"text": "large money managers"}, {"text": "endowments"}, {"text": "indication"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "large money managers and hedge funds", "keywords": [{"text": "hedge funds"}, {"text": "large money managers"}], "entities": []}, "sentence": " Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.", "object": {"text": "a company will outperform the market over the long term", "keywords": [{"text": "long term"}, {"text": "company"}, {"text": "market"}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believe", "normalized": "believe"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics beats Arsanis on 6 of the 11 factors compared between the two stocks.", "object": {"text": "Arsanis", "keywords": [{"text": "Arsanis"}]}, "action": {"verb": {"text": "beat", "tense": "present"}, "text": "beats", "normalized": "beat"}}, {"subject": {"text": "the 11 factors", "keywords": [{"text": "factors"}]}, "sentence": " Seattle Genetics beats Arsanis on 6 of the 11 factors compared between the two stocks.", "object": {"text": "between the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "It"}, "sentence": " It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.", "object": {"text": "ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma", "keywords": [{"text": "Hodgkin lymphoma"}, {"text": "antibody-drug conjugate"}, {"text": "ADCETRIS"}, {"text": "treatment"}], "entities": [{"type": "Company", "text": "ADCETRIS"}, {"type": "HealthCondition", "text": "Hodgkin"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "markets", "normalized": "market"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer", "keywords": [{"text": "Nectin-4-positive solid tumors"}, {"text": "bladder cancer"}, {"text": "enfortumab vedotin"}, {"text": "clinical trial"}], "entities": [{"type": "Person", "text": "enfortumab vedotin"}, {"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "enfortumab vedotin", "keywords": [{"text": "enfortumab vedotin"}], "entities": [{"type": "Person", "text": "enfortumab vedotin"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "in Phase 1 clinical trial", "keywords": [{"text": "Phase"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "tisotumab vedotin that", "keywords": [{"text": "tisotumab vedotin"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "in Phase II clinical trial for patients with cervical cancer and solid tumors", "keywords": [{"text": "cervical cancer"}, {"text": "solid tumors"}, {"text": "clinical trial"}, {"text": "Phase"}], "entities": [{"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma.", "object": {"text": "phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "stage classical Hodgkin"}, {"text": "clinical trials"}, {"text": "CD30-expressing MTCL"}], "entities": [{"type": "Company", "text": "ADCETRIS"}, {"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "conducts", "normalized": "conduct"}}, {"subject": {"text": "ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "sentence": " In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma.", "object": {"text": "3 clinical trials of ADCETRIS", "keywords": [{"text": "clinical trials"}, {"text": "ADCETRIS"}], "entities": [{"type": "Company", "text": "ADCETRIS"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF", "keywords": [{"text": "ADC programs"}, {"text": "ladiratuzumab vedotin"}, {"text": "denintuzumab mafodotin"}, {"text": "immuno-oncology agents"}]}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "the company's earlier stage clinical pipeline", "keywords": [{"text": "stage clinical pipeline"}, {"text": "company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "six other ADC programs", "keywords": [{"text": "ADC programs"}]}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A,", "keywords": [{"text": "ladiratuzumab vedotin"}, {"text": "denintuzumab mafodotin"}, {"text": "SGN-CD19B"}, {"text": "SGN-CD123A"}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consisting", "normalized": "consist"}}, {"subject": {"text": "SEA-CD40 and SGN-2FF"}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "two immuno-oncology agents", "keywords": [{"text": "immuno-oncology agents"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "It"}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG", "keywords": [{"text": "Bayer Pharma AG"}, {"text": "AbbVie Biotechnology Ltd."}, {"text": "various biotechnology"}, {"text": "ADC technology"}], "entities": [{"type": "Company", "text": "AbbVie Biotechnology Ltd."}, {"type": "Company", "text": "Bayer Pharma AG"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "AbbVie Biotechnology Ltd.; Bayer Pharma AG", "keywords": [{"text": "Bayer Pharma AG"}, {"text": "AbbVie Biotechnology Ltd."}], "entities": [{"type": "Company", "text": "AbbVie Biotechnology Ltd."}, {"type": "Company", "text": "Bayer Pharma AG"}]}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "various biotechnology and pharmaceutical companies", "keywords": [{"text": "various biotechnology"}, {"text": "pharmaceutical companies"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S", "keywords": [{"text": "PSMA Development Company"}, {"text": "Unum Therapeutics"}, {"text": "Genmab A/S"}, {"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "PSMA Development Company LLC"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Unum Therapeutics, Inc."}, {"type": "Company", "text": "Genmab A/S", "disambiguation": {"subtype": ["Company"], "name": "Genmab", "dbpedia_resource": "http://dbpedia.org/resource/Genmab"}}]}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "co-development agreement with Agensys, Inc", "keywords": [{"text": "co-development agreement"}, {"text": "Agensys"}], "entities": [{"type": "Company", "text": "Agensys, Inc"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Seattle Genetics, Inc.", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "object": {"text": "founded in 1998"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "object": {"text": "headquartered in Bothell, Washington", "keywords": [{"text": "Bothell"}, {"text": "Washington"}], "entities": [{"type": "Location", "text": "Bothell", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Bothell, Washington", "dbpedia_resource": "http://dbpedia.org/resource/Bothell,_Washington"}}, {"type": "Location", "text": "Washington", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics, Inc.", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Arsanis, Inc., a clinical-stage biopharmaceutical company,", "keywords": [{"text": "clinical-stage biopharmaceutical company"}, {"text": "Arsanis"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases.", "object": {"text": "monoclonal antibody (mAb) immunotherapies", "keywords": [{"text": ") immunotherapies"}, {"text": "monoclonal antibody"}]}, "action": {"verb": {"text": "apply", "tense": "future"}, "text": "applying", "normalized": "apply"}}, {"subject": {"text": "monoclonal antibody (mAb)", "keywords": [{"text": "monoclonal antibody"}, {"text": "mAb"}]}, "sentence": " Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases.", "object": {"text": "infectious diseases", "keywords": [{"text": "infectious diseases"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "immunotherapies to address", "normalized": "immunotherapies to address"}}, {"subject": {"text": "Its lead product candidate", "keywords": [{"text": "lead product candidate"}]}, "sentence": " Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "object": {"text": "ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia", "keywords": [{"text": "staphylococcus aureus pneumonia"}, {"text": "clinical development"}, {"text": "mAb"}, {"text": "Phase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "mAbs", "keywords": [{"text": "mAbs"}]}, "sentence": " The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.", "object": {"text": "various bacterial and viral pathogens", "keywords": [{"text": "viral pathogens"}]}, "action": {"verb": {"text": "target", "tense": "present"}, "text": "targeting", "normalized": "target"}}, {"subject": {"text": "respiratory syncytial virus", "keywords": [{"text": "respiratory syncytial virus"}], "entities": []}, "sentence": " The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.", "object": {"text": "various bacterial and viral pathogens", "keywords": [{"text": "viral pathogens"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "object": {"text": "founded in 2010"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "object": {"text": "headquartered in Waltham, Massachusetts", "keywords": [{"text": "Waltham"}, {"text": "Massachusetts"}], "entities": [{"type": "Location", "text": "Waltham", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Waltham, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Waltham,_Massachusetts"}}, {"type": "Location", "text": "Massachusetts", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "News & Ratings for Seattle Genetics Daily -", "keywords": [{"text": "Seattle Genetics Daily"}, {"text": "Ratings"}, {"text": "News"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter .", "object": {"text": "your email address", "keywords": [{"text": "email address"}]}, "action": {"verb": {"text": "Enter", "tense": "present"}, "text": "Enter", "normalized": "Enter"}}], "concepts": [{"text": "Clinical trial", "relevance": 0.952499, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Pharmaceutical industry", "relevance": 0.872982, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pharmacology", "relevance": 0.760692, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pre-clinical development", "relevance": 0.713042, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Biotechnology", "relevance": 0.680997, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Drug discovery", "relevance": 0.615419, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Drug development", "relevance": 0.611992, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Anaplastic large cell lymphoma", "relevance": 0.567672, "dbpedia_resource": "http://dbpedia.org/resource/Anaplastic_large_cell_lymphoma"}, {"text": "The Canon of Medicine", "relevance": 0.545264, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Lymphoma", "relevance": 0.533014, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Cancer", "relevance": 0.532765, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Hodgkin's lymphoma", "relevance": 0.514677, "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}, {"text": "Clinical research", "relevance": 0.482087, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Clinical trial protocol", "relevance": 0.480234, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial_protocol"}, {"text": "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use", "relevance": 0.478492, "dbpedia_resource": "http://dbpedia.org/resource/International_Conference_on_Harmonisation_of_Technical_Requirements_for_Registration_of_Pharmaceuticals_for_Human_Use"}, {"text": "Monoclonal antibodies", "relevance": 0.473389, "dbpedia_resource": "http://dbpedia.org/resource/Monoclonal_antibodies"}, {"text": "Good clinical practice", "relevance": 0.451203, "dbpedia_resource": "http://dbpedia.org/resource/Good_clinical_practice"}, {"text": "Informed consent", "relevance": 0.450896, "dbpedia_resource": "http://dbpedia.org/resource/Informed_consent"}, {"text": "Staphylococcus aureus", "relevance": 0.442991, "dbpedia_resource": "http://dbpedia.org/resource/Staphylococcus_aureus"}], "categories": [{"score": 0.876199, "label": "/health and fitness/disease/cancer"}, {"score": 0.836319, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.825546, "label": "/health and fitness/therapy"}], "relations": [{"type": "employedBy", "sentence": "33.8% of Seattle Genetics shares are held by company insiders.", "score": 0.662994, "arguments": [{"text": "insiders", "location": [156, 164], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "company", "location": [148, 155], "entities": [{"type": "Organization", "text": "Institutional Ownership"}]}]}, {"type": "employedBy", "sentence": "Comparatively, 50.9% of Arsanis shares are held by company insiders.", "score": 0.662994, "arguments": [{"text": "insiders", "location": [225, 233], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "company", "location": [217, 224], "entities": [{"type": "Organization", "text": "Institutional Ownership"}]}]}, {"type": "locatedAt", "sentence": "Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "score": 0.990399, "arguments": [{"text": "Waltham", "location": [2744, 2751], "entities": [{"type": "GeopoliticalEntity", "text": "Waltham"}]}, {"text": "Massachusetts", "location": [2753, 2766], "entities": [{"type": "GeopoliticalEntity", "text": "Massachusetts"}]}]}, {"type": "partOf", "sentence": "Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter .", "score": 0.557419, "arguments": [{"text": "companies", "location": [2960, 2969], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Seattle Genetics", "location": [2931, 2947], "entities": [{"type": "Organization", "text": "Seattle Genetics\nSeattle Genetics, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "score": 0.813646, "arguments": [{"text": "patients", "location": [1032, 1040], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cervical cancer", "location": [1046, 1061], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "partOfMany", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.586522, "arguments": [{"text": "AbbVie Biotechnology Ltd.", "location": [1820, 1845], "entities": [{"type": "Organization", "text": "AbbVie Biotechnology Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [1784, 1808], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.621299, "arguments": [{"text": "Bayer Pharma AG", "location": [1847, 1862], "entities": [{"type": "Organization", "text": "Bayer Pharma AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [1784, 1808], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.985491, "arguments": [{"text": "Bothell", "location": [2180, 2187], "entities": [{"type": "GeopoliticalEntity", "text": "Bothell"}]}, {"text": "Washington", "location": [2189, 2199], "entities": [{"type": "GeopoliticalEntity", "text": "Washington"}]}]}, {"type": "employedBy", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.401099, "arguments": [{"text": "candidate", "location": [2385, 2394], "entities": [{"type": "Person", "text": "ASN100"}]}, {"text": "Its", "location": [2368, 2371], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "hasAttribute", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.950221, "arguments": [{"text": "ASN100", "location": [2398, 2404], "entities": [{"type": "Person", "text": "ASN100"}]}, {"text": "pneumonia", "location": [2501, 2510], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "hasAttribute", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.845239, "arguments": [{"text": "patients", "location": [2538, 2546], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "pneumonia", "location": [2501, 2510], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "foundedOn", "sentence": "Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "score": 0.72754, "arguments": [{"text": "Arsanis, Inc.", "location": [2686, 2699], "entities": [{"type": "Organization", "text": "Arsanis\nArsanis, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "2010", "location": [2715, 2719], "entities": [{"type": "Date", "text": "2010", "disambiguation": {"subtype": ["Starting"]}}]}]}], "keywords": [{"text": "company insiders", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.766699, "count": 2}, {"text": "Seattle Genetics shares", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.743159, "count": 1}, {"text": "clinical trial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.639595, "count": 2}, {"text": "company", "sentiment": {"score": 0.959343, "label": "positive"}, "relevance": 0.615402, "count": 2}, {"text": "Inc. Seattle Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609241, "count": 1}, {"text": "email address", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.59905, "count": 1}, {"text": "concise daily summary of the latest news", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.598791, "count": 1}, {"text": "Inc.", "sentiment": {"score": -0.551027, "label": "negative"}, "relevance": 0.581186, "count": 8}, {"text": "advanced stage", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.578143, "count": 1}, {"text": "SGN-CD123A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576617, "count": 1}, {"text": "biotechnology company", "sentiment": {"score": -0.551027, "label": "negative"}, "relevance": 0.57655, "count": 1}, {"text": "development agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570127, "count": 1}, {"text": "pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562499, "count": 1}, {"text": "development", "sentiment": {"score": -0.551027, "label": "negative"}, "relevance": 0.560728, "count": 1}, {"text": "Arsanis shares", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.560594, "count": 2}, {"text": "CD30", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.558498, "count": 1}, {"text": "News", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.557366, "count": 1}, {"text": "Hodgkin lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55489, "count": 1}, {"text": "Seattle Genetics", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.551125, "count": 2}, {"text": "antibody-drug conjugate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551021, "count": 1}, {"text": "SGN-CD19B", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54923, "count": 1}, {"text": "Ratings", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.549128, "count": 1}, {"text": "hedge funds", "sentiment": {"score": 0.959343, "label": "positive"}, "relevance": 0.547799, "count": 1}, {"text": "related companies", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.545931, "count": 1}, {"text": "Phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542463, "count": 3}, {"text": "PSMA Development Company LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538205, "count": 1}, {"text": "monoclonal antibody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537803, "count": 1}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537615, "count": 1}, {"text": "solid tumors", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.536926, "count": 2}, {"text": "Celldex Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536625, "count": 1}, {"text": "patients", "sentiment": {"score": -0.562563, "label": "negative"}, "relevance": 0.536045, "count": 5}, {"text": "lead product candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533258, "count": 1}, {"text": "GlaxoSmithKline LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531724, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531668, "count": 1}, {"text": "bladder cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531568, "count": 1}, {"text": "phase", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.528347, "count": 1}, {"text": "institutional investors", "sentiment": {"score": -0.801265, "label": "negative"}, "relevance": 0.525068, "count": 1}, {"text": "addition", "sentiment": {"score": -0.588328, "label": "negative"}, "relevance": 0.523955, "count": 1}, {"text": "mAb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523669, "count": 2}, {"text": "analysts' ratings", "sentiment": {"score": 0.882981, "label": "positive"}, "relevance": 0.521762, "count": 1}, {"text": "company's earlier stage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521365, "count": 1}, {"text": "Genentech", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520784, "count": 1}, {"text": "collaborations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520449, "count": 1}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519799, "count": 1}, {"text": "cervical cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519758, "count": 1}, {"text": "Bayer Pharma AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519396, "count": 1}, {"text": "various biotechnology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517952, "count": 1}, {"text": "indication", "sentiment": {"score": 0.959343, "label": "positive"}, "relevance": 0.517732, "count": 1}, {"text": "endowments", "sentiment": {"score": 0.959343, "label": "positive"}, "relevance": 0.517586, "count": 1}, {"text": "market", "sentiment": {"score": 0.959343, "label": "positive"}, "relevance": 0.517397, "count": 1}]}, "extracted_metadata": {"sha1": "46211852a8a3ea3a01662159ab9140250028c150", "filename": "1542456504754.zip-732589a6a8d1a66752d917ced7ef5e2c.xml", "file_type": "json"}, "title": "Reviewing Seattle Genetics (SGEN) & Arsanis (ASNS)", "forum_title": "WKRB News"}, {"id": "1P6o7Z2JrpeS_RwinKQNqbeHR2XGsghNXGXectQrWQszGWw2sDUf7tVDm8VnyiUM", "result_metadata": {"score": 35.12872}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.533075, "label": "negative"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.993249, "label": "/health and fitness/disorders"}, {"score": 0.77038, "label": "/health and fitness/disorders/mental disorder"}], "relations": [], "keywords": [{"text": "Gastrointestinal Disorder Therapeutics Market", "sentiment": {"score": -0.533075, "label": "negative"}, "relevance": 0.990566, "count": 1}, {"text": "Significant Pace", "sentiment": {"score": -0.533075, "label": "negative"}, "relevance": 0.009434, "count": 1}]}, "crawl_date": "2018-11-16T17:01:02Z", "url": "https://industrytoday.co.uk/health_and_safety/gastrointestinal-disorder-therapeutics-market-anticipated-to-grow-at-a-significant-pace-by-2021/167659/167659", "host": "industrytoday.co.uk", "text": "Various key players contributing to the global gastrointestinal disorder therapeutics market comprises are AstraZeneca, Takeda Pharmaceutical Company, Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Salix Pharmaceuticals and others.Request for Report TOC : https://www.persistencemarketresearch.com/toc/5489 Contact information Persistence Market Research Pvt.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T13:29:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": -0.69496, "label": "negative"}, "text": "gastrointestinal disorders", "relevance": 0.932574, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Persistence Market Research", "relevance": 0.361661, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.854819, "label": "negative"}, "text": "bowel syndrome", "relevance": 0.197114, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.8677, "label": "negative"}, "text": "diarrhea", "relevance": 0.143455, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Diarrhea", "dbpedia_resource": "http://dbpedia.org/resource/Diarrhea"}}, {"count": 1, "sentiment": {"score": -0.742098, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.140552, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.139668, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": -0.474684, "label": "negative"}, "text": "North America", "relevance": 0.137321, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.583027, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.133328, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.128967, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.304476, "label": "negative"}, "text": "Salix Pharmaceuticals", "relevance": 0.126279, "type": "Company", "disambiguation": {"subtype": [], "name": "Salix Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Salix_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.125226, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.11733, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.0986547, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@IndustryToday", "relevance": 0.0986547, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.644689, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " Persistence Market Research has announced the addition of the \u201cGastrointestinal Disorder Therapeutics Market\" report to their offering.", "object": {"text": "announced the addition of the \u201cGastrointestinal Disorder Therapeutics Market\" report to their offering", "keywords": [{"text": "Gastrointestinal Disorder Therapeutics"}, {"text": "addition"}, {"text": "Market"}, {"text": "report"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " Persistence Market Research has announced the addition of the \u201cGastrointestinal Disorder Therapeutics Market\" report to their offering.", "object": {"text": "the addition of the \u201cGastrointestinal Disorder Therapeutics Market\" report to their offering", "keywords": [{"text": "Gastrointestinal Disorder Therapeutics"}, {"text": "addition"}, {"text": "Market"}, {"text": "report"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "has announced", "normalized": "have announce"}}, {"subject": {"text": "us"}, "sentence": " Follow us on Twitter @IndustryToday", "object": {"text": "on Twitter @IndustryToday", "keywords": [{"text": "Twitter"}], "entities": [{"type": "TwitterHandle", "text": "@IndustryToday"}]}, "action": {"verb": {"text": "Follow", "tense": "present"}, "text": "Follow", "normalized": "Follow"}}, {"subject": {"text": "Gastrointestinal disorder", "keywords": [{"text": "Gastrointestinal disorder"}], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "sentence": " Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food.", "object": {"text": "mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food", "keywords": [{"text": "gastrointestinal functions"}, {"text": "poisonous food"}, {"text": "impairment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Gastrointestinal disorder", "keywords": [{"text": "Gastrointestinal disorder"}], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "sentence": " Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food.", "object": {"text": "with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food", "keywords": [{"text": "gastrointestinal functions"}, {"text": "poisonous food"}, {"text": "impairment"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "is mainly associated", "normalized": "be mainly associate"}}, {"subject": {"text": "gastrointestinal functions", "keywords": [{"text": "gastrointestinal functions"}]}, "sentence": " Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food.", "object": {"text": "affected mainly by contaminated or poisonous food", "keywords": [{"text": "poisonous food"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by contaminated or poisonous food", "keywords": [{"text": "poisonous food"}]}, "sentence": " Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food.", "object": {"text": "gastrointestinal functions", "keywords": [{"text": "gastrointestinal functions"}]}, "action": {"verb": {"text": "affect", "tense": "past"}, "text": "are affected", "normalized": "be affect"}}, {"subject": {"text": "irritable bowel syndrome", "keywords": [{"text": "irritable bowel syndrome"}], "entities": [{"type": "HealthCondition", "text": "bowel syndrome"}]}, "sentence": " Gastrointestinal disorders includes irritable bowel syndrome, gastroesophageal reflux diseases and peptic ulcer diseases.", "object": {"text": "Gastrointestinal disorders", "keywords": [{"text": "Gastrointestinal disorders"}], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "These"}, "sentence": " These are the functional disorders in which gastrointestinal bowel doesn\u2019t work properly.", "object": {"text": "the functional disorders in which gastrointestinal bowel doesn\u2019t work properly", "keywords": [{"text": "gastrointestinal bowel"}, {"text": "functional disorders"}, {"text": "n\u2019t work"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "gastrointestinal bowel", "keywords": [{"text": "gastrointestinal bowel"}]}, "sentence": " These are the functional disorders in which gastrointestinal bowel doesn\u2019t work properly.", "object": {"text": "n\u2019t work", "keywords": [{"text": "n\u2019t work"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "does", "normalized": "do"}}, {"subject": {"text": "Bleeding, gastrointestinal infections and diarrhea", "keywords": [{"text": "gastrointestinal infections"}, {"text": "diarrhea"}], "entities": [{"type": "HealthCondition", "text": "diarrhea", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Diarrhea", "dbpedia_resource": "http://dbpedia.org/resource/Diarrhea"}}]}, "sentence": " Bleeding, gastrointestinal infections and diarrhea are some of the common symptoms during gastrointestinal disorder.", "object": {"text": "some of the common symptoms", "keywords": [{"text": "common symptoms"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Nexium, Aciphex, Tysabri, Humira", "keywords": [{"text": "Nexium"}, {"text": "Aciphex"}, {"text": "Humira"}, {"text": "Tysabri"}]}, "sentence": " Nexium, Aciphex, Tysabri, Humira are some of the gastrointestinal therapeutics commercially available in the market.", "object": {"text": "some of the gastrointestinal therapeutics commercially available in the market", "keywords": [{"text": "gastrointestinal therapeutics"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Increasing incidences of gastrointestinal disorders", "keywords": [{"text": "gastrointestinal disorders"}, {"text": "incidences"}], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "sentence": " Increasing incidences of gastrointestinal disorders that demands treatment by these therapeutics will boost the growth of this market.", "object": {"text": "treatment", "keywords": [{"text": "treatment"}]}, "action": {"verb": {"text": "demand", "tense": "present"}, "text": "demands", "normalized": "demand"}}, {"subject": {"text": "Increasing incidences of gastrointestinal disorders that demands treatment by these therapeutics", "keywords": [{"text": "gastrointestinal disorders"}, {"text": "incidences"}, {"text": "therapeutics"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "sentence": " Increasing incidences of gastrointestinal disorders that demands treatment by these therapeutics will boost the growth of this market.", "object": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "will boost", "normalized": "will boost"}}, {"subject": {"text": "increasing stress, unhealthy dietary habits and geriatric population", "keywords": [{"text": "unhealthy dietary habits"}, {"text": "geriatric population"}, {"text": "stress"}]}, "sentence": " In addition, increasing stress, unhealthy dietary habits and geriatric population drives the growth of this market.", "object": {"text": "the growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drives", "normalized": "drive"}}, {"subject": {"text": "key players", "keywords": [{"text": "key players"}]}, "sentence": " Furthermore, increasing R&D activities of key players in order to develop new drugs will further drive the market growth.", "object": {"text": "new drugs", "keywords": [{"text": "new drugs"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "increasing R&D activities of key players in order to develop new drugs", "keywords": [{"text": "new drugs"}, {"text": "R&D activities"}, {"text": "key players"}]}, "sentence": " Furthermore, increasing R&D activities of key players in order to develop new drugs will further drive the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "drive", "normalized": "drive"}}, {"subject": {"text": "the key players", "keywords": [{"text": "key players"}]}, "sentence": " However, high competition among the key players to gain the market share may ultimately lead to price erosion.", "object": {"text": "the market share", "keywords": [{"text": "market share"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "to gain", "normalized": "to gain"}}, {"subject": {"text": "these disorders", "keywords": [{"text": "disorders"}]}, "sentence": " In addition, these disorders have low diagnosis rates and therapeutics have high side effects that may restrain the market growth.Request for Report Sample : https://www.persistencemarketresearch.com/samples/5489", "object": {"text": "low diagnosis rates", "keywords": [{"text": "low diagnosis rates"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "these disorders have low diagnosis rates and therapeutics", "keywords": [{"text": "low diagnosis rates"}, {"text": "therapeutics"}, {"text": "disorders"}]}, "sentence": " In addition, these disorders have low diagnosis rates and therapeutics have high side effects that may restrain the market growth.Request for Report Sample : https://www.persistencemarketresearch.com/samples/5489", "object": {"text": "high side effects that may restrain the market growth.Request for Report Sample", "keywords": [{"text": "high side effects"}, {"text": "market growth.Request"}, {"text": "Report Sample"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "high side effects", "keywords": [{"text": "high side effects"}]}, "sentence": " In addition, these disorders have low diagnosis rates and therapeutics have high side effects that may restrain the market growth.Request for Report Sample : https://www.persistencemarketresearch.com/samples/5489", "object": {"text": "the market growth.Request for Report Sample", "keywords": [{"text": "market growth.Request"}, {"text": "Report Sample"}]}, "action": {"verb": {"text": "restrain", "tense": "future"}, "text": "may restrain", "normalized": "may restrain"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Geographically, North America is considered to be the largest market of gastrointestinal therapeutics due to the large pool of patients of gastrointestinal disorders.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is considered to be", "normalized": "be consider to be"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Geographically, North America is considered to be the largest market of gastrointestinal therapeutics due to the large pool of patients of gastrointestinal disorders.", "object": {"text": "to be the largest market of gastrointestinal therapeutics", "keywords": [{"text": "gastrointestinal therapeutics"}, {"text": "largest market"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "considered", "normalized": "consider"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Geographically, North America is considered to be the largest market of gastrointestinal therapeutics due to the large pool of patients of gastrointestinal disorders.", "object": {"text": "the largest market of gastrointestinal therapeutics due to the large pool of patients of gastrointestinal disorders", "keywords": [{"text": "gastrointestinal therapeutics"}, {"text": "gastrointestinal disorders"}, {"text": "largest market"}, {"text": "large pool"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is considered to be", "normalized": "be consider to be"}}, {"subject": {"text": "launch of new and advanced drugs by key players", "keywords": [{"text": "advanced drugs"}, {"text": "key players"}, {"text": "launch"}]}, "sentence": " In addition, launch of new and advanced drugs by key players coupled with increasing uptake of these drugs by consumers will further drive the market growth.", "object": {"text": "with increasing uptake of these drugs by consumers will further drive the market growth", "keywords": [{"text": "uptake"}, {"text": "market growth"}, {"text": "drugs"}, {"text": "consumers"}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "launch of new and advanced drugs by key players coupled with increasing uptake of these drugs by consumers", "keywords": [{"text": "advanced drugs"}, {"text": "key players"}, {"text": "uptake"}, {"text": "launch"}]}, "sentence": " In addition, launch of new and advanced drugs by key players coupled with increasing uptake of these drugs by consumers will further drive the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "will further drive", "normalized": "will far drive"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe is considered as second largest market of gastrointestinal disorders therapeutics.", "object": {"text": "considered as second largest market of gastrointestinal disorders therapeutics", "keywords": [{"text": "gastrointestinal disorders"}, {"text": "therapeutics"}, {"text": "market"}], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe is considered as second largest market of gastrointestinal disorders therapeutics.", "object": {"text": "as second largest market of gastrointestinal disorders therapeutics", "keywords": [{"text": "gastrointestinal disorders"}, {"text": "largest market"}, {"text": "therapeutics"}], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Digestive disease", "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "is considered", "normalized": "be consider"}}, {"subject": {"text": "key players", "keywords": [{"text": "key players"}]}, "sentence": " Efforts of domiciled key players to fill their product pipeline with innovative drugs attracts number of customers and hence drives the market growth.", "object": {"text": "their product pipeline", "keywords": [{"text": "product pipeline"}]}, "action": {"verb": {"text": "fill", "tense": "future"}, "text": "to fill", "normalized": "to fill"}}, {"subject": {"text": "Efforts of domiciled key players to fill their product pipeline with innovative drugs", "keywords": [{"text": "domiciled key players"}, {"text": "product pipeline"}, {"text": "innovative drugs"}, {"text": "Efforts"}]}, "sentence": " Efforts of domiciled key players to fill their product pipeline with innovative drugs attracts number of customers and hence drives the market growth.", "object": {"text": "number of customers", "keywords": [{"text": "number"}, {"text": "customers"}]}, "action": {"verb": {"text": "attract", "tense": "present"}, "text": "attracts", "normalized": "attract"}}, {"subject": {"text": "Efforts of domiciled key players", "keywords": [{"text": "domiciled key players"}, {"text": "Efforts"}]}, "sentence": " Efforts of domiciled key players to fill their product pipeline with innovative drugs attracts number of customers and hence drives the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drives", "normalized": "drive"}}, {"subject": {"text": "Asia-Pacific region", "keywords": [{"text": "Asia-Pacific region"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " In addition, Asia-Pacific region is the emerging market for gastrointestinal disorders market because of rising incidences of peptic ulcer, ulcerative colitis, irritable bowel syndrome and crohn\u2019s disease.", "object": {"text": "the emerging market for gastrointestinal disorders market", "keywords": [{"text": "gastrointestinal disorders market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Various key players contributing to the global gastrointestinal disorder therapeutics market comprises", "keywords": [{"text": "gastrointestinal disorder therapeutics"}, {"text": "Various key players"}]}, "sentence": " Various key players contributing to the global gastrointestinal disorder therapeutics market comprises are AstraZeneca, Takeda Pharmaceutical Company, Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Salix Pharmaceuticals and others.Request for Report TOC : https://www.persistencemarketresearch.com/toc/5489 Contact information", "object": {"text": "AstraZeneca, Takeda Pharmaceutical Company, Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Salix Pharmaceuticals and others.Request for Report TOC", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Salix Pharmaceuticals"}, {"text": "Abbott Laboratories"}, {"text": "Report TOC"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Company", "text": "Abbott Laboratories", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"type": "Company", "text": "Salix Pharmaceuticals", "disambiguation": {"subtype": [], "name": "Salix Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Salix_Pharmaceuticals"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Gastroenterology", "relevance": 0.955258, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Ulcerative colitis", "relevance": 0.818503, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Irritable bowel syndrome", "relevance": 0.813171, "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}, {"text": "Peptic ulcer", "relevance": 0.750425, "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}, {"text": "Gastroesophageal reflux disease", "relevance": 0.730715, "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}, {"text": "Abdominal pain", "relevance": 0.721274, "dbpedia_resource": "http://dbpedia.org/resource/Abdominal_pain"}, {"text": "Crohn's disease", "relevance": 0.623908, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Colitis", "relevance": 0.598815, "dbpedia_resource": "http://dbpedia.org/resource/Colitis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.584261, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Digestive diseases", "relevance": 0.583429, "dbpedia_resource": "http://dbpedia.org/resource/Digestive_diseases"}, {"text": "Digestive disease", "relevance": 0.57684, "dbpedia_resource": "http://dbpedia.org/resource/Digestive_disease"}, {"text": "Medicine", "relevance": 0.526819, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Flatulence", "relevance": 0.513903, "dbpedia_resource": "http://dbpedia.org/resource/Flatulence"}, {"text": "Dietary fiber", "relevance": 0.499604, "dbpedia_resource": "http://dbpedia.org/resource/Dietary_fiber"}], "categories": [{"score": 0.98834, "label": "/health and fitness/disorders"}, {"score": 0.986687, "label": "/health and fitness/disease/ibs and crohn's disease"}, {"score": 0.713536, "label": "/health and fitness/therapy"}], "relations": [{"type": "partOf", "sentence": "Gastrointestinal Disorder Therapeutics Market Anticipated to Grow at a Significant Pace by 2021 Persistence Market Research has announced the addition of the \"Gastrointestinal Disorder Therapeutics Market\" report to their offering.", "score": 0.53957, "arguments": [{"text": "Significant Pace", "location": [71, 87], "entities": [{"type": "Organization", "text": "Significant Pace"}]}, {"text": "Persistence Market Research", "location": [96, 123], "entities": [{"type": "Organization", "text": "Persistence Market Research Pvt."}]}]}, {"type": "agentOf", "sentence": "Gastrointestinal Disorder Therapeutics Market Anticipated to Grow at a Significant Pace by 2021 Persistence Market Research has announced the addition of the \"Gastrointestinal Disorder Therapeutics Market\" report to their offering.", "score": 0.484484, "arguments": [{"text": "their", "location": [216, 221], "entities": [{"type": "Person", "text": "their"}]}, {"text": "report", "location": [206, 212], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOf", "sentence": "Follow us on Twitter @IndustryToday Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food.", "score": 0.761256, "arguments": [{"text": "Gastrointestinal disorder", "location": [296, 321], "entities": [{"type": "Organization", "text": "Gastrointestinal Disorder Therapeutics Market"}]}, {"text": "Twitter", "location": [273, 280], "entities": [{"type": "Organization", "text": "Twitter"}]}]}, {"type": "locatedAt", "sentence": "Nexium, Aciphex, Tysabri, Humira are some of the gastrointestinal therapeutics commercially available in the market.", "score": 0.503452, "arguments": [{"text": "Aciphex", "location": [790, 797], "entities": [{"type": "GeopoliticalEntity", "text": "Aciphex"}]}, {"text": "Tysabri", "location": [799, 806], "entities": [{"type": "GeopoliticalEntity", "text": "Tysabri"}]}]}, {"type": "locatedAt", "sentence": "Nexium, Aciphex, Tysabri, Humira are some of the gastrointestinal therapeutics commercially available in the market.", "score": 0.910396, "arguments": [{"text": "Tysabri", "location": [799, 806], "entities": [{"type": "GeopoliticalEntity", "text": "Tysabri"}]}, {"text": "Humira", "location": [808, 814], "entities": [{"type": "GeopoliticalEntity", "text": "Humira"}]}]}, {"type": "memberOf", "sentence": "Request for Report Sample : https://www.persistencemarketresearch.com/samples/5489 Geographically, North America is considered to be the largest market of gastrointestinal therapeutics due to the large pool of patients of gastrointestinal disorders.", "score": 0.422747, "arguments": [{"text": "patients", "location": [1770, 1778], "entities": [{"type": "Person", "text": "consumers"}]}, {"text": "disorders", "location": [1799, 1808], "entities": [{"type": "Organization", "text": "Gastrointestinal Disorder Therapeutics Market"}]}]}, {"type": "locatedAt", "sentence": "Request for Report TOC : https://www.persistencemarketresearch.com/toc/5489 Contact information Persistence Market Research Pvt. Ltd.305 Broadway,7th Floor", "score": 0.508613, "arguments": [{"text": "Contact", "location": [2732, 2739], "entities": [{"type": "Organization", "text": "Contact"}]}, {"text": "Broadway", "location": [2793, 2801], "entities": [{"type": "Facility", "text": "Broadway"}]}]}, {"type": "locatedAt", "sentence": "Request for Report TOC : https://www.persistencemarketresearch.com/toc/5489 Contact information Persistence Market Research Pvt. Ltd.305 Broadway,7th Floor", "score": 0.661086, "arguments": [{"text": "Persistence Market Research Pvt.", "location": [2752, 2784], "entities": [{"type": "Organization", "text": "Persistence Market Research Pvt."}]}, {"text": "Broadway", "location": [2793, 2801], "entities": [{"type": "Facility", "text": "Broadway"}]}]}, {"type": "partOfMany", "sentence": "Request for Report TOC : https://www.persistencemarketresearch.com/toc/5489 Contact information Persistence Market Research Pvt. Ltd.305 Broadway,7th Floor", "score": 0.896431, "arguments": [{"text": "Broadway", "location": [2793, 2801], "entities": [{"type": "Facility", "text": "Broadway"}]}, {"text": "Floor", "location": [2806, 2811], "entities": [{"type": "Facility", "text": "Floor"}]}]}], "keywords": [{"text": "Gastrointestinal Disorder Therapeutics Market", "sentiment": {"score": -0.942228, "label": "negative"}, "relevance": 0.894001, "count": 2}, {"text": "R&D activities of key players", "sentiment": {"score": 0.3512, "label": "positive"}, "relevance": 0.72329, "count": 1}, {"text": "Persistence Market Research", "sentiment": {"score": -0.942228, "label": "negative"}, "relevance": 0.710114, "count": 1}, {"text": "addition", "sentiment": {"score": -0.714918, "mixed": "1", "label": "negative"}, "relevance": 0.660026, "count": 5}, {"text": "North America", "sentiment": {"score": -0.939172, "label": "negative"}, "relevance": 0.601274, "count": 1}, {"text": "market", "sentiment": {"score": -0.63991, "label": "negative"}, "relevance": 0.591625, "count": 2}, {"text": "new drugs", "sentiment": {"score": 0.3512, "label": "positive"}, "relevance": 0.582545, "count": 1}, {"text": "Asia-Pacific region", "sentiment": {"score": -0.626613, "label": "negative"}, "relevance": 0.580135, "count": 1}, {"text": "key players", "sentiment": {"score": 0.51176, "mixed": "1", "label": "positive"}, "relevance": 0.579982, "count": 3}, {"text": "Gastrointestinal disorder", "sentiment": {"score": -0.699088, "label": "negative"}, "relevance": 0.578434, "count": 1}, {"text": "irritable bowel syndrome", "sentiment": {"score": -0.685473, "label": "negative"}, "relevance": 0.565016, "count": 2}, {"text": "high competition", "sentiment": {"score": -0.767445, "label": "negative"}, "relevance": 0.556246, "count": 1}, {"text": "Abbott Laboratories", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.555488, "count": 1}, {"text": "Johnson", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.555024, "count": 2}, {"text": "market share", "sentiment": {"score": -0.767445, "label": "negative"}, "relevance": 0.551237, "count": 1}, {"text": "Efforts", "sentiment": {"score": 0.809764, "label": "positive"}, "relevance": 0.547597, "count": 1}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.546734, "count": 1}, {"text": "low diagnosis rates", "sentiment": {"score": -0.939172, "label": "negative"}, "relevance": 0.546453, "count": 1}, {"text": "therapeutics", "sentiment": {"score": -0.73724, "label": "negative"}, "relevance": 0.544966, "count": 2}, {"text": "common symptoms", "sentiment": {"score": -0.923946, "label": "negative"}, "relevance": 0.541923, "count": 1}, {"text": "ulcerative colitis", "sentiment": {"score": -0.626613, "label": "negative"}, "relevance": 0.540043, "count": 1}, {"text": "largest market of gastrointestinal therapeutics", "sentiment": {"score": -0.939172, "label": "negative"}, "relevance": 0.539077, "count": 1}, {"text": "Ltd", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.537034, "count": 2}, {"text": "disorders", "sentiment": {"score": -0.939172, "label": "negative"}, "relevance": 0.533837, "count": 1}, {"text": "launch", "sentiment": {"score": 0.826922, "label": "positive"}, "relevance": 0.531094, "count": 1}, {"text": "Gastrointestinal disorders", "sentiment": {"score": -0.73843, "label": "negative"}, "relevance": 0.53021, "count": 1}, {"text": "impairment of gastrointestinal functions", "sentiment": {"score": -0.699088, "label": "negative"}, "relevance": 0.529558, "count": 1}, {"text": "AstraZeneca", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.528487, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.62273, "label": "negative"}, "relevance": 0.52585, "count": 1}, {"text": "advanced drugs", "sentiment": {"score": 0.826922, "label": "positive"}, "relevance": 0.521247, "count": 1}, {"text": "order", "sentiment": {"score": 0.3512, "label": "positive"}, "relevance": 0.520062, "count": 1}, {"text": "stress", "sentiment": {"score": -0.9283, "label": "negative"}, "relevance": 0.519697, "count": 1}, {"text": "diarrhea", "sentiment": {"score": -0.923946, "label": "negative"}, "relevance": 0.519644, "count": 1}, {"text": "growth of this market", "sentiment": {"score": -0.737951, "mixed": "1", "label": "negative"}, "relevance": 0.51854, "count": 3}, {"text": "report", "sentiment": {"score": -0.942228, "label": "negative"}, "relevance": 0.517772, "count": 1}, {"text": "Request", "sentiment": {"score": -0.890415, "label": "negative"}, "relevance": 0.517634, "count": 2}, {"text": "Various key players", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.516325, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.373338, "label": "negative"}, "relevance": 0.514035, "count": 1}, {"text": "others", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.513703, "count": 1}, {"text": "incidences of gastrointestinal disorders", "sentiment": {"score": -0.373338, "label": "negative"}, "relevance": 0.512346, "count": 1}, {"text": "Eisai Co.", "sentiment": {"score": -0.833296, "label": "negative"}, "relevance": 0.510782, "count": 1}, {"text": "consumers", "sentiment": {"score": 0.826922, "label": "positive"}, "relevance": 0.510486, "count": 1}, {"text": "large pool of patients of gastrointestinal disorders", "sentiment": {"score": -0.413507, "mixed": "1", "label": "negative"}, "relevance": 0.508319, "count": 1}, {"text": "Twitter", "sentiment": {"score": -0.699088, "label": "negative"}, "relevance": 0.506251, "count": 1}, {"text": "erosion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506251, "count": 1}, {"text": "work", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506251, "count": 1}, {"text": "gastrointestinal therapeutics", "sentiment": {"score": -0.832609, "label": "negative"}, "relevance": 0.505309, "count": 1}, {"text": "high side effects", "sentiment": {"score": -0.939172, "label": "negative"}, "relevance": 0.505047, "count": 1}, {"text": "gastrointestinal infections", "sentiment": {"score": -0.923946, "label": "negative"}, "relevance": 0.4993, "count": 1}, {"text": "functional disorders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497523, "count": 1}]}, "extracted_metadata": {"sha1": "7729a2c4318efe86c0cd186f695348d25d646cbb", "filename": "1542387662445.zip-e790d2273455dfe37c528fb7998c19b2.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/toc/5489", "http://twitter.com/IndustryToday", "https://www.persistencemarketresearch.com/samples/5489", "https://www.persistencemarketresearch.com/market-research/gastrointestinal-disorder-therapeutics-market.asp"], "title": "Gastrointestinal Disorder Therapeutics Market Anticipated to Grow at a Significant Pace by 2021", "forum_title": "Industry Today"}, {"id": "bSgFYnQQQ36QhahOWf1BoO3tZH9vPQafoVUGVoGFB0WQkQ_LDPyOGnp-TvcsL1SH", "result_metadata": {"score": 35.075726}, "author": "Zacks.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.529181, "label": "positive"}, "text": "Seattle", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}], "sentiment": {"document": {"score": 0.727959, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Seattle Genetics' Adcetris", "keywords": [{"text": "Seattle Genetics"}, {"text": "Adcetris"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "object": {"text": "Breakthrough Therapy Status", "keywords": [{"text": "Therapy Status"}]}, "action": {"verb": {"text": "Gets", "tense": "present"}, "text": "Gets", "normalized": "Gets"}}], "concepts": [{"text": "Rock music", "relevance": 0.859886, "dbpedia_resource": "http://dbpedia.org/resource/Rock_music"}], "categories": [{"score": 0.999999, "label": "/health and fitness/therapy"}, {"score": 0.999998, "label": "/science/medicine/genetics"}], "relations": [{"type": "partOf", "sentence": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "score": 0.478864, "arguments": [{"text": "Adcetris", "location": [18, 26], "entities": [{"type": "Organization", "text": "Adcetris", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Seattle Genetics", "location": [0, 16], "entities": [{"type": "Organization", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "sentiment": {"score": 0.727959, "label": "positive"}, "relevance": 0.5, "count": 1}]}, "crawl_date": "2018-11-16T20:54:01Z", "url": "https://www.nasdaq.com/article/seattle-genetics39-adcetris-gets-breakthrough-therapy-status-cm1057100", "host": "nasdaq.com", "text": "Seattle Genetics has an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris.", "main_image_url": "https://www.nasdaq.com/images/dreamit.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T07:59:00-06:00", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": 0.348412, "label": "positive"}, "text": "Seattle Genetics", "relevance": 0.890209, "type": "PrintMedia"}, {"count": 3, "sentiment": {"score": -0.42452, "label": "negative"}, "text": "large cell lymphoma", "relevance": 0.404054, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"count": 3, "sentiment": {"score": -0.275959, "label": "negative"}, "text": "classical Hodgkin lymphoma", "relevance": 0.348452, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "peripheral T-cell lymphoma", "relevance": 0.343266, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Peripheral T-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_T-cell_lymphoma"}}, {"count": 3, "sentiment": {"score": 0.496147, "label": "positive"}, "text": "Eli Lilly", "relevance": 0.317494, "type": "Person", "disambiguation": {"subtype": [], "name": "Eli Lilly (industrialist)", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_(industrialist)"}}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adcetris", "relevance": 0.307771, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "lymphoma", "relevance": 0.292662, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.274685, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.698028, "label": "negative"}, "text": "Breakthrough Therapy", "relevance": 0.263764, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seattle", "relevance": 0.254308, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 4, "sentiment": {"score": -0.251432, "label": "negative"}, "text": "United States", "relevance": 0.253517, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "PTCL", "relevance": 0.248033, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.235742, "type": "Organization"}, {"count": 2, "sentiment": {"score": -0.293198, "label": "negative"}, "text": "Merck", "relevance": 0.226179, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "cHL", "relevance": 0.210496, "type": "Organization", "disambiguation": {"subtype": ["SportsAssociation"], "name": "Central Hockey League (1963\u20131984)", "dbpedia_resource": "http://dbpedia.org/resource/Central_Hockey_League_(1963\u20131984)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SGEN", "relevance": 0.194256, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.193802, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Society of Hematology", "relevance": 0.186261, "type": "Organization", "disambiguation": {"subtype": [], "name": "American Society of Hematology", "dbpedia_resource": "http://dbpedia.org/resource/American_Society_of_Hematology"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.178449, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "cyclophosphamide", "relevance": 0.176683, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BMY Opdivo", "relevance": 0.175535, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.496147, "label": "positive"}, "text": "Company LLY", "relevance": 0.173584, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.251432, "label": "negative"}, "text": "Europe", "relevance": 0.173251, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "prednisone", "relevance": 0.166824, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRK", "relevance": 0.164803, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SGEN", "relevance": 0.163687, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "doxorubicin", "relevance": 0.155298, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.152754, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRK Keytruda", "relevance": 0.151338, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.146587, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.132655, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "four quarters", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "30 Days", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "60 days", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10.03%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "104.9%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "109.3%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "115.0%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.42", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.54", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.65", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.80", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20.6%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "21.9%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "32.9%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "67.1%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "98.6%", "relevance": 0.132655, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.7%", "relevance": 0.132655, "type": "Quantity"}], "sentiment": {"document": {"score": 0.45167, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "SGEN", "keywords": [{"text": "SGEN"}], "entities": [{"type": "Company", "text": "SGEN"}]}, "sentence": " SGEN announced that the FDA has granted Breakthrough Therapy designation to Adcetrisfor the frontline treatment of certain lymphoma subtypes.", "object": {"text": "that the FDA has granted Breakthrough Therapy designation to Adcetrisfor the frontline treatment of certain lymphoma subtypes", "keywords": [{"text": "certain lymphoma subtypes"}, {"text": "Breakthrough Therapy designation"}, {"text": "frontline treatment"}, {"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA"}, {"type": "JobTitle", "text": "Breakthrough Therapy"}, {"type": "HealthCondition", "text": "lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The designation", "keywords": [{"text": "designation"}]}, "sentence": " The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "object": {"text": "granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide", "keywords": [{"text": "peripheral T-cell lymphomas"}, {"text": "angioimmunoblastic T-cell lymphoma"}, {"text": "large cell lymphoma"}, {"text": "cyclophosphamide"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"type": "Organization", "text": "PTCL", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"type": "Drug", "text": "cyclophosphamide"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "object": {"text": "with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL", "keywords": [{"text": "peripheral T-cell lymphomas"}, {"text": "angioimmunoblastic T-cell lymphoma"}, {"text": "large cell lymphoma"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"type": "Organization", "text": "PTCL", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "is granted to treat", "normalized": "be grant to treat"}}, {"subject": {"text": "angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone)", "keywords": [{"text": "angioimmunoblastic T-cell lymphoma"}, {"text": "cyclophosphamide"}, {"text": "prednisone"}, {"text": "CHP"}], "entities": [{"type": "Drug", "text": "cyclophosphamide"}, {"type": "Drug", "text": "doxorubicin"}, {"type": "Drug", "text": "prednisone"}]}, "sentence": " The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "object": {"text": "PTCL)", "keywords": [{"text": "PTCL"}], "entities": [{"type": "Organization", "text": "PTCL", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The Breakthrough Therapy designation", "keywords": [{"text": "Breakthrough Therapy designation"}], "entities": [{"type": "JobTitle", "text": "Breakthrough Therapy"}]}, "sentence": " The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life-threatening conditions.", "object": {"text": "granted to speed up the development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Breakthrough Therapy designation", "keywords": [{"text": "Breakthrough Therapy designation"}], "entities": [{"type": "JobTitle", "text": "Breakthrough Therapy"}]}, "sentence": " The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life-threatening conditions.", "object": {"text": "the development and review of drugs that target serious or life-threatening conditions", "keywords": [{"text": "drugs"}, {"text": "development"}, {"text": "review"}, {"text": "conditions"}]}, "action": {"verb": {"text": "speed", "tense": "future"}, "text": "is granted to speed", "normalized": "be grant to speed"}}, {"subject": {"text": "The FDA's decision", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " The FDA's decision was based on results from the phase III ECHELON-2 study, and the updated results will be presented at the American Society of Hematology Annual Meeting in December this year.", "object": {"text": "on results from the phase III ECHELON-2 study", "keywords": [{"text": "phase III ECHELON-2"}, {"text": "study"}, {"text": "results"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "was based", "normalized": "be base"}}, {"subject": {"text": "the updated results", "keywords": [{"text": "results"}]}, "sentence": " The FDA's decision was based on results from the phase III ECHELON-2 study, and the updated results will be presented at the American Society of Hematology Annual Meeting in December this year.", "object": {"text": "presented"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the updated results", "keywords": [{"text": "results"}]}, "sentence": " The FDA's decision was based on results from the phase III ECHELON-2 study, and the updated results will be presented at the American Society of Hematology Annual Meeting in December this year.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "Seattle Genetics along with Takeda", "keywords": [{"text": "Takeda"}, {"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Person", "text": "Takeda"}]}, "sentence": " Seattle Genetics along with Takeda announced that the phase III ECHELON-2 study on Adcetris has met its primary endpoint as well as all key secondary endpoints.", "object": {"text": "that the phase III ECHELON-2 study on Adcetris has met its primary endpoint as well as all key secondary endpoints", "keywords": [{"text": "key secondary endpoints"}, {"text": "primary endpoint"}, {"text": "phase III ECHELON-2"}, {"text": "study"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Adcetris combined with chemotherapy", "keywords": [{"text": "chemotherapy"}, {"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": " Adcetris combined with chemotherapy demonstrated a statistically significant improvement in progression-free survival as compared to the control arm.", "object": {"text": "a statistically significant improvement in progression-free survival", "keywords": [{"text": "statistically significant improvement"}, {"text": "progression-free survival"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "The study", "keywords": [{"text": "study"}]}, "sentence": " The study also achieved all key secondary endpoints and improved the overall survival in front-line CD30-expressing peripheral T-cell lymphoma (PTCL).", "object": {"text": "the overall survival", "keywords": [{"text": "overall survival"}]}, "action": {"verb": {"text": "improve", "tense": "past"}, "text": "improved", "normalized": "improve"}}, {"subject": {"text": "The drug", "keywords": [{"text": "drug"}]}, "sentence": " The drug is not currently approved for use in case of frontline PTCL.", "action": {"verb": {"text": "approve", "tense": "past", "negated": true}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Seattle Genetics' shares", "keywords": [{"text": "Seattle Genetics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics' shares have returned 1.7% so far this year against the industry 's decline of 20.6%.", "object": {"text": "1.7%", "entities": [{"type": "Quantity", "text": "1.7"}]}, "action": {"verb": {"text": "return", "tense": "past"}, "text": "have returned", "normalized": "have return"}}, {"subject": {"text": "Adcetris", "keywords": [{"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": " Adcetris is the only marketed product of Seattle Genetics.", "object": {"text": "the only marketed product of Seattle Genetics", "keywords": [{"text": "marketed product"}, {"text": "Seattle Genetics"}], "entities": [{"type": "Person", "text": "Adcetris"}, {"type": "PrintMedia", "text": "Seattle Genetics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The drug", "keywords": [{"text": "drug"}]}, "sentence": " The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "object": {"text": "approved for relapsed Hodgkin lymphoma", "keywords": [{"text": "Hodgkin lymphoma"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The drug", "keywords": [{"text": "drug"}]}, "sentence": " The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "object": {"text": "Hodgkin lymphoma", "keywords": [{"text": "Hodgkin lymphoma"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "relapse", "tense": "past"}, "text": "relapsed", "normalized": "relapse"}}, {"subject": {"text": "systemic anaplastic large cell lymphoma", "keywords": [{"text": "anaplastic large cell"}, {"text": "lymphoma"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}]}, "sentence": " The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "action": {"verb": {"text": "relapse", "tense": "past"}, "text": "relapsed", "normalized": "relapse"}}, {"subject": {"text": "It"}, "sentence": " It is also approved in the United States and Europe for the treatment of patients suffering from classical Hodgkin lymphoma (cHL) with no prior treatment and who are at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.", "object": {"text": "for the treatment of patients suffering from classical Hodgkin lymphoma (cHL) with no prior treatment and who are at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "post-autologous hematopoietic stem"}, {"text": ") consolidation"}, {"text": "prior treatment"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"type": "Organization", "text": "cHL", "disambiguation": {"subtype": ["SportsAssociation"], "name": "Central Hockey League (1963\u20131984)", "dbpedia_resource": "http://dbpedia.org/resource/Central_Hockey_League_(1963\u20131984)"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is also approved", "normalized": "be also approve"}}, {"subject": {"text": "It"}, "sentence": " It is also approved in combination with chemotherapy for the treatment of stage III or IV classical Hodgkin lymphoma (cHL) in patients with no previous treatment history.", "object": {"text": "with chemotherapy for the treatment of stage III or IV classical Hodgkin lymphoma (cHL) in patients with no previous treatment history", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "previous treatment history"}, {"text": "chemotherapy"}, {"text": "cHL"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"type": "Organization", "text": "cHL", "disambiguation": {"subtype": ["SportsAssociation"], "name": "Central Hockey League (1963\u20131984)", "dbpedia_resource": "http://dbpedia.org/resource/Central_Hockey_League_(1963\u20131984)"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is also approved", "normalized": "be also approve"}}, {"subject": {"text": "It"}, "sentence": " It is also approved for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States.", "object": {"text": "for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States", "keywords": [{"text": "CD30-expressing mycosis fungoides"}, {"text": "anaplastic large cell"}, {"text": "United States"}, {"text": "MF"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is also approved", "normalized": "be also approve"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics has an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris.", "object": {"text": "an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "commercialization"}, {"text": "agreement"}, {"text": "Ltd."}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Location", "text": "Adcetris", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "object": {"text": "all rights to sell Adcetris in the United States and Canada", "keywords": [{"text": "United States"}, {"text": "rights"}, {"text": "Adcetris"}, {"text": "Canada"}], "entities": [{"type": "Company", "text": "Adcetris"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "action": {"verb": {"text": "retain", "tense": "present"}, "text": "retains", "normalized": "retain"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "object": {"text": "Adcetris", "keywords": [{"text": "Adcetris"}], "entities": [{"type": "Company", "text": "Adcetris"}]}, "action": {"verb": {"text": "sell", "tense": "future"}, "text": "to sell", "normalized": "to sell"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "object": {"text": "commercial rights to the drug in the rest of the world", "keywords": [{"text": "commercial rights"}, {"text": "rest"}, {"text": "drug"}, {"text": "world"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the drug", "keywords": [{"text": "drug"}]}, "sentence": " However, the drug has several competitors, including 's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "object": {"text": "several competitors", "keywords": [{"text": "competitors"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "'s BMY Opdivo and Merck's MRK Keytruda", "keywords": [{"text": "Merck"}, {"text": "BMY Opdivo"}, {"text": "MRK Keytruda"}], "entities": [{"type": "Person", "text": "BMY Opdivo"}, {"type": "Company", "text": "Merck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "MRK Keytruda"}]}, "sentence": " However, the drug has several competitors, including 's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "object": {"text": "several competitors", "keywords": [{"text": "competitors"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "'s BMY Opdivo and Merck's MRK Keytruda", "keywords": [{"text": "Merck"}, {"text": "BMY Opdivo"}, {"text": "MRK Keytruda"}], "entities": [{"type": "Person", "text": "BMY Opdivo"}, {"type": "Company", "text": "Merck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "MRK Keytruda"}]}, "sentence": " However, the drug has several competitors, including 's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "object": {"text": "approved for relapsed or refractory cHL", "keywords": [{"text": "refractory cHL"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "PrintMedia", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Location", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics currently carries a Zacks Rank #3 (Hold).", "object": {"text": "a Zacks Rank #3 (Hold)", "keywords": [{"text": "Rank  (Hold)"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carries", "normalized": "carry"}}, {"subject": {"text": "A better-ranked stock worth considering", "keywords": [{"text": "better-ranked stock"}]}, "sentence": " A better-ranked stock worth considering is Eli Lilly and Company LLY , carrying a Zacks Rank #2 (Buy).", "object": {"text": "Eli Lilly and Company LLY", "keywords": [{"text": "Eli Lilly"}, {"text": "Company"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["Person"], "name": "Eli Lilly (industrialist)", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_(industrialist)"}}, {"type": "Company", "text": "Company LLY"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Eli Lilly and Company LLY", "keywords": [{"text": "Eli Lilly"}, {"text": "Company"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["Person"], "name": "Eli Lilly (industrialist)", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_(industrialist)"}}, {"type": "Company", "text": "Company LLY"}]}, "sentence": " A better-ranked stock worth considering is Eli Lilly and Company LLY , carrying a Zacks Rank #2 (Buy).", "object": {"text": "a Zacks Rank #2 (Buy)", "keywords": [{"text": "Zacks Rank"}, {"text": "Buy"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carrying", "normalized": "carry"}}, {"subject": {"text": "You"}, "sentence": " You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .", "object": {"text": "the complete list of today's Zacks #1 Rank (Strong Buy) stocks here", "keywords": [{"text": "Zacks  Rank"}, {"text": "Strong Buy"}, {"text": "complete list"}, {"text": "stocks"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "can see", "normalized": "can see"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 10.03%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": " Shares of the company have increased 32.9% year to date.", "object": {"text": "increased 32.9% year", "entities": [{"type": "Quantity", "text": "32.9"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": " Shares of the company have increased 32.9% year to date.", "object": {"text": "32.9% year", "entities": [{"type": "Quantity", "text": "32.9"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "have increased", "normalized": "have increase"}}, {"subject": {"text": "It"}, "sentence": " It's hard to believe, even for us at Zacks.", "object": {"text": "to believe"}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.", "object": {"text": "+21.9%", "entities": [{"type": "Quantity", "text": "21.9"}]}, "action": {"verb": {"text": "gain", "tense": "past"}, "text": "gained", "normalized": "gain"}}, {"subject": {"text": "our top stock-picking screens", "keywords": [{"text": "stock-picking screens"}]}, "sentence": " But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.", "object": {"text": "+115.0%", "entities": [{"type": "Quantity", "text": "115.0"}]}, "action": {"verb": {"text": "return", "tense": "past"}, "text": "have returned", "normalized": "have return"}}, {"subject": {"text": "this outperformance", "keywords": [{"text": "outperformance"}]}, "sentence": " And this outperformance has not just been a recent phenomenon.", "object": {"text": "not just been a recent phenomenon", "keywords": [{"text": "recent phenomenon"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "this outperformance", "keywords": [{"text": "outperformance"}]}, "sentence": " And this outperformance has not just been a recent phenomenon.", "object": {"text": "a recent phenomenon", "keywords": [{"text": "recent phenomenon"}]}, "action": {"verb": {"text": "be", "tense": "past", "negated": true}, "text": "been", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Over the years it has been remarkably consistent.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "the composite yearly average gain for these strategies", "keywords": [{"text": "yearly average gain"}, {"text": "strategies"}]}, "sentence": " From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over.", "object": {"text": "beaten the market more than 19X over", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the composite yearly average gain for these strategies", "keywords": [{"text": "yearly average gain"}, {"text": "strategies"}]}, "sentence": " From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "beat", "tense": "past"}, "text": "has beaten", "normalized": "have beat"}}, {"subject": {"text": "even more remarkable"}, "sentence": " Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.", "object": {"text": "the fact that we're willing to share their latest stocks", "keywords": [{"text": "latest stocks"}, {"text": "fact"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.", "object": {"text": "their latest stocks", "keywords": [{"text": "latest stocks"}]}, "action": {"verb": {"text": "share", "tense": "future"}, "text": "to share", "normalized": "to share"}}, {"subject": {"text": "you"}, "sentence": " Today, you can download 7 Best Stocks for the Next 30 Days.", "object": {"text": "7 Best Stocks", "keywords": [{"text": "Best Stocks"}]}, "action": {"verb": {"text": "download", "tense": "future"}, "text": "can download", "normalized": "can download"}}, {"subject": {"text": "this"}, "sentence": " Click to get this free report", "object": {"text": "free report", "keywords": [{"text": "free report"}]}, "action": {"verb": {"text": "get", "tense": "future"}, "text": "to get", "normalized": "to get"}}, {"subject": {"text": "this article", "keywords": [{"text": "article"}]}, "sentence": " To read this article on Zacks.com click here.", "action": {"verb": {"text": "read", "tense": "future"}, "text": "To read", "normalized": "To read"}}], "concepts": [{"text": "Lymphoma", "relevance": 0.974071, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Anaplastic large cell lymphoma", "relevance": 0.698948, "dbpedia_resource": "http://dbpedia.org/resource/Anaplastic_large_cell_lymphoma"}, {"text": "Non-Hodgkin lymphoma", "relevance": 0.697689, "dbpedia_resource": "http://dbpedia.org/resource/Non-Hodgkin_lymphoma"}, {"text": "Hodgkin's lymphoma", "relevance": 0.652344, "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}, {"text": "Hematology", "relevance": 0.637676, "dbpedia_resource": "http://dbpedia.org/resource/Hematology"}, {"text": "Types of cancer", "relevance": 0.523602, "dbpedia_resource": "http://dbpedia.org/resource/Types_of_cancer"}, {"text": "Chemotherapy", "relevance": 0.511265, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.439658, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "T-cell lymphoma", "relevance": 0.437908, "dbpedia_resource": "http://dbpedia.org/resource/T-cell_lymphoma"}, {"text": "Blood disorders", "relevance": 0.421071, "dbpedia_resource": "http://dbpedia.org/resource/Blood_disorders"}, {"text": "B-cell lymphoma", "relevance": 0.387386, "dbpedia_resource": "http://dbpedia.org/resource/B-cell_lymphoma"}, {"text": "Stock", "relevance": 0.380455, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Doxorubicin", "relevance": 0.36105, "dbpedia_resource": "http://dbpedia.org/resource/Doxorubicin"}, {"text": "Thomas Hodgkin", "relevance": 0.347878, "dbpedia_resource": "http://dbpedia.org/resource/Thomas_Hodgkin"}, {"text": "United States", "relevance": 0.346395, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Hematopoietic stem cell transplantation", "relevance": 0.335445, "dbpedia_resource": "http://dbpedia.org/resource/Hematopoietic_stem_cell_transplantation"}], "categories": [{"score": 0.975533, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.946414, "label": "/health and fitness/therapy"}, {"score": 0.581733, "label": "/health and fitness/disorders"}], "relations": [{"type": "agentOf", "sentence": "Shutterstock photo Seattle Genetics, Inc. SGEN announced that the FDA has granted Breakthrough Therapy designation to Adcetrisfor the frontline treatment of certain lymphoma subtypes.", "score": 0.973353, "arguments": [{"text": "Inc. SGEN", "location": [37, 46], "entities": [{"type": "Organization", "text": "Inc. SGEN", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [47, 56], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "score": 0.495082, "arguments": [{"text": "Adcetris", "location": [2478, 2486], "entities": [{"type": "Person", "text": "Adcetris"}]}, {"text": "United States", "location": [2494, 2507], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Seattle Genetics retains all rights to sell Adcetris in the United States and Canada, while Takeda has commercial rights to the drug in the rest of the world.", "score": 0.60372, "arguments": [{"text": "drug", "location": [2562, 2566], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "world", "location": [2586, 2591], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "However, the drug has several competitors, including 's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.65007, "arguments": [{"text": "Merck", "location": [2664, 2669], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [2623, 2634], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "However, the drug has several competitors, including 's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.655075, "arguments": [{"text": "MRK Keytruda", "location": [2672, 2684], "entities": [{"type": "Organization", "text": "MRK Keytruda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [2623, 2634], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "However, the drug has several competitors, including 's BMY Opdivo and Merck's MRK Keytruda, which are approved for relapsed or refractory cHL.", "score": 0.679787, "arguments": [{"text": "MRK Keytruda", "location": [2672, 2684], "entities": [{"type": "Organization", "text": "MRK Keytruda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merck", "location": [2664, 2669], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "A better-ranked stock worth considering is Eli Lilly and Company LLY , carrying a Zacks Rank #2 (Buy).", "score": 0.524749, "arguments": [{"text": "Zacks Rank #2", "location": [2999, 3012], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "Buy", "location": [3014, 3017], "entities": [{"type": "Organization", "text": "Strong Buy", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Lilly's earnings per share estimates have increased from $5.42 to $5.54 for 2018 and from $5.65 to $5.80 for 2019 over the past 60 days.", "score": 0.569526, "arguments": [{"text": "Lilly", "location": [3102, 3107], "entities": [{"type": "Organization", "text": "Lilly", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$5.42", "location": [3159, 3164], "entities": [{"type": "Money", "text": "$5.42"}]}]}, {"type": "hasAttribute", "sentence": "Lilly's earnings per share estimates have increased from $5.42 to $5.54 for 2018 and from $5.65 to $5.80 for 2019 over the past 60 days.", "score": 0.644751, "arguments": [{"text": "Lilly", "location": [3102, 3107], "entities": [{"type": "Organization", "text": "Lilly", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$5.54", "location": [3168, 3173], "entities": [{"type": "Money", "text": "$5.54"}]}]}, {"type": "partOfMany", "sentence": "Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks.", "score": 0.647365, "arguments": [{"text": "Zacks", "location": [3491, 3496], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "us", "location": [3485, 3487], "entities": [{"type": "Person", "text": "us"}]}]}, {"type": "employedBy", "sentence": "See Them Free>> Want the latest recommendations from Zacks Investment Research?", "score": 0.50589, "arguments": [{"text": "See Them Free>>", "location": [3985, 4000], "entities": [{"type": "Person", "text": "See Them Free>>"}]}, {"text": "Zacks Investment Research", "location": [4038, 4063], "entities": [{"type": "Organization", "text": "Zacks Investment Research", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The designation is granted to treat patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).", "score": 0.968879, "arguments": [{"text": "CD30", "location": [304, 308], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "expressing", "location": [309, 319], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "awardedTo", "sentence": "Today, you can download 7 Best Stocks for the Next 30 Days.", "score": 0.909052, "arguments": [{"text": "Best Stocks", "location": [4091, 4102], "entities": [{"type": "EntertainmentAward", "text": "Best Stocks"}]}, {"text": "you", "location": [4072, 4075], "entities": [{"type": "Person", "text": "you"}]}]}, {"type": "agentOf", "sentence": "Click to get this free report  Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here.", "score": 0.568488, "arguments": [{"text": "SGEN", "location": [4330, 4334], "entities": [{"type": "Organization", "text": "Seattle Genetics, Inc. Price\nSeattle Genetics, Inc. Price", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [4357, 4363], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Click to get this free report  Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here.", "score": 0.766168, "arguments": [{"text": "Zacks.com", "location": [4388, 4397], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "Report", "location": [4357, 4363], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Seattle Genetics along with Takeda announced that the phase III ECHELON-2 study on Adcetris has met its primary endpoint as well as all key secondary endpoints.", "score": 0.937162, "arguments": [{"text": "Takeda", "location": [878, 884], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "announced", "location": [885, 894], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "The study also achieved all key secondary endpoints and improved the overall survival in front-line CD30-expressing peripheral T-cell lymphoma (PTCL).", "score": 0.520951, "arguments": [{"text": "CD30", "location": [1261, 1265], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "expressing", "location": [1266, 1276], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "employedBy", "sentence": "Adcetris is the only marketed product of Seattle Genetics.", "score": 0.601607, "arguments": [{"text": "Adcetris", "location": [1485, 1493], "entities": [{"type": "Person", "text": "Adcetris"}]}, {"text": "Seattle Genetics", "location": [1526, 1542], "entities": [{"type": "Organization", "text": "Seattle Genetics, Inc. Price\nSeattle Genetics, Inc. Price", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, EU and Japan.", "score": 0.438182, "arguments": [{"text": "lymphoma", "location": [1639, 1647], "entities": [{"type": "Person", "text": "lymphoma subtypes"}]}, {"text": "United States", "location": [1663, 1676], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "It is also approved for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States.", "score": 0.658092, "arguments": [{"text": "CD30", "location": [2240, 2244], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "lymphoma", "location": [2218, 2226], "entities": [{"type": "Person", "text": "lymphoma subtypes"}]}]}, {"type": "agentOf", "sentence": "It is also approved for primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) in the United States.", "score": 0.875053, "arguments": [{"text": "CD30", "location": [2240, 2244], "entities": [{"type": "Person", "text": "CD30"}]}, {"text": "expressing", "location": [2245, 2255], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "employedBy", "sentence": "Seattle Genetics has an agreement with Takeda Pharmaceutical Company Ltd. for further development and commercialization of Adcetris.", "score": 0.77111, "arguments": [{"text": "Takeda Pharmaceutical", "location": [2340, 2361], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "Company Ltd.", "location": [2362, 2374], "entities": [{"type": "Organization", "text": "Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Seattle Genetics", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.889399, "count": 6}, {"text": "Seattle Genetics' shares", "sentiment": {"score": -0.890144, "label": "negative"}, "relevance": 0.725732, "count": 1}, {"text": "Inc. SGEN", "sentiment": {"score": 0.866417, "label": "positive"}, "relevance": 0.660291, "count": 1}, {"text": "product of Seattle Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.654898, "count": 1}, {"text": "Breakthrough Therapy designation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.617079, "count": 2}, {"text": "phase III ECHELON-2 study", "sentiment": {"score": 0.630847, "label": "positive"}, "relevance": 0.610891, "count": 2}, {"text": "Inc. Price", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.597998, "count": 1}, {"text": "Adcetris", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.586254, "count": 4}, {"text": "frontline treatment of certain lymphoma subtypes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583066, "count": 1}, {"text": "United States", "sentiment": {"score": -0.734681, "label": "negative"}, "relevance": 0.581011, "count": 4}, {"text": "systemic anaplastic large cell lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576187, "count": 2}, {"text": "review of drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569516, "count": 1}, {"text": "market", "sentiment": {"score": 0.896403, "label": "positive"}, "relevance": 0.556936, "count": 2}, {"text": "FDA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55658, "count": 1}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554781, "count": 1}, {"text": "drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553116, "count": 4}, {"text": "peripheral T-cell lymphomas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546293, "count": 1}, {"text": "progression-free survival", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.543258, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542269, "count": 2}, {"text": "Hodgkin lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541637, "count": 1}, {"text": "Merck's MRK Keytruda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539732, "count": 1}, {"text": "commercial rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538928, "count": 1}, {"text": "designation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536617, "count": 1}, {"text": "complete list of today", "sentiment": {"score": -0.246317, "label": "negative"}, "relevance": 0.533631, "count": 1}, {"text": "Stock", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.532845, "count": 1}, {"text": "stock", "sentiment": {"score": 0.717051, "label": "positive"}, "relevance": 0.532845, "count": 1}, {"text": "FDA's decision", "sentiment": {"score": 0.630847, "label": "positive"}, "relevance": 0.529768, "count": 1}, {"text": "development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529148, "count": 1}, {"text": "commercialization of Adcetris", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528825, "count": 1}, {"text": "rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527949, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527655, "count": 1}, {"text": "study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526258, "count": 1}, {"text": "Inc. Quote", "sentiment": {"score": 0.324864, "label": "positive"}, "relevance": 0.5252, "count": 1}, {"text": "results", "sentiment": {"score": 0.630847, "label": "positive"}, "relevance": 0.524187, "count": 2}, {"text": "Eli Lilly", "sentiment": {"score": 0.717051, "label": "positive"}, "relevance": 0.52268, "count": 1}, {"text": "overall survival", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522472, "count": 1}, {"text": "stocks", "sentiment": {"score": -0.753246, "label": "negative"}, "relevance": 0.521914, "count": 1}, {"text": "Zacks Rank", "sentiment": {"score": 0.435402, "mixed": "1", "label": "positive"}, "relevance": 0.521238, "count": 3}, {"text": "competitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521107, "count": 1}, {"text": "significant improvement", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.521033, "count": 1}, {"text": "BMY Opdivo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520369, "count": 1}, {"text": "Canada", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518817, "count": 1}, {"text": "Today", "sentiment": {"score": 0.758467, "label": "positive"}, "relevance": 0.518527, "count": 1}, {"text": "patients", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518217, "count": 2}, {"text": "chemotherapy", "sentiment": {"score": 0.833832, "label": "positive"}, "relevance": 0.518093, "count": 2}, {"text": "combination", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516956, "count": 2}, {"text": "Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516604, "count": 1}, {"text": "further development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515488, "count": 1}, {"text": "strategies", "sentiment": {"score": -0.591693, "label": "negative"}, "relevance": 0.515304, "count": 1}, {"text": "cHL", "sentiment": {"score": -0.734681, "label": "negative"}, "relevance": 0.514804, "count": 2}]}, "extracted_metadata": {"sha1": "d19d4660ae4c6939025ddb62df723ce94f1cd593", "filename": "1542401641620.zip-b4353b851294cbe40ec8dd6f39fecd86.xml", "file_type": "json"}, "external_links": ["http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=MRK&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=SGEN&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "https://www.zacks.com/stocks/industry-rank/industry/medical-biomedical-and-genetics-105", "https://www.zacks.com/stock/chart/SGEN/fundamental/price", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=BMY&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link", "https://www.zacks.com/registration/rw/welcome/eoffer/38a7?site=ZCOM_RW_ANALYSTBLOG_IND_HOTSTRAT_111618&icid=EOAC-ANALYSTBLOG-tx-RW111618", "http://www.zacks.com/", "https://www.zacks.com/stock/quote/SGEN", "http://www.zacks.com/stock/news/337948/seattle-genetics-adcetris-gets-breakthrough-therapy-status?cid=CS-NASDAQ-FT-337948", "http://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948", "http://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=LLY&ADID=NASDAQ_CONTENT_ZER_ARTCAT_ANALYST_BLOG_256&cid=CS-NASDAQ-FT-337948"], "title": "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "forum_title": "Bristol-Myers Squibb Company (BMY) Stock Report \u2013 NASDAQ.com - NASDAQ.com"}, {"id": "FiIiM-QKD_YFCqLqn3pSKLOcdva_QPOsXwAOmyUnbm7VZrFAwDj37Md6Os1cr2CS", "result_metadata": {"score": 31.341532}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brentuximab Vedotin", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PTCL", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frontline", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.594956, "label": "/technology and computing/internet technology/isps"}, {"score": 0.577176, "label": "/health and fitness/drugs"}, {"score": 0.538838, "label": "/technology and computing/internet technology/internet cafes"}], "relations": [{"type": "partOf", "sentence": "FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL", "score": 0.985426, "arguments": [{"text": "CD30+ PTCL", "location": [47, 57], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}, {"text": "Frontline", "location": [37, 46], "entities": [{"type": "Organization", "text": "Frontline"}]}]}], "keywords": [{"text": "Brentuximab Vedotin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.994203, "count": 1}, {"text": "FDA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.989818, "count": 1}, {"text": "Frontline CD30", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509493, "count": 1}, {"text": "PTCL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.060572, "count": 1}]}, "crawl_date": "2018-11-16T19:33:44Z", "url": "https://www.onclive.com/web-exclusives/fda-approves-brentuximab-vedotin-for-frontline-cd30-ptcl", "host": "onclive.com", "text": "Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin, will be presenting additional ECHELON-2 findings at the 2018 ASH Annual Meeting.", "main_image_url": "https://onclive.s3.amazonaws.com/_media/_upload_image/FDA-logo-thumb.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T16:18:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brentuximab Vedotin", "relevance": 0.904096, "type": "Person"}, {"count": 7, "sentiment": {"score": 0.423782, "label": "positive"}, "text": "FDA", "relevance": 0.709069, "type": "Organization"}, {"count": 2, "sentiment": {"score": -0.605534, "label": "negative"}, "text": "peripheral T-cell lymphoma", "relevance": 0.678383, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Peripheral T-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_T-cell_lymphoma"}}, {"count": 4, "sentiment": {"score": -0.396195, "label": "negative"}, "text": "classical Hodgkin lymphoma", "relevance": 0.667227, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "large cell lymphoma", "relevance": 0.560639, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"count": 3, "sentiment": {"score": -0.356972, "label": "negative"}, "text": "PTCL", "relevance": 0.519287, "type": "Company", "disambiguation": {"subtype": [], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"count": 6, "sentiment": {"score": -0.433346, "label": "negative"}, "text": "ABVD", "relevance": 0.508331, "type": "Drug"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "doxorubicin", "relevance": 0.484755, "type": "Drug"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "dacarbazine", "relevance": 0.45725, "type": "Drug"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "vinblastine", "relevance": 0.453609, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Steven Horwitz", "relevance": 0.420586, "type": "Person", "disambiguation": {"subtype": ["Academic"], "name": "Steven Horwitz", "dbpedia_resource": "http://dbpedia.org/resource/Steven_Horwitz"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seattle", "relevance": 0.416133, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "MD", "relevance": 0.39912, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "AirportOperator", "StateOrCounty"], "name": "Maryland", "dbpedia_resource": "http://dbpedia.org/resource/Maryland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "progressive multifocal leukoencephalopathy", "relevance": 0.39165, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Progressive multifocal leukoencephalopathy", "dbpedia_resource": "http://dbpedia.org/resource/Progressive_multifocal_leukoencephalopathy"}}, {"count": 2, "sentiment": {"score": 0.460068, "label": "positive"}, "text": "RTOR", "relevance": 0.388597, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frontline", "relevance": 0.379397, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Richard Pazdur", "relevance": 0.370286, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "bleomycin", "relevance": 0.357716, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.356486, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.390889, "label": "negative"}, "text": "febrile neutropenia", "relevance": 0.353604, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Febrile neutropenia", "dbpedia_resource": "http://dbpedia.org/resource/Febrile_neutropenia"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "cyclophosphamide", "relevance": 0.352696, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lymphoma Service", "relevance": 0.34352, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "prednisone", "relevance": 0.334363, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.459629, "label": "negative"}, "text": "peripheral neuropathy", "relevance": 0.33265, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Peripheral neuropathy", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_neuropathy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jason M. Broderick", "relevance": 0.322771, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "independent review", "relevance": 0.320927, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": -0.433346, "label": "negative"}, "text": "Hodgkin", "relevance": 0.310572, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.280607, "label": "negative"}, "text": "Memorial Sloan Kettering Cancer Center", "relevance": 0.308934, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "independent review committee", "relevance": 0.307563, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Breakthrough Therapy Designation", "relevance": 0.302264, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.563563, "label": "negative"}, "text": "vomiting", "relevance": 0.299619, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "Symptom"], "name": "Vomiting", "dbpedia_resource": "http://dbpedia.org/resource/Vomiting"}}, {"count": 1, "sentiment": {"score": -0.270491, "label": "negative"}, "text": "mucositis", "relevance": 0.299584, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Mucositis", "dbpedia_resource": "http://dbpedia.org/resource/Mucositis"}}, {"count": 1, "sentiment": {"score": 0.365487, "label": "positive"}, "text": "Atlanta", "relevance": 0.292923, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AVBD", "relevance": 0.284563, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Connors J", "relevance": 0.284294, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "vincristine", "relevance": 0.281411, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0.387495, "label": "positive"}, "text": "director", "relevance": 0.277387, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "official", "relevance": 0.271084, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.387495, "label": "positive"}, "text": "Office of Hematology and Oncology Products", "relevance": 0.26917, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.387495, "label": "positive"}, "text": "acting director", "relevance": 0.268365, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.387495, "label": "positive"}, "text": "Oncology Center of Excellence", "relevance": 0.267422, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Department of Medicine", "relevance": 0.265294, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Straus", "relevance": 0.253613, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.297296, "label": "positive"}, "text": "Jurczak W", "relevance": 0.241778, "type": "Person"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "95%", "relevance": 0.241778, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "2-year", "relevance": 0.241778, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "82.1%", "relevance": 0.241778, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@jasoncology", "relevance": 0.241778, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "24.9 months", "relevance": 0.241778, "type": "Quantity"}], "sentiment": {"document": {"score": -0.449096, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "1 Key secondary endpoints", "keywords": [{"text": "Key secondary endpoints"}]}, "sentence": " 1 Key secondary endpoints also demonstrated superiority with the brentuximab vedotin combination, including objective response rate (83% vs 72%; P = .003), complete remission rate (CR; 68% vs 56%; P = .007), and progression-free survival (PFS) in patients with systemic anaplastic large cell lymphoma (sALCL; HR = 0.59; 95% CI, 0.42-0.84; P = .003).No new safety signals emerged with brentuximab vedotin.", "object": {"text": "superiority", "keywords": [{"text": "superiority"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "also demonstrated", "normalized": "also demonstrate"}}, {"subject": {"text": "objective response rate (83% vs 72%; P = .003), complete remission rate (CR; 68% vs 56%; P = .007), and progression-free survival (PFS) in patients with systemic anaplastic large cell lymphoma (sALCL; HR = 0.59; 95% CI, 0.42-0.84; P = .003).No new safety signals", "keywords": [{"text": "complete remission rate"}, {"text": "objective response rate"}, {"text": "anaplastic large cell"}, {"text": "new safety signals"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"type": "Quantity", "text": "56"}, {"type": "Quantity", "text": "68"}, {"type": "Quantity", "text": "72"}, {"type": "Quantity", "text": "83"}, {"type": "Quantity", "text": "95"}]}, "sentence": " 1 Key secondary endpoints also demonstrated superiority with the brentuximab vedotin combination, including objective response rate (83% vs 72%; P = .003), complete remission rate (CR; 68% vs 56%; P = .007), and progression-free survival (PFS) in patients with systemic anaplastic large cell lymphoma (sALCL; HR = 0.59; 95% CI, 0.42-0.84; P = .003).No new safety signals emerged with brentuximab vedotin.", "object": {"text": "the brentuximab vedotin combination", "keywords": [{"text": "brentuximab vedotin combination"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "P = .003).No new safety signals", "keywords": [{"text": "new safety signals"}]}, "sentence": " 1 Key secondary endpoints also demonstrated superiority with the brentuximab vedotin combination, including objective response rate (83% vs 72%; P = .003), complete remission rate (CR; 68% vs 56%; P = .007), and progression-free survival (PFS) in patients with systemic anaplastic large cell lymphoma (sALCL; HR = 0.59; 95% CI, 0.42-0.84; P = .003).No new safety signals emerged with brentuximab vedotin.", "object": {"text": "with brentuximab vedotin", "keywords": [{"text": "brentuximab vedotin"}], "entities": [{"type": "Person", "text": "Brentuximab Vedotin"}]}, "action": {"verb": {"text": "emerge", "tense": "past"}, "text": "emerged", "normalized": "emerge"}}, {"subject": {"text": "a Boxed Warning regarding the risk of progressive multifocal leukoencephalopathy", "keywords": [{"text": "progressive multifocal leukoencephalopathy"}, {"text": "Boxed Warning"}, {"text": "risk"}], "entities": [{"type": "HealthCondition", "text": "progressive multifocal leukoencephalopathy", "disambiguation": {"subtype": ["Disease"], "name": "Progressive multifocal leukoencephalopathy", "dbpedia_resource": "http://dbpedia.org/resource/Progressive_multifocal_leukoencephalopathy"}}]}, "sentence": " The label for the antibody-drug conjugate does include a Boxed Warning regarding the risk of progressive multifocal leukoencephalopathy.", "object": {"text": "The label for the antibody-drug conjugate", "keywords": [{"text": "antibody-drug conjugate"}, {"text": "label"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "does include", "normalized": "do include"}}, {"subject": {"text": "a Boxed Warning", "keywords": [{"text": "Boxed Warning"}]}, "sentence": " The label for the antibody-drug conjugate does include a Boxed Warning regarding the risk of progressive multifocal leukoencephalopathy.", "object": {"text": "the risk of progressive multifocal leukoencephalopathy", "keywords": [{"text": "progressive multifocal leukoencephalopathy"}, {"text": "risk"}], "entities": [{"type": "HealthCondition", "text": "progressive multifocal leukoencephalopathy", "disambiguation": {"subtype": ["Disease"], "name": "Progressive multifocal leukoencephalopathy", "dbpedia_resource": "http://dbpedia.org/resource/Progressive_multifocal_leukoencephalopathy"}}]}, "action": {"verb": {"text": "regard", "tense": "present"}, "text": "regarding", "normalized": "regard"}}, {"subject": {"text": "Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin,", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "co-developers"}, {"text": "Seattle Genetics"}, {"text": "brentuximab vedotin"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin, will be presenting additional ECHELON-2 findings at the 2018 ASH Annual Meeting.", "object": {"text": "presenting additional ECHELON-2 findings", "keywords": [{"text": "findings"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin,", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "co-developers"}, {"text": "Seattle Genetics"}, {"text": "brentuximab vedotin"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin, will be presenting additional ECHELON-2 findings at the 2018 ASH Annual Meeting.", "object": {"text": "additional ECHELON-2 findings", "keywords": [{"text": "findings"}]}, "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presenting", "normalized": "will be present"}}, {"subject": {"text": "The current standard of care for initial treatment of peripheral T-cell lymphoma", "keywords": [{"text": "peripheral T-cell lymphoma"}, {"text": "initial treatment"}, {"text": "current standard"}, {"text": "care"}], "entities": [{"type": "HealthCondition", "text": "peripheral T-cell lymphoma", "disambiguation": {"subtype": [], "name": "Peripheral T-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_T-cell_lymphoma"}}]}, "sentence": " \u201cThe current standard of care for initial treatment of peripheral T-cell lymphoma is multi-agent chemotherapy.", "object": {"text": "multi-agent chemotherapy", "keywords": [{"text": "multi-agent chemotherapy"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "That treatment", "keywords": [{"text": "treatment"}]}, "sentence": " That treatment has not significantly changed in decades and is too often unsuccessful in leading to long-term remissions, underscoring the need for new treatments,\u201d Steven Horwitz, MD, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, said in a statement.\u201cThe ECHELON-2 clinical trial demonstrated Adcetris plus CHP was superior to the current standard of care, CHOP, for both progression-free survival and all other key secondary endpoints, including, most importantly, overall survival.", "object": {"text": "not significantly changed in decades", "keywords": [{"text": "decades"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "That treatment", "keywords": [{"text": "treatment"}]}, "sentence": " That treatment has not significantly changed in decades and is too often unsuccessful in leading to long-term remissions, underscoring the need for new treatments,\u201d Steven Horwitz, MD, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, said in a statement.\u201cThe ECHELON-2 clinical trial demonstrated Adcetris plus CHP was superior to the current standard of care, CHOP, for both progression-free survival and all other key secondary endpoints, including, most importantly, overall survival.", "action": {"verb": {"text": "change", "tense": "past", "negated": true}, "text": "changed", "normalized": "change"}}, {"subject": {"text": "The ECHELON-2 clinical trial", "keywords": [{"text": "ECHELON-2 clinical trial"}]}, "sentence": " That treatment has not significantly changed in decades and is too often unsuccessful in leading to long-term remissions, underscoring the need for new treatments,\u201d Steven Horwitz, MD, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, said in a statement.\u201cThe ECHELON-2 clinical trial demonstrated Adcetris plus CHP was superior to the current standard of care, CHOP, for both progression-free survival and all other key secondary endpoints, including, most importantly, overall survival.", "object": {"text": "Adcetris plus CHP", "keywords": [{"text": "CHP"}, {"text": "Adcetris"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "overall survival", "keywords": [{"text": "overall survival"}]}, "sentence": " That treatment has not significantly changed in decades and is too often unsuccessful in leading to long-term remissions, underscoring the need for new treatments,\u201d Steven Horwitz, MD, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, said in a statement.\u201cThe ECHELON-2 clinical trial demonstrated Adcetris plus CHP was superior to the current standard of care, CHOP, for both progression-free survival and all other key secondary endpoints, including, most importantly, overall survival.", "object": {"text": "both progression-free survival and all other key secondary endpoints", "keywords": [{"text": "key secondary endpoints"}, {"text": "progression-free survival"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "clinicians", "keywords": [{"text": "clinicians"}]}, "sentence": " With this approval, clinicians have the opportunity to transform the way newly diagnosed CD30-expressing PTCL patients are treated,\u201d added Horwitz.", "object": {"text": "the opportunity to transform the way newly diagnosed CD30-expressing PTCL patients are treated", "keywords": [{"text": "CD30-expressing PTCL patients"}, {"text": "opportunity"}, {"text": "way"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "clinicians", "keywords": [{"text": "clinicians"}]}, "sentence": " With this approval, clinicians have the opportunity to transform the way newly diagnosed CD30-expressing PTCL patients are treated,\u201d added Horwitz.", "object": {"text": "the way", "keywords": [{"text": "way"}]}, "action": {"verb": {"text": "transform", "tense": "future"}, "text": "to transform", "normalized": "to transform"}}, {"subject": {"text": "the FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In a statement, the FDA noted that a new review program had acclerated the pace of the approval, which occurred less than 2 weeks from the date that the complete application was submitted.", "object": {"text": "that a new review program had acclerated the pace of the approval, which occurred less than 2 weeks from the date that the complete application was submitted", "keywords": [{"text": "new review program"}, {"text": "complete application"}, {"text": "approval"}, {"text": "pace"}], "entities": [{"type": "Quantity", "text": "2 weeks"}]}, "action": {"verb": {"text": "note", "tense": "past"}, "text": "noted", "normalized": "note"}}, {"subject": {"text": "the approval", "keywords": [{"text": "approval"}]}, "sentence": " In a statement, the FDA noted that a new review program had acclerated the pace of the approval, which occurred less than 2 weeks from the date that the complete application was submitted.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "RTOR", "entities": [{"type": "Organization", "text": "RTOR"}]}, "sentence": " RTOR allowed the FDA to approve this indication within two weeks of the completed application\u2019s submission,\u201d added Pazdur.", "object": {"text": "the FDA to approve this indication within two weeks of the completed application\u2019s submission", "keywords": [{"text": "indication"}, {"text": "FDA"}, {"text": "application"}, {"text": "submission"}], "entities": [{"type": "Organization", "text": "FDA"}, {"type": "Quantity", "text": "two weeks"}]}, "action": {"verb": {"text": "allow", "tense": "past"}, "text": "allowed", "normalized": "allow"}}, {"subject": {"text": "RTOR", "entities": [{"type": "Organization", "text": "RTOR"}]}, "sentence": " RTOR allowed the FDA to approve this indication within two weeks of the completed application\u2019s submission,\u201d added Pazdur.", "object": {"text": "the FDA to approve this indication within two weeks of the completed application\u2019s submission", "keywords": [{"text": "indication"}, {"text": "FDA"}, {"text": "application"}, {"text": "submission"}], "entities": [{"type": "Organization", "text": "FDA"}, {"type": "Quantity", "text": "two weeks"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "added", "normalized": "add"}}, {"subject": {"text": "PFS per independent review", "keywords": [{"text": "PFS"}, {"text": "independent review"}], "entities": [{"type": "PrintMedia", "text": "independent review"}]}, "sentence": " PFS per independent review was the primary endpoint, with secondary endpoints including overall survival, PFS in patients with sALCL; approximately 75% of the overall population), objective response rate, CR rate, and safety.", "object": {"text": "the primary endpoint", "keywords": [{"text": "primary endpoint"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "overall survival, PFS in patients with sALCL; approximately 75% of the overall population), objective response rate, CR rate, and safety", "keywords": [{"text": "objective response rate"}, {"text": "overall survival"}, {"text": "CR rate"}, {"text": "overall population"}], "entities": [{"type": "Quantity", "text": "75"}]}, "sentence": " PFS per independent review was the primary endpoint, with secondary endpoints including overall survival, PFS in patients with sALCL; approximately 75% of the overall population), objective response rate, CR rate, and safety.", "object": {"text": "secondary endpoints", "keywords": [{"text": "secondary endpoints"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "\u226520% of patients", "keywords": [{"text": "patients"}], "entities": [{"type": "Quantity", "text": "20"}]}, "sentence": " According to Seattle Genetics, adverse events (AEs) across all grades reported in \u226520% of patients receiving the brentuximab vedotin combination were peripheral neuropathy, nausea, diarrhea, neutropenia, lymphopenia, fatigue, mucositis, constipation, alopecia, pyrexia, vomiting, and anemia.", "object": {"text": "the brentuximab vedotin combination", "keywords": [{"text": "brentuximab vedotin combination"}]}, "action": {"verb": {"text": "receive", "tense": "present"}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "the brentuximab vedotin combination", "keywords": [{"text": "brentuximab vedotin combination"}]}, "sentence": " According to Seattle Genetics, adverse events (AEs) across all grades reported in \u226520% of patients receiving the brentuximab vedotin combination were peripheral neuropathy, nausea, diarrhea, neutropenia, lymphopenia, fatigue, mucositis, constipation, alopecia, pyrexia, vomiting, and anemia.", "object": {"text": "peripheral neuropathy", "keywords": [{"text": "peripheral neuropathy"}], "entities": [{"type": "HealthCondition", "text": "peripheral neuropathy", "disambiguation": {"subtype": ["Disease"], "name": "Peripheral neuropathy", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_neuropathy"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Serious AEs", "keywords": [{"text": "AEs"}]}, "sentence": " Serious AEs occurring in \u22652% of patients in the brentuximab vedotin arm were febrile neutropenia, pneumonia, pyrexia, and sepsis.", "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurring", "normalized": "occur"}}, {"subject": {"text": "Serious AEs occurring in \u22652% of patients in the brentuximab vedotin arm", "keywords": [{"text": "brentuximab vedotin arm"}, {"text": "AEs"}, {"text": "patients"}], "entities": [{"type": "Quantity", "text": "2"}]}, "sentence": " Serious AEs occurring in \u22652% of patients in the brentuximab vedotin arm were febrile neutropenia, pneumonia, pyrexia, and sepsis.", "object": {"text": "febrile neutropenia, pneumonia, pyrexia, and sepsis", "keywords": [{"text": "febrile neutropenia"}, {"text": "sepsis"}, {"text": "pneumonia"}, {"text": "pyrexia"}], "entities": [{"type": "HealthCondition", "text": "febrile neutropenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Febrile neutropenia", "dbpedia_resource": "http://dbpedia.org/resource/Febrile_neutropenia"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "the investigators", "keywords": [{"text": "investigators"}]}, "sentence": " Based on the study results, the investigators recommend that patients with PTCL being treated with frontline brentuximab vedotin plus CHP should receive G-CSF beginning at cycle 1.", "object": {"text": "that patients with PTCL being treated with frontline brentuximab vedotin plus CHP should receive G-CSF beginning at cycle 1", "keywords": [{"text": "frontline brentuximab vedotin"}, {"text": "CHP"}, {"text": "patients"}, {"text": "PTCL"}], "entities": [{"type": "Company", "text": "PTCL", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}]}, "action": {"verb": {"text": "recommend", "tense": "present"}, "text": "recommend", "normalized": "recommend"}}, {"subject": {"text": "the phase III ECHELON-1 trial", "keywords": [{"text": "phase III ECHELON-1"}, {"text": "trial"}]}, "sentence": " In March brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma based on findings from the phase III ECHELON-1 trial, which demonstrated superior PFS with brentuximab vedotin plus Adriamycin, vinblastine, and dacarbazine (AVD) compared with standard ABVD (AVD plus bleomycin).", "object": {"text": "superior PFS", "keywords": [{"text": "superior PFS"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "brentuximab vedotin plus Adriamycin, vinblastine, and dacarbazine (AVD)", "keywords": [{"text": "dacarbazine"}, {"text": "brentuximab vedotin"}, {"text": "AVD"}, {"text": "Adriamycin"}], "entities": [{"type": "Drug", "text": "vinblastine"}, {"type": "Drug", "text": "dacarbazine"}]}, "sentence": " In March brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma based on findings from the phase III ECHELON-1 trial, which demonstrated superior PFS with brentuximab vedotin plus Adriamycin, vinblastine, and dacarbazine (AVD) compared with standard ABVD (AVD plus bleomycin).", "object": {"text": "with standard ABVD (AVD plus bleomycin", "keywords": [{"text": "bleomycin"}], "entities": [{"type": "Drug", "text": "ABVD"}, {"type": "Drug", "text": "bleomycin"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "the brentuximab vedotin regimen", "keywords": [{"text": "brentuximab vedotin regimen"}]}, "sentence": " In the study, the brentuximab vedotin regimen reduced the risk of progression, death, or initiation of new therapy by 23% compared with ABVD.", "object": {"text": "the risk of progression, death, or initiation of new therapy by 23%", "keywords": [{"text": "new therapy"}, {"text": "progression"}, {"text": "initiation"}, {"text": "risk"}], "entities": [{"type": "Quantity", "text": "23"}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "new therapy by 23%", "keywords": [{"text": "new therapy"}], "entities": [{"type": "Quantity", "text": "23"}]}, "sentence": " In the study, the brentuximab vedotin regimen reduced the risk of progression, death, or initiation of new therapy by 23% compared with ABVD.", "object": {"text": "with ABVD", "keywords": [{"text": "ABVD"}], "entities": [{"type": "Drug", "text": "ABVD"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "The 2-year modified PFS rate", "keywords": [{"text": "2-year modified PFS"}, {"text": "rate"}], "entities": [{"type": "Quantity", "text": "2-year"}]}, "sentence": " The 2-year modified PFS rate was 82.1% with brentuximab vedotin compared with 77.25% for standard chemotherapy (HR, 0.77; 95% CI, 0.60-0.98; P = .035). 2 The phase III ECHELON-1 trial enrolled 1334 patients with stage III/IV classical Hodgkin lymphoma.", "object": {"text": "82.1% with brentuximab vedotin compared with 77.25% for standard chemotherapy", "keywords": [{"text": "standard chemotherapy"}, {"text": "brentuximab vedotin"}], "entities": [{"type": "Person", "text": "brentuximab vedotin"}, {"type": "Quantity", "text": "77.25"}, {"type": "Quantity", "text": "82.1"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "All patients", "keywords": [{"text": "patients"}]}, "sentence": " All patients had not received prior treatment with systemic chemotherapy or radiotherapy and had an ECOG performance status of \u22642.", "object": {"text": "not received prior treatment with systemic chemotherapy or radiotherapy", "keywords": [{"text": "systemic chemotherapy"}, {"text": "prior treatment"}, {"text": "radiotherapy"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "All patients", "keywords": [{"text": "patients"}]}, "sentence": " All patients had not received prior treatment with systemic chemotherapy or radiotherapy and had an ECOG performance status of \u22642.", "action": {"verb": {"text": "receive", "tense": "past", "negated": true}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Patients", "keywords": [{"text": "Patients"}]}, "sentence": " Patients ranged in age from 18 to 83, the median age was 36 years, and 58% were men.", "object": {"text": "in age", "keywords": [{"text": "age"}]}, "action": {"verb": {"text": "range", "tense": "past"}, "text": "ranged", "normalized": "range"}}, {"subject": {"text": "the median age", "keywords": [{"text": "median age"}]}, "sentence": " Patients ranged in age from 18 to 83, the median age was 36 years, and 58% were men.", "object": {"text": "36 years", "entities": [{"type": "Quantity", "text": "36 years"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "58%", "entities": [{"type": "Quantity", "text": "58"}]}, "sentence": " Patients ranged in age from 18 to 83, the median age was 36 years, and 58% were men.", "object": {"text": "men", "keywords": [{"text": "men"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "treatment", "keywords": [{"text": "treatment"}]}, "sentence": " In both arms, treatment was given on days 1 and 15 of a 28-day cycle.", "action": {"verb": {"text": "give", "tense": "past"}, "text": "was given", "normalized": "be give"}}, {"subject": {"text": "Doxorubicin", "keywords": [{"text": "Doxorubicin"}], "entities": [{"type": "Drug", "text": "doxorubicin"}]}, "sentence": " Doxorubicin was given at 25 mg/m 2 , vinblastine was administered at 6 mg/m 2 , and patients received dacarbazine at 375 mg/m 2 .", "object": {"text": "at 25 mg/m 2", "keywords": [{"text": "mg/m"}], "entities": [{"type": "Quantity", "text": "25 mg"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "was given", "normalized": "be give"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " Doxorubicin was given at 25 mg/m 2 , vinblastine was administered at 6 mg/m 2 , and patients received dacarbazine at 375 mg/m 2 .", "object": {"text": "dacarbazine", "keywords": [{"text": "dacarbazine"}], "entities": [{"type": "Drug", "text": "dacarbazine"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "brentuximab vedotin", "keywords": [{"text": "brentuximab vedotin"}], "entities": [{"type": "Person", "text": "brentuximab vedotin"}]}, "sentence": " In the investigational arm, brentuximab vedotin was administered at 1.2 mg/kg and in the control group bleomycin was administered at 10 units/m 2 .", "action": {"verb": {"text": "administer", "tense": "past"}, "text": "was administered", "normalized": "be administer"}}, {"subject": {"text": "1.2 mg/kg and in the control group bleomycin", "keywords": [{"text": "control group bleomycin"}, {"text": "mg/kg"}], "entities": [{"type": "Drug", "text": "bleomycin"}, {"type": "Quantity", "text": "1.2 mg"}]}, "sentence": " In the investigational arm, brentuximab vedotin was administered at 1.2 mg/kg and in the control group bleomycin was administered at 10 units/m 2 .", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was administered", "normalized": "be administer"}}, {"subject": {"text": "The primary endpoint of the study", "keywords": [{"text": "primary endpoint"}, {"text": "study"}]}, "sentence": " The primary endpoint of the study was modified PFS by independent review committee.", "object": {"text": "modified PFS by independent review committee", "keywords": [{"text": "independent review committee"}, {"text": "PFS"}], "entities": [{"type": "PrintMedia", "text": "independent review committee"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "PFS", "keywords": [{"text": "PFS"}]}, "sentence": " Under the modified criteria, PFS was defined as time to progression, death, or receipt of additional therapy for those not in CR.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was defined", "normalized": "be define"}}, {"subject": {"text": "PFS", "keywords": [{"text": "PFS"}]}, "sentence": " Under the modified criteria, PFS was defined as time to progression, death, or receipt of additional therapy for those not in CR.", "object": {"text": "as time to progression, death, or receipt of additional therapy for those not in CR", "keywords": [{"text": "additional therapy"}, {"text": "receipt"}, {"text": "progression"}, {"text": "CR"}]}, "action": {"verb": {"text": "define", "tense": "past"}, "text": "was defined", "normalized": "be define"}}, {"subject": {"text": "The modified endpoint", "keywords": [{"text": "endpoint"}]}, "sentence": " The modified endpoint was meant to eliminate the potential impact of consolidation treatment with chemotherapy or radiotherapy.", "object": {"text": "meant"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The modified endpoint", "keywords": [{"text": "endpoint"}]}, "sentence": " The modified endpoint was meant to eliminate the potential impact of consolidation treatment with chemotherapy or radiotherapy.", "object": {"text": "the potential impact of consolidation treatment with chemotherapy or radiotherapy", "keywords": [{"text": "consolidation treatment"}, {"text": "radiotherapy"}, {"text": "chemotherapy"}, {"text": "potential impact"}]}, "action": {"verb": {"text": "eliminate", "tense": "past"}, "text": "was meant to eliminate", "normalized": "be mean to eliminate"}}, {"subject": {"text": "overall survival and safety", "keywords": [{"text": "overall survival"}, {"text": "safety"}]}, "sentence": " Secondary endpoints included overall survival and safety.", "object": {"text": "Secondary endpoints", "keywords": [{"text": "Secondary endpoints"}]}, "action": {"verb": {"text": "include", "tense": "past"}, "text": "included", "normalized": "include"}}, {"subject": {"text": "PFS", "keywords": [{"text": "PFS"}]}, "sentence": " PFS was met with 117 events in the brentuximab vedotin arm and 146 events in the AVBD arm.", "action": {"verb": {"text": "meet", "tense": "past"}, "text": "was met", "normalized": "be meet"}}, {"subject": {"text": "the 2-year modified PFS", "keywords": [{"text": "2-year modified PFS"}], "entities": [{"type": "Quantity", "text": "2-year"}]}, "sentence": " At a median follow-up of 24.9 months, the 2-year modified PFS was 82.1% (95% CI, 78.7-85.0) with the brentuximab vedotin regimen compared with 77.2% (95% CI, 73.7-80.4) with ABVD.", "object": {"text": "82.1% (95% CI, 78.7-85.0)", "keywords": [{"text": "CI"}], "entities": [{"type": "Quantity", "text": "82.1"}, {"type": "Quantity", "text": "95"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The CR rate", "keywords": [{"text": "CR rate"}]}, "sentence": " The CR rate was 73% for the brentuximab vedotin arm and 70% for the ABVD arm.", "object": {"text": "73% for the brentuximab vedotin arm and 70% for the ABVD arm", "keywords": [{"text": "brentuximab vedotin arm"}, {"text": "ABVD arm"}], "entities": [{"type": "Drug", "text": "ABVD"}, {"type": "Quantity", "text": "70"}, {"type": "Quantity", "text": "73"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "researchers", "keywords": [{"text": "researchers"}]}, "sentence": " In addition, researchers found that 33% fewer patients treated with the brentuximab vedotin regimen received subsequent chemotherapy or high-dose chemotherapy and transplant compared with the patients treated with ABVD.", "object": {"text": "33% fewer patients treated with the brentuximab vedotin regimen received subsequent chemotherapy or high-dose chemotherapy and transplant compared with the patients treated with ABVD", "keywords": [{"text": "brentuximab vedotin regimen"}, {"text": "high-dose chemotherapy"}, {"text": "subsequent chemotherapy"}, {"text": "fewer patients"}], "entities": [{"type": "Drug", "text": "ABVD"}, {"type": "Quantity", "text": "33"}]}, "action": {"verb": {"text": "find", "tense": "past"}, "text": "found", "normalized": "find"}}], "concepts": [{"text": "Lymphoma", "relevance": 0.961398, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Chemotherapy", "relevance": 0.792204, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Chemotherapy regimens", "relevance": 0.706852, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy_regimens"}, {"text": "Hodgkin's lymphoma", "relevance": 0.623331, "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}, {"text": "Vincristine", "relevance": 0.536103, "dbpedia_resource": "http://dbpedia.org/resource/Vincristine"}, {"text": "Non-Hodgkin lymphoma", "relevance": 0.511864, "dbpedia_resource": "http://dbpedia.org/resource/Non-Hodgkin_lymphoma"}, {"text": "Doxorubicin", "relevance": 0.452275, "dbpedia_resource": "http://dbpedia.org/resource/Doxorubicin"}, {"text": "ABVD", "relevance": 0.429183, "dbpedia_resource": "http://dbpedia.org/resource/ABVD"}, {"text": "Anaplastic large cell lymphoma", "relevance": 0.420385, "dbpedia_resource": "http://dbpedia.org/resource/Anaplastic_large_cell_lymphoma"}, {"text": "Hematology", "relevance": 0.409619, "dbpedia_resource": "http://dbpedia.org/resource/Hematology"}, {"text": "Vinblastine", "relevance": 0.392952, "dbpedia_resource": "http://dbpedia.org/resource/Vinblastine"}, {"text": "Oncology", "relevance": 0.335464, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Clinical trial", "relevance": 0.334611, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Fever", "relevance": 0.334485, "dbpedia_resource": "http://dbpedia.org/resource/Fever"}, {"text": "T-cell lymphoma", "relevance": 0.316992, "dbpedia_resource": "http://dbpedia.org/resource/T-cell_lymphoma"}, {"text": "CHOP", "relevance": 0.313369, "dbpedia_resource": "http://dbpedia.org/resource/CHOP"}, {"text": "Breast cancer", "relevance": 0.310275, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Types of cancer", "relevance": 0.297529, "dbpedia_resource": "http://dbpedia.org/resource/Types_of_cancer"}, {"text": "Hematopoietic stem cell transplantation", "relevance": 0.297524, "dbpedia_resource": "http://dbpedia.org/resource/Hematopoietic_stem_cell_transplantation"}, {"text": "B-cell lymphoma", "relevance": 0.281325, "dbpedia_resource": "http://dbpedia.org/resource/B-cell_lymphoma"}, {"text": "Chemotherapeutic agents", "relevance": 0.264565, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapeutic_agents"}, {"text": "Cancer", "relevance": 0.260958, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Blood disorders", "relevance": 0.258704, "dbpedia_resource": "http://dbpedia.org/resource/Blood_disorders"}, {"text": "Stanford V", "relevance": 0.257007, "dbpedia_resource": "http://dbpedia.org/resource/Stanford_V"}, {"text": "Thomas Hodgkin", "relevance": 0.251426, "dbpedia_resource": "http://dbpedia.org/resource/Thomas_Hodgkin"}, {"text": "Prednisone", "relevance": 0.237003, "dbpedia_resource": "http://dbpedia.org/resource/Prednisone"}, {"text": "Melanoma", "relevance": 0.228503, "dbpedia_resource": "http://dbpedia.org/resource/Melanoma"}, {"text": "BEACOPP", "relevance": 0.226647, "dbpedia_resource": "http://dbpedia.org/resource/BEACOPP"}, {"text": "Ann Arbor staging", "relevance": 0.226126, "dbpedia_resource": "http://dbpedia.org/resource/Ann_Arbor_staging"}], "categories": [{"score": 0.992839, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.978392, "label": "/health and fitness/therapy"}, {"score": 0.616336, "label": "/health and fitness/disorders"}], "relations": [{"type": "partOf", "sentence": "FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL Jason M. Broderick @jasoncology Published: Friday, Nov 16, 2018 The FDA has approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).", "score": 0.873784, "arguments": [{"text": "CD30+ PTCL", "location": [47, 57], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}, {"text": "Frontline", "location": [37, 46], "entities": [{"type": "Organization", "text": "Frontline Peripheral T-Cell Lymphomas"}]}]}, {"type": "agentOf", "sentence": "That treatment has not significantly changed in decades and is too often unsuccessful in leading to long-term remissions, underscoring the need for new treatments,\" Steven Horwitz, MD, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, said in a statement.", "score": 0.636348, "arguments": [{"text": "Steven Horwitz", "location": [1746, 1760], "entities": [{"type": "Person", "text": "Steven Horwitz"}]}, {"text": "said", "location": [1848, 1852], "entities": [{"type": "EventCommunication", "text": "added"}]}]}, {"type": "timeOf", "sentence": "\"The ECHELON-2 clinical trial demonstrated Adcetris plus CHP was superior to the current standard of care, CHOP, for both progression-free survival and all other key secondary endpoints, including, most importantly, overall survival.", "score": 0.900045, "arguments": [{"text": "ECHELON-2", "location": [1873, 1882], "entities": [{"type": "Date", "text": "ECHELON-2"}]}, {"text": "trial", "location": [1892, 1897], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "agentOf", "sentence": "With this approval, clinicians have the opportunity to transform the way newly diagnosed CD30-expressing PTCL patients are treated,\" added Horwitz.", "score": 0.928885, "arguments": [{"text": "CD30", "location": [2191, 2195], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}, {"text": "expressing", "location": [2196, 2206], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "affectedBy", "sentence": "With this approval, clinicians have the opportunity to transform the way newly diagnosed CD30-expressing PTCL patients are treated,\" added Horwitz.", "score": 0.522551, "arguments": [{"text": "patients", "location": [2212, 2220], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "expressing", "location": [2196, 2206], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "employedBy", "sentence": "With this approval, clinicians have the opportunity to transform the way newly diagnosed CD30-expressing PTCL patients are treated,\" added Horwitz.", "score": 0.340272, "arguments": [{"text": "patients", "location": [2212, 2220], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "PTCL", "location": [2207, 2211], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}]}, {"type": "affectedBy", "sentence": "With this approval, clinicians have the opportunity to transform the way newly diagnosed CD30-expressing PTCL patients are treated,\" added Horwitz.", "score": 0.554326, "arguments": [{"text": "Horwitz", "location": [2241, 2248], "entities": [{"type": "Person", "text": "Steven Horwitz"}]}, {"text": "added", "location": [2235, 2240], "entities": [{"type": "EventCommunication", "text": "added"}]}]}, {"type": "agentOf", "sentence": "In a statement, the FDA noted that a new review program had acclerated the pace of the approval, which occurred less than 2 weeks from the date that the complete application was submitted.", "score": 0.991071, "arguments": [{"text": "FDA", "location": [2270, 2273], "entities": [{"type": "Organization", "text": "FDA Grants", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "noted", "location": [2274, 2279], "entities": [{"type": "EventCommunication", "text": "added"}]}]}, {"type": "managerOf", "sentence": "\"The Real-Time Oncology Review (RTOR) program allows the FDA to access key data prior to the official submission of the application allowing the review team to begin their review earlier and communicate with the sponsor prior to the application's actual submission,\" Richard Pazdur, MD, director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products, said in a statement.", "score": 0.644986, "arguments": [{"text": "director", "location": [2726, 2734], "entities": [{"type": "Person", "text": "Richard Pazdur"}]}, {"text": "Oncology Center of Excellence", "location": [2748, 2777], "entities": [{"type": "Organization", "text": "Oncology Center of Excellence"}]}]}, {"type": "partOf", "sentence": "\"The Real-Time Oncology Review (RTOR) program allows the FDA to access key data prior to the official submission of the application allowing the review team to begin their review earlier and communicate with the sponsor prior to the application's actual submission,\" Richard Pazdur, MD, director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products, said in a statement.", "score": 0.83912, "arguments": [{"text": "Oncology Center of Excellence", "location": [2748, 2777], "entities": [{"type": "Organization", "text": "Oncology Center of Excellence"}]}, {"text": "FDA", "location": [2742, 2745], "entities": [{"type": "Organization", "text": "FDA Grants", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "employedBy", "sentence": "\"The Real-Time Oncology Review (RTOR) program allows the FDA to access key data prior to the official submission of the application allowing the review team to begin their review earlier and communicate with the sponsor prior to the application's actual submission,\" Richard Pazdur, MD, director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products, said in a statement.", "score": 0.511136, "arguments": [{"text": "director", "location": [2789, 2797], "entities": [{"type": "Person", "text": "Richard Pazdur"}]}, {"text": "Office of Hematology and Oncology Products", "location": [2805, 2847], "entities": [{"type": "Organization", "text": "Office of Hematology and Oncology Products"}]}]}, {"type": "employedBy", "sentence": "FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL Jason M. Broderick @jasoncology Published: Friday, Nov 16, 2018 The FDA has approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).", "score": 0.79994, "arguments": [{"text": "Jason M. Broderick", "location": [58, 76], "entities": [{"type": "Person", "text": "Jason M. Broderick"}]}, {"text": "CD30+ PTCL", "location": [47, 57], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}]}, {"type": "agentOf", "sentence": "RTOR allowed the FDA to approve this indication within two weeks of the completed application's submission,\" added Pazdur.", "score": 0.895103, "arguments": [{"text": "Pazdur", "location": [3161, 3167], "entities": [{"type": "Person", "text": "Richard Pazdur"}]}, {"text": "added", "location": [3155, 3160], "entities": [{"type": "EventCommunication", "text": "added"}]}]}, {"type": "timeOf", "sentence": "The double-blind, multicenter, placebo-controlled phase III ECHELON-2 trial randomized approximately 450 newly diagnosed patients with CD30-expressing PTCL, also known as mature T-cell lymphoma, to brentuximab vedotin plus CHP or standard CHOP.", "score": 0.878192, "arguments": [{"text": "ECHELON-2", "location": [3229, 3238], "entities": [{"type": "Date", "text": "ECHELON-2"}]}, {"text": "trial", "location": [3239, 3244], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "affectedBy", "sentence": "The double-blind, multicenter, placebo-controlled phase III ECHELON-2 trial randomized approximately 450 newly diagnosed patients with CD30-expressing PTCL, also known as mature T-cell lymphoma, to brentuximab vedotin plus CHP or standard CHOP.", "score": 0.504633, "arguments": [{"text": "patients", "location": [3290, 3298], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "trial", "location": [3239, 3244], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "employedBy", "sentence": "The double-blind, multicenter, placebo-controlled phase III ECHELON-2 trial randomized approximately 450 newly diagnosed patients with CD30-expressing PTCL, also known as mature T-cell lymphoma, to brentuximab vedotin plus CHP or standard CHOP.", "score": 0.530082, "arguments": [{"text": "patients", "location": [3290, 3298], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "CD30", "location": [3304, 3308], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}]}, {"type": "agentOf", "sentence": "The double-blind, multicenter, placebo-controlled phase III ECHELON-2 trial randomized approximately 450 newly diagnosed patients with CD30-expressing PTCL, also known as mature T-cell lymphoma, to brentuximab vedotin plus CHP or standard CHOP.", "score": 0.556556, "arguments": [{"text": "patients", "location": [3290, 3298], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "expressing", "location": [3309, 3319], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "agentOf", "sentence": "The double-blind, multicenter, placebo-controlled phase III ECHELON-2 trial randomized approximately 450 newly diagnosed patients with CD30-expressing PTCL, also known as mature T-cell lymphoma, to brentuximab vedotin plus CHP or standard CHOP.", "score": 0.426393, "arguments": [{"text": "PTCL", "location": [3320, 3324], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}, {"text": "expressing", "location": [3309, 3319], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "hasAttribute", "sentence": "According to Seattle Genetics, adverse events (AEs) across all grades reported in \u226520% of patients receiving the brentuximab vedotin combination were peripheral neuropathy, nausea, diarrhea, neutropenia, lymphopenia, fatigue, mucositis, constipation, alopecia, pyrexia, vomiting, and anemia.", "score": 0.747908, "arguments": [{"text": "patients", "location": [3730, 3738], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diarrhea", "location": [3821, 3829], "entities": [{"type": "HealthCondition", "text": "diarrhea"}]}]}, {"type": "hasAttribute", "sentence": "Serious AEs occurring in \u22652% of patients in the brentuximab vedotin arm were febrile neutropenia, pneumonia, pyrexia, and sepsis.", "score": 0.829065, "arguments": [{"text": "patients", "location": [3964, 3972], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "pneumonia", "location": [4030, 4039], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "hasAttribute", "sentence": "Serious AEs occurring in \u22652% of patients in the brentuximab vedotin arm were febrile neutropenia, pneumonia, pyrexia, and sepsis.", "score": 0.52056, "arguments": [{"text": "patients", "location": [3964, 3972], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "pyrexia", "location": [4041, 4048], "entities": [{"type": "HealthCondition", "text": "pyrexia"}]}]}, {"type": "agentOf", "sentence": "Based on the study results, the investigators recommend that patients with PTCL being treated with frontline brentuximab vedotin plus CHP should receive G-CSF beginning at cycle 1.", "score": 0.989902, "arguments": [{"text": "investigators", "location": [4094, 4107], "entities": [{"type": "Person", "text": "investigators"}]}, {"text": "recommend", "location": [4108, 4117], "entities": [{"type": "EventCommunication", "text": "recommend"}]}]}, {"type": "employedBy", "sentence": "FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL Jason M. Broderick @jasoncology Published: Friday, Nov 16, 2018 The FDA has approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).", "score": 0.493814, "arguments": [{"text": "patients", "location": [246, 254], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "CD30", "location": [260, 264], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}]}, {"type": "affectedBy", "sentence": "In March brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma based on findings from the phase III ECHELON-1 trial, which demonstrated superior PFS with brentuximab vedotin plus Adriamycin, vinblastine, and dacarbazine (AVD) compared with standard ABVD (AVD plus bleomycin).", "score": 0.406992, "arguments": [{"text": "Hodgkin lymphoma", "location": [4388, 4404], "entities": [{"type": "Person", "text": "Hodgkin lymphoma"}]}, {"text": "trial", "location": [4452, 4457], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "affectedBy", "sentence": "2 The phase III ECHELON-1 trial enrolled 1334 patients with stage III/IV classical Hodgkin lymphoma.", "score": 0.39167, "arguments": [{"text": "Hodgkin lymphoma", "location": [4995, 5011], "entities": [{"type": "Person", "text": "Hodgkin lymphoma"}]}, {"text": "trial", "location": [4938, 4943], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "timeOf", "sentence": "In March brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma based on findings from the phase III ECHELON-1 trial, which demonstrated superior PFS with brentuximab vedotin plus Adriamycin, vinblastine, and dacarbazine (AVD) compared with standard ABVD (AVD plus bleomycin).", "score": 0.885598, "arguments": [{"text": "ECHELON-1", "location": [4442, 4451], "entities": [{"type": "Date", "text": "ECHELON-1"}]}, {"text": "trial", "location": [4452, 4457], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "timeOf", "sentence": "2 The phase III ECHELON-1 trial enrolled 1334 patients with stage III/IV classical Hodgkin lymphoma.", "score": 0.901002, "arguments": [{"text": "ECHELON-1", "location": [4928, 4937], "entities": [{"type": "Date", "text": "ECHELON-1"}]}, {"text": "trial", "location": [4938, 4943], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "affectedBy", "sentence": "2 The phase III ECHELON-1 trial enrolled 1334 patients with stage III/IV classical Hodgkin lymphoma.", "score": 0.390177, "arguments": [{"text": "patients", "location": [4958, 4966], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "trial", "location": [4938, 4943], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "agentOf", "sentence": "Brentuximab vedotin also has approved indications for patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation; classical Hodgkin lymphoma after failure of auto-HSCT or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates; sALCL after failure of at least one prior multiagent chemotherapy regimen; and primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides in patients who have received prior systemic therapy.", "score": 0.833373, "arguments": [{"text": "CD30", "location": [7068, 7072], "entities": [{"type": "Organization", "text": "CD30+ PTCL"}]}, {"text": "expressing", "location": [7073, 7083], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "partOf", "sentence": "References FDA Grants Breakthrough Therapy Designation to ADCETRIS\u00ae (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas.", "score": 0.708712, "arguments": [{"text": "Breakthrough Therapy Designation", "location": [7178, 7210], "entities": [{"type": "Organization", "text": "Breakthrough Therapy Designation"}]}, {"text": "FDA Grants", "location": [7167, 7177], "entities": [{"type": "Organization", "text": "FDA Grants", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "hasAttribute", "sentence": "Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): the phase 3 echelon-1 study.", "score": 0.495484, "arguments": [{"text": "Brentuximab vedotin", "location": [7419, 7438], "entities": [{"type": "Organization", "text": "Brentuximab vedotin"}]}, {"text": "HL", "location": [7652, 7654], "entities": [{"type": "Ticker", "text": "HL"}]}]}, {"type": "agentOf", "sentence": "FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL Jason M. Broderick @jasoncology Published: Friday, Nov 16, 2018 The FDA has approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).", "score": 0.480183, "arguments": [{"text": "patients", "location": [246, 254], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "expressing", "location": [265, 275], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "timeOf", "sentence": "The approval, which follows a breakthrough therapy designation, is based on the phase III ECHELON-2 trial, in which combining frontline brentuximab vedotin with CHP (cyclophosphamide, doxorubicin, prednisone) reduced the risk of death by 34% (HR, 0.66; 95% CI, 0.46-0.95; P = .024) and the risk of disease progression or death by 29% (0.71; 95% CI, 0.54-0.93; P = .011) compared with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).", "score": 0.916182, "arguments": [{"text": "ECHELON-2", "location": [400, 409], "entities": [{"type": "Date", "text": "ECHELON-2"}]}, {"text": "trial", "location": [410, 415], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "populationOf", "sentence": "1 Key secondary endpoints also demonstrated superiority with the brentuximab vedotin combination, including objective response rate (83% vs 72%; P = .003), complete remission rate (CR; 68% vs 56%; P = .007), and progression-free survival (PFS) in patients with systemic anaplastic large cell lymphoma (sALCL; HR = 0.59; 95% CI, 0.42-0.84; P = .003).", "score": 0.202916, "arguments": [{"text": ".007", "location": [962, 966], "entities": [{"type": "Cardinal", "text": ".007"}]}, {"text": "P =", "location": [958, 961], "entities": [{"type": "Organization", "text": "P =", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin, will be presenting additional ECHELON-2 findings at the 2018 ASH Annual Meeting.", "score": 0.745129, "arguments": [{"text": "Takeda Pharmaceutical", "location": [1324, 1345], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "presenting", "location": [1397, 1407], "entities": [{"type": "EventCommunication", "text": "presenting"}]}]}, {"type": "timeOf", "sentence": "Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin, will be presenting additional ECHELON-2 findings at the 2018 ASH Annual Meeting.", "score": 0.607901, "arguments": [{"text": "ECHELON-2", "location": [1419, 1428], "entities": [{"type": "Date", "text": "ECHELON-2"}]}, {"text": "presenting", "location": [1397, 1407], "entities": [{"type": "EventCommunication", "text": "presenting"}]}]}, {"type": "timeOf", "sentence": "Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin, will be presenting additional ECHELON-2 findings at the 2018 ASH Annual Meeting.", "score": 0.570846, "arguments": [{"text": "2018", "location": [1445, 1449], "entities": [{"type": "Date", "text": "2018"}]}, {"text": "presenting", "location": [1397, 1407], "entities": [{"type": "EventCommunication", "text": "presenting"}]}]}], "keywords": [{"text": "Brentuximab Vedotin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.722091, "count": 2}, {"text": "frontline treatment of patients", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.672839, "count": 1}, {"text": "brentuximab vedotin", "sentiment": {"score": -0.526026, "mixed": "1", "label": "negative"}, "relevance": 0.61714, "count": 6}, {"text": "peripheral T-cell lymphoma", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.607761, "count": 1}, {"text": "phase III ECHELON-2 trial", "sentiment": {"score": -0.656873, "mixed": "1", "label": "negative"}, "relevance": 0.606543, "count": 2}, {"text": "patients", "sentiment": {"score": -0.757337, "mixed": "1", "label": "negative"}, "relevance": 0.588469, "count": 14}, {"text": "new review program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.582152, "count": 1}, {"text": "Key secondary endpoints", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.571312, "count": 1}, {"text": "Frontline CD30", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567652, "count": 1}, {"text": "progression-free survival", "sentiment": {"score": 0.703415, "label": "positive"}, "relevance": 0.566512, "count": 3}, {"text": "breakthrough therapy designation", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.557552, "count": 1}, {"text": "frontline brentuximab vedotin", "sentiment": {"score": 0.352833, "label": "positive"}, "relevance": 0.557539, "count": 2}, {"text": "Real-Time Oncology Review", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548996, "count": 1}, {"text": "PTCL Jason M. Broderick", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.54705, "count": 1}, {"text": "PFS", "sentiment": {"score": -0.444346, "mixed": "1", "label": "negative"}, "relevance": 0.546472, "count": 7}, {"text": "FDA", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.544615, "count": 5}, {"text": "systemic anaplastic large cell lymphoma", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.544152, "count": 1}, {"text": "risk of disease progression", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.541484, "count": 1}, {"text": "PTCL patients", "sentiment": {"score": 0.939722, "label": "positive"}, "relevance": 0.537443, "count": 1}, {"text": "brentuximab vedotin combination", "sentiment": {"score": -0.633774, "mixed": "1", "label": "negative"}, "relevance": 0.537414, "count": 2}, {"text": "chemotherapy", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.537391, "count": 3}, {"text": "classical Hodgkin lymphoma", "sentiment": {"score": -0.859435, "label": "negative"}, "relevance": 0.535263, "count": 4}, {"text": "prior treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53466, "count": 1}, {"text": "Seattle Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532805, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.800397, "label": "negative"}, "relevance": 0.531583, "count": 2}, {"text": "Memorial Sloan Kettering Cancer Center", "sentiment": {"score": -0.800397, "label": "negative"}, "relevance": 0.531482, "count": 1}, {"text": "clinical trial", "sentiment": {"score": 0.896976, "label": "positive"}, "relevance": 0.530397, "count": 1}, {"text": "overall survival", "sentiment": {"score": 0.919513, "label": "positive"}, "relevance": 0.52919, "count": 3}, {"text": "adverse events", "sentiment": {"score": -0.889055, "label": "negative"}, "relevance": 0.529158, "count": 1}, {"text": "independent review", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528457, "count": 1}, {"text": "antibody-drug conjugate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527729, "count": 1}, {"text": "approval", "sentiment": {"score": 0.742803, "label": "positive"}, "relevance": 0.526675, "count": 2}, {"text": "primary endpoint", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526544, "count": 1}, {"text": "high-dose chemotherapy", "sentiment": {"score": -0.548823, "label": "negative"}, "relevance": 0.526045, "count": 1}, {"text": "review", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525179, "count": 1}, {"text": "brentuximab vedotin regimen", "sentiment": {"score": -0.669603, "label": "negative"}, "relevance": 0.52399, "count": 3}, {"text": "adult patients", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52394, "count": 1}, {"text": "complete application", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52354, "count": 1}, {"text": "risk of death", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.52337, "count": 1}, {"text": "current standard of care", "sentiment": {"score": 0.896976, "label": "positive"}, "relevance": 0.523184, "count": 2}, {"text": "key secondary endpoints", "sentiment": {"score": 0.896976, "label": "positive"}, "relevance": 0.523077, "count": 1}, {"text": "study", "sentiment": {"score": -0.768854, "label": "negative"}, "relevance": 0.522059, "count": 1}, {"text": "additional ECHELON-2 findings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521914, "count": 1}, {"text": "study results", "sentiment": {"score": 0.307632, "label": "positive"}, "relevance": 0.521235, "count": 1}, {"text": "review team", "sentiment": {"score": 0.956981, "label": "positive"}, "relevance": 0.520801, "count": 2}, {"text": "combination", "sentiment": {"score": 0.398396, "label": "positive"}, "relevance": 0.52048, "count": 2}, {"text": "program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518896, "count": 1}, {"text": "superior PFS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518566, "count": 1}, {"text": "peripheral neuropathy", "sentiment": {"score": -0.889055, "label": "negative"}, "relevance": 0.518556, "count": 1}, {"text": "thorough review", "sentiment": {"score": 0.956981, "label": "positive"}, "relevance": 0.51832, "count": 1}]}, "extracted_metadata": {"sha1": "3d061a87713dbb1d7e77631c464842a2fa7c7df9", "filename": "1542396824883.zip-7257a6f023a84f44bada467f4757369d.xml", "file_type": "json"}, "external_links": ["http://www.facebook.com/2008/fbml", "https://bit.ly/2zeyd7p.", "https://twitter.com/jasoncology"], "title": "FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL", "forum_title": "Onclive Articles"}, {"id": "0fIHqF6nnhk2OcNWwGgVTSaeEsHh7pD3q1io0XQ7NpQI-N9dCAMNjtOmcbiZeStp", "result_metadata": {"score": 29.715664}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics Markets", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Others", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.869997, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Strategic management", "relevance": 0.853464, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Trade", "relevance": 0.745527, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Greek loanwords", "relevance": 0.682598, "dbpedia_resource": "http://dbpedia.org/resource/Greek_loanwords"}], "categories": [{"score": 0.999983, "label": "/science/medicine/oncology"}], "relations": [], "keywords": [{"text": "Companion Diagnostics Markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.99665, "count": 1}, {"text": "Oncology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.783985, "count": 1}, {"text": "Global Strategic Business Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.770715, "count": 1}, {"text": "Neurology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.769966, "count": 1}, {"text": "Others", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.75324, "count": 1}, {"text": "com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594538, "count": 1}, {"text": "ResearchAndMarkets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.1407, "count": 1}]}, "crawl_date": "2018-11-17T02:34:59Z", "url": "https://www.businesswire.com/news/home/20181116005158/en/Companion-Diagnostics-Markets-2015-2022-Oncology-Neurology--", "host": "businesswire.com", "text": "Hoffmann-La Roche Ltd.", "main_image_url": "https://mms.businesswire.com/media/20181116005158/en/371054/23/ResearchAndMarkets_800px.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T11:24:00-06:00", "enriched_text": {"entities": [{"count": 23, "sentiment": {"score": -0.234361, "label": "negative"}, "text": "Companion Diagnostics", "relevance": 0.869931, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics in Oncology", "relevance": 0.311659, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics in Clinical Trials", "relevance": 0.304971, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.643894, "label": "negative"}, "text": "CDx Market", "relevance": 0.3025, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oncology CDx Testing", "relevance": 0.255439, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quest Diagnostics, Inc.", "relevance": 0.216392, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.609676, "label": "negative"}, "text": "Cancer", "relevance": 0.189073, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 4, "sentiment": {"score": 0.0904137, "label": "positive"}, "text": "Personalized Medicine", "relevance": 0.184599, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostic Manufacturer", "relevance": 0.180967, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": -0.464862, "label": "negative"}, "text": "Europe", "relevance": 0.175988, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 4, "sentiment": {"score": 0.452379, "label": "positive"}, "text": "US", "relevance": 0.171862, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 6, "sentiment": {"score": 0.633936, "label": "positive"}, "text": "FDA", "relevance": 0.17106, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.17043, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 3, "sentiment": {"score": 0.601571, "label": "positive"}, "text": "Thermo Fisher Scientific", "relevance": 0.160866, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}, {"count": 3, "sentiment": {"score": -0.651164, "label": "negative"}, "text": "Canada", "relevance": 0.156151, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 2, "sentiment": {"score": -0.411196, "label": "negative"}, "text": "Foundation Medicine", "relevance": 0.153778, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.148181, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.740065, "label": "negative"}, "text": "Breast Cancer", "relevance": 0.147188, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Breast cancer", "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}}, {"count": 1, "sentiment": {"score": 0.256271, "label": "positive"}, "text": "Streamlined Drug Discovery & Development", "relevance": 0.143747, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laboratory Corporation of America Holdings", "relevance": 0.14358, "type": "Company", "disambiguation": {"subtype": [], "name": "LabCorp", "dbpedia_resource": "http://dbpedia.org/resource/LabCorp"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aid Cancer Treatment", "relevance": 0.143208, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.142052, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": -0.317013, "label": "negative"}, "text": "Major Market Driver", "relevance": 0.141545, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.411196, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.140491, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Foundation Medicine, Inc.", "relevance": 0.134366, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.131367, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Danaher Corporation", "relevance": 0.130903, "type": "Company", "disambiguation": {"subtype": [], "name": "Danaher Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Danaher_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ResearchAndMarkets.com", "relevance": 0.129226, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.329022, "label": "positive"}, "text": "Thermo Fisher Scientific, Inc.", "relevance": 0.127982, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Agilent Technologies, Inc.", "relevance": 0.127481, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Foundation Medicine Inks", "relevance": 0.12685, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Fully Acquire Foundation Medicine", "relevance": 0.126166, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.12592, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0.330333, "label": "positive"}, "text": "DUBLIN", "relevance": 0.125724, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.125586, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": -0.734861, "label": "negative"}, "text": "Irritable Bowel Disease", "relevance": 0.12516, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Irritable bowel syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.125105, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Germany", "dbpedia_resource": "http://dbpedia.org/resource/Germany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Qiagen", "relevance": 0.124614, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.122813, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Hoffmann-La Roche", "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.121615, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.121567, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NeoGenomics, Inc.", "relevance": 0.121439, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adjuvant Treatment Decision", "relevance": 0.121188, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HIV", "relevance": 0.1205, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}, {"count": 1, "sentiment": {"score": 0.673325, "label": "positive"}, "text": "Myriad Bags Manufacturing", "relevance": 0.120037, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Agilent", "relevance": 0.119556, "type": "Company", "disambiguation": {"subtype": [], "name": "Agilent Technologies", "dbpedia_resource": "http://dbpedia.org/resource/Agilent_Technologies"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cepheid", "relevance": 0.119232, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.528544, "label": "positive"}, "text": "Breakthrough Innovation", "relevance": 0.117426, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.114789, "type": "Organization"}], "sentiment": {"document": {"score": 0.839094, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Global Strategic Business Report\" report", "keywords": [{"text": "Global Strategic Business"}]}, "sentence": "DUBLIN- The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "added to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "DUBLIN- The \"Companion Diagnostics - Global Strategic Business Report\" report", "keywords": [{"text": "Global Strategic Business"}, {"text": "Companion Diagnostics"}, {"text": "report"}], "entities": [{"type": "Location", "text": "DUBLIN", "disambiguation": {"subtype": ["City"]}}, {"type": "Company", "text": "Companion Diagnostics"}]}, "sentence": "DUBLIN- The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "object": {"text": "separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World", "keywords": [{"text": "separate comprehensive analytics"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}, {"text": "Rest"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "object": {"text": "provided"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "are provided", "normalized": "be provide"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "provided for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "Market data and analytics", "keywords": [{"text": "analytics"}, {"text": "Market data"}]}, "sentence": " Market data and analytics are derived from primary and secondary research.", "object": {"text": "from primary and secondary research", "keywords": [{"text": "secondary research"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "are derived", "normalized": "be derive"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "object": {"text": "the worldwide markets for Companion Diagnostics in US$ Million", "keywords": [{"text": "Companion Diagnostics"}, {"text": "worldwide markets"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}, {"type": "Company", "text": "Companion Diagnostics"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies including many key and niche players", "keywords": [{"text": "niche players"}, {"text": "companies"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "many key and niche players such as", "keywords": [{"text": "niche players"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "CDx", "keywords": [{"text": "CDx"}]}, "sentence": " Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development", "object": {"text": "the One-Size-Fits-All Approach", "keywords": [{"text": "One-Size-Fits-All Approach"}]}, "action": {"verb": {"text": "Quashing", "tense": "present"}, "text": "Quashing", "normalized": "Quashing"}}, {"subject": {"text": "Healthy Growth", "keywords": [{"text": "Healthy Growth"}]}, "sentence": " Healthy Growth Projected over the Next Few Years", "action": {"verb": {"text": "Projected", "tense": "past"}, "text": "Projected", "normalized": "Projected"}}, {"subject": {"text": "Northbound Trajectory in R&D Spending", "keywords": [{"text": "Northbound Trajectory"}, {"text": "R&D Spending"}]}, "sentence": " Northbound Trajectory in R&D Spending Creates Conducive Environment", "object": {"text": "Conducive Environment", "keywords": [{"text": "Conducive Environment"}]}, "action": {"verb": {"text": "Creates", "tense": "present"}, "text": "Creates", "normalized": "Creates"}}, {"subject": {"text": "Prevailing Economic Scenario", "keywords": [{"text": "Economic Scenario"}]}, "sentence": " Prevailing Economic Scenario Favors Funding Pattern", "object": {"text": "Funding Pattern", "keywords": [{"text": "Funding Pattern"}]}, "action": {"verb": {"text": "Favors", "tense": "present"}, "text": "Favors", "normalized": "Favors"}}, {"subject": {"text": "Herceptin", "keywords": [{"text": "Herceptin"}]}, "sentence": " Herceptin Lays the Road for Companion Diagnostics", "object": {"text": "the Road", "keywords": [{"text": "Road"}]}, "action": {"verb": {"text": "Lays", "tense": "present"}, "text": "Lays", "normalized": "Lays"}}, {"subject": {"text": "Regulatory Scenario", "keywords": [{"text": "Regulatory Scenario"}]}, "sentence": " Regulatory Scenario Favors CDx Market", "object": {"text": "CDx Market", "keywords": [{"text": "CDx Market"}], "entities": [{"type": "Company", "text": "CDx Market"}]}, "action": {"verb": {"text": "Favors", "tense": "present"}, "text": "Favors", "normalized": "Favors"}}, {"subject": {"text": "them"}, "sentence": " Companion Diagnostics: What Makes them Work", "object": {"text": "Work", "keywords": [{"text": "Work"}]}, "action": {"verb": {"text": "Makes", "tense": "present"}, "text": "Makes", "normalized": "Makes"}}, {"subject": {"text": "Techniques", "keywords": [{"text": "Techniques"}]}, "sentence": " Techniques Used in Companion Diagnostics", "action": {"verb": {"text": "Used", "tense": "past"}, "text": "Used", "normalized": "Used"}}, {"subject": {"text": "Companion Diagnostics", "keywords": [{"text": "Companion Diagnostics"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "sentence": " Select Companion Diagnostics in Cancer", "object": {"text": "in Cancer", "keywords": [{"text": "Cancer"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "Select", "tense": "present"}, "text": "Select", "normalized": "Select"}}, {"subject": {"text": "Assay", "keywords": [{"text": "Assay"}]}, "sentence": " Trofile Assay to Aid in HIV Treatment", "object": {"text": "to Aid in HIV Treatment", "keywords": [{"text": "HIV Treatment"}, {"text": "Aid"}], "entities": [{"type": "HealthCondition", "text": "HIV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}]}, "action": {"verb": {"text": "Trofile", "tense": "present"}, "text": "Trofile", "normalized": "Trofile"}}, {"subject": {"text": "Players", "keywords": [{"text": "Players"}]}, "sentence": " Leading Players in the World Companion Diagnostics Market", "action": {"verb": {"text": "Leading", "tense": "present"}, "text": "Leading", "normalized": "Leading"}}, {"subject": {"text": "Vendors", "keywords": [{"text": "Vendors"}]}, "sentence": " Vendors Rely on Collaborations to Widen Market Footprint", "object": {"text": "on Collaborations", "keywords": [{"text": "Collaborations"}]}, "action": {"verb": {"text": "Rely", "tense": "present"}, "text": "Rely", "normalized": "Rely"}}, {"subject": {"text": "Foundation Medicine", "keywords": [{"text": "Foundation Medicine"}], "entities": [{"type": "Company", "text": "Foundation Medicine"}]}, "sentence": " Foundation Medicine Unveils FoundationOne CDx", "object": {"text": "FoundationOne CDx", "keywords": [{"text": "FoundationOne CDx"}]}, "action": {"verb": {"text": "Unveils", "tense": "present"}, "text": "Unveils", "normalized": "Unveils"}}, {"subject": {"text": "Roche", "keywords": [{"text": "Roche"}], "entities": [{"type": "Person", "text": "Roche"}]}, "sentence": " Roche to Fully Acquire Foundation Medicine", "object": {"text": "Foundation Medicine", "keywords": [{"text": "Foundation Medicine"}]}, "action": {"verb": {"text": "Acquire", "tense": "present"}, "text": "to Fully Acquire", "normalized": "to Fully Acquire"}}, {"subject": {"text": "Qiagen and Freenome", "keywords": [{"text": "Qiagen"}, {"text": "Freenome"}], "entities": [{"type": "Person", "text": "Qiagen"}]}, "sentence": " Qiagen and Freenome to Develop NGS-based Companion Diagnostics", "object": {"text": "NGS-based Companion Diagnostics", "keywords": [{"text": "NGS-based Companion Diagnostics"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "action": {"verb": {"text": "Develop", "tense": "future"}, "text": "to Develop", "normalized": "to Develop"}}, {"subject": {"text": "Foundation Medicine and Merck", "keywords": [{"text": "Merck"}, {"text": "Foundation Medicine"}], "entities": [{"type": "Company", "text": "Foundation Medicine"}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " Foundation Medicine and Merck to Develop CDx Tests", "object": {"text": "CDx Tests", "keywords": [{"text": "CDx Tests"}]}, "action": {"verb": {"text": "Develop", "tense": "future"}, "text": "to Develop", "normalized": "to Develop"}}, {"subject": {"text": "NeoGenomics", "keywords": [{"text": "NeoGenomics"}], "entities": [{"type": "Company", "text": "NeoGenomics"}]}, "sentence": " NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program", "object": {"text": "Thermo Fisher's CDx Center of Excellence Program", "keywords": [{"text": "Thermo Fisher"}, {"text": "CDx Center"}, {"text": "Excellence"}, {"text": "Program"}], "entities": [{"type": "Company", "text": "Thermo Fisher Scientific", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}, {"type": "Organization", "text": "Center of Excellence Program"}]}, "action": {"verb": {"text": "Join", "tense": "future"}, "text": "to Join", "normalized": "to Join"}}, {"subject": {"text": "Robust Personalized Medicine Market", "keywords": [{"text": "Robust Personalized Medicine"}, {"text": "Market"}]}, "sentence": " Robust Personalized Medicine Market Offers Potential", "object": {"text": "Potential"}, "action": {"verb": {"text": "Offers", "tense": "present"}, "text": "Offers", "normalized": "Offers"}}], "concepts": [{"text": "Hoffmann\u2013La Roche", "relevance": 0.983947, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Pharmaceutical industry", "relevance": 0.844747, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Genentech", "relevance": 0.592739, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Drug development", "relevance": 0.531482, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Breast cancer", "relevance": 0.528402, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Thermo Fisher Scientific", "relevance": 0.527299, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}, {"text": "Bristol-Myers Squibb", "relevance": 0.518964, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Food and Drug Administration", "relevance": 0.50898, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Fisher Scientific", "relevance": 0.499668, "dbpedia_resource": "http://dbpedia.org/resource/Fisher_Scientific"}, {"text": "Cancer", "relevance": 0.484773, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Hoffmann-La Roche", "relevance": 0.446065, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}, {"text": "Pharmacology", "relevance": 0.444839, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Thermo Electron", "relevance": 0.435632, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Electron"}, {"text": "Drug discovery", "relevance": 0.424287, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Benzodiazepine", "relevance": 0.403779, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine"}, {"text": "Oncology", "relevance": 0.376912, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Research support companies", "relevance": 0.375704, "dbpedia_resource": "http://dbpedia.org/resource/Research_support_companies"}, {"text": "Basel", "relevance": 0.373736, "dbpedia_resource": "http://dbpedia.org/resource/Basel"}, {"text": "Medicine", "relevance": 0.368102, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Assay", "relevance": 0.364988, "dbpedia_resource": "http://dbpedia.org/resource/Assay"}, {"text": "Financial markets", "relevance": 0.357462, "dbpedia_resource": "http://dbpedia.org/resource/Financial_markets"}, {"text": "Laboratory equipment", "relevance": 0.351987, "dbpedia_resource": "http://dbpedia.org/resource/Laboratory_equipment"}, {"text": "In vitro diagnostics", "relevance": 0.3464, "dbpedia_resource": "http://dbpedia.org/resource/In_vitro_diagnostics"}, {"text": "Clopidogrel", "relevance": 0.344912, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "GlaxoSmithKline", "relevance": 0.33964, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "United States", "relevance": 0.329855, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Generic drug", "relevance": 0.326728, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}], "categories": [{"score": 0.922393, "label": "/health and fitness/disease/cancer"}, {"score": 0.763548, "label": "/science/medicine/oncology"}, {"score": 0.757722, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "locatedAt", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.903349, "arguments": [{"text": "Pacific", "location": [224, 231], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Latin America", "location": [233, 246], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.39781, "arguments": [{"text": "Witnesses", "location": [1505, 1514], "entities": [{"type": "Person", "text": "Witnesses"}]}, {"text": "Key Revenue Contributors\nMarket", "location": [1473, 1504], "entities": [{"type": "Organization", "text": "Key Revenue Contributors\nMarket", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.981572, "arguments": [{"text": "Fast Paced Growth", "location": [1515, 1532], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Witnesses", "location": [1505, 1514], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.618396, "arguments": [{"text": "Economic Scenario Favors Funding Pattern\n3", "location": [1634, 1676], "entities": [{"type": "Person", "text": "Economic Scenario Favors Funding Pattern\n3"}]}, {"text": "Witnesses", "location": [1505, 1514], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.515846, "arguments": [{"text": "Fast Paced Growth", "location": [1515, 1532], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Northbound Trajectory", "location": [1555, 1576], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.951464, "arguments": [{"text": "Northbound Trajectory", "location": [1555, 1576], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}, {"text": "Developing Regions", "location": [1536, 1554], "entities": [{"type": "GeopoliticalEntity", "text": "Developing Regions"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.564321, "arguments": [{"text": "CDx\nEmphasis", "location": [1929, 1941], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "CDx Tests Steers Momentum\nHerceptin Lays", "location": [1979, 2019], "entities": [{"type": "Organization", "text": "CDx Tests Steers Momentum\nHerceptin Lays", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.434281, "arguments": [{"text": "CDx\nEmphasis", "location": [1929, 1941], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "Road", "location": [2024, 2028], "entities": [{"type": "Facility", "text": "Road"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.419741, "arguments": [{"text": "Companion Diagnostics", "location": [2427, 2448], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx", "location": [2449, 2591], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx"}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.707006, "arguments": [{"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx", "location": [2449, 2591], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx"}]}, {"text": "US", "location": [2595, 2597], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Critical for Future Growth of CDx Market Key Issues in a Nutshell 4.", "score": 0.544116, "arguments": [{"text": "Critical for Future Growth of CDx Market\nKey Issues", "location": [2650, 2701], "entities": [{"type": "Organization", "text": "Critical for Future Growth of CDx Market\nKey Issues"}]}, {"text": "Nutshell\n4", "location": [2707, 2717], "entities": [{"type": "GeopoliticalEntity", "text": "Nutshell\n4"}]}]}, {"type": "locatedAt", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.524283, "arguments": [{"text": "Latin America", "location": [233, 246], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}, {"text": "World", "location": [260, 265], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.742631, "arguments": [{"text": "Companion Diagnostics\nCompanion Diagnostics", "location": [2787, 2830], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Personalized Medicine\nGenetic Tests", "location": [2751, 2786], "entities": [{"type": "Organization", "text": "Personalized Medicine\nGenetic Tests"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.744955, "arguments": [{"text": "Companion Diagnostics", "location": [3042, 3063], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Drug Development Process", "location": [3017, 3041], "entities": [{"type": "Organization", "text": "Drug Development Process"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.627167, "arguments": [{"text": "Companion Diagnostics", "location": [3083, 3104], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Clinical Trials", "location": [3067, 3082], "entities": [{"type": "Organization", "text": "Clinical Trials", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.314304, "arguments": [{"text": "Select Therapeutic", "location": [3108, 3126], "entities": [{"type": "Organization", "text": "Select Therapeutic"}]}, {"text": "Areas", "location": [3127, 3132], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.374683, "arguments": [{"text": "Companion Diagnostics", "location": [3133, 3154], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Areas", "location": [3127, 3132], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.701942, "arguments": [{"text": "Companion Diagnostics", "location": [3174, 3195], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Oncology\nSelect", "location": [3158, 3173], "entities": [{"type": "Organization", "text": "Oncology\nSelect", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.415113, "arguments": [{"text": "Oncotype DX\nQuantitative Recurrence Score\nOncotype DX Test", "location": [3206, 3264], "entities": [{"type": "Person", "text": "Oncotype DX\nQuantitative Recurrence Score\nOncotype DX Test"}]}, {"text": "Cancer", "location": [3199, 3205], "entities": [{"type": "GeopoliticalEntity", "text": "Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.624131, "arguments": [{"text": "IndexSM", "location": [3424, 3431], "entities": [{"type": "Person", "text": "IndexSM"}]}, {"text": "Breast Cancer", "location": [3410, 3423], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.699588, "arguments": [{"text": "Assays", "location": [3517, 3523], "entities": [{"type": "Person", "text": "Assays"}]}, {"text": "Breast Cancer", "location": [3503, 3516], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.570184, "arguments": [{"text": "Companion Diagnostics", "location": [3658, 3679], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Inflammatory Diseases\nPROMETHEUS IBD Serology 7", "location": [3683, 3730], "entities": [{"type": "Organization", "text": "Inflammatory Diseases\nPROMETHEUS IBD Serology 7"}]}]}, {"type": "residesIn", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.280592, "arguments": [{"text": "Rest", "location": [252, 256], "entities": [{"type": "Cardinal", "text": "Rest"}]}, {"text": "World", "location": [260, 265], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.905081, "arguments": [{"text": "Companion Diagnostics", "location": [3759, 3780], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Bowel Disease", "location": [3745, 3758], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.392566, "arguments": [{"text": "Companion Diagnostics", "location": [3759, 3780], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Infectious Diseases\nTrofile Assay", "location": [3784, 3817], "entities": [{"type": "Organization", "text": "Infectious Diseases\nTrofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.386574, "arguments": [{"text": "Aid", "location": [3821, 3824], "entities": [{"type": "Organization", "text": "Aid Cancer Treatment\nc-Kit pharmDx Assay"}]}, {"text": "Infectious Diseases\nTrofile Assay", "location": [3784, 3817], "entities": [{"type": "Organization", "text": "Infectious Diseases\nTrofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.852005, "arguments": [{"text": "CYP450 Test\nHILOmet PhyzioType System", "location": [3893, 3930], "entities": [{"type": "Organization", "text": "CYP450 Test\nHILOmet PhyzioType System"}]}, {"text": "Drug Metabolism\nAmpliChip", "location": [3867, 3892], "entities": [{"type": "Organization", "text": "Drug Metabolism\nAmpliChip"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.570465, "arguments": [{"text": "Companion Diagnostic Manufacturer", "location": [4082, 4115], "entities": [{"type": "Person", "text": "Companion Diagnostic Manufacturer"}]}, {"text": "Diagnostic Company", "location": [4062, 4080], "entities": [{"type": "Organization", "text": "Diagnostic Company"}]}]}, {"type": "partOfMany", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.530278, "arguments": [{"text": "Companion Diagnostics Market\nVendors Rely", "location": [4220, 4261], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Players", "location": [4199, 4206], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "participantIn", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.860623, "arguments": [{"text": "Companion Diagnostics Market\nVendors Rely", "location": [4220, 4261], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "World", "location": [4214, 4219], "entities": [{"type": "SportingEvent", "text": "World"}]}]}, {"type": "agentOf", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.935809, "arguments": [{"text": "Widen Market Footprint\nSelect CDx Collaborative Deals", "location": [4283, 4336], "entities": [{"type": "Organization", "text": "Widen Market Footprint\nSelect CDx Collaborative Deals"}]}, {"text": "Announced", "location": [4337, 4346], "entities": [{"type": "EventCommunication", "text": "Announced"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.735672, "arguments": [{"text": "Dako PD-L1 IHC 22C3 pharmDx Assay", "location": [4509, 4542], "entities": [{"type": "Person", "text": "Dako PD-L1 IHC 22C3 pharmDx Assay"}]}, {"text": "Launches\nFoundation Medicine Unveils FoundationOne CDx\nAgilent Bags FDA Approval for", "location": [4424, 4508], "entities": [{"type": "Organization", "text": "Launches\nFoundation Medicine Unveils FoundationOne CDx\nAgilent Bags FDA Approval for"}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.52738, "arguments": [{"text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "location": [4666, 4747], "entities": [{"type": "Organization", "text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Urothelial Carcinoma\nRoche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test", "location": [4563, 4662], "entities": [{"type": "Organization", "text": "Urothelial Carcinoma\nRoche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test"}]}]}, {"type": "residesIn", "sentence": "This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "score": 0.589667, "arguments": [{"text": "Companion Diagnostics", "location": [533, 554], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "US$ Million", "location": [558, 569], "entities": [{"type": "GeopoliticalEntity", "text": "US$ Million"}]}]}, {"type": "basedIn", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.91448, "arguments": [{"text": "Roche Wins US", "location": [4757, 4770], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [4751, 4756], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.712751, "arguments": [{"text": "FDA", "location": [4771, 4774], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Roche Wins US", "location": [4757, 4770], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.534595, "arguments": [{"text": "Roche Wins US", "location": [4757, 4770], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Approval", "location": [4775, 4783], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.9814, "arguments": [{"text": "FDA", "location": [4771, 4774], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Approval", "location": [4775, 4783], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.625668, "arguments": [{"text": "Test v2", "location": [4808, 4815], "entities": [{"type": "Person", "text": "Test v2"}]}, {"text": "Approval", "location": [4775, 4783], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.427874, "arguments": [{"text": "CDx", "location": [4821, 4824], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "IRESSA\nMyriad Genetics Bags US FDA Approval for BRACAnalysis CDx\nMolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug\nThermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments", "location": [4830, 5066], "entities": [{"type": "Organization", "text": "IRESSA\nMyriad Genetics Bags US FDA Approval for BRACAnalysis CDx\nMolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug\nThermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments"}]}]}, {"type": "employedBy", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.257144, "arguments": [{"text": "Companion Diagnostics\nBristol-Myers Squibb", "location": [5263, 5305], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Hands", "location": [5312, 5317], "entities": [{"type": "Organization", "text": "Acquire Foundation Medicine\nThermo Fisher Scientific Joins Hands"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.455009, "arguments": [{"text": "NeoGenomics\nLabCorp Collaborates", "location": [5392, 5424], "entities": [{"type": "Organization", "text": "NeoGenomics\nLabCorp Collaborates"}]}, {"text": "Dx\nPPD forms Strategic Alliance", "location": [5355, 5386], "entities": [{"type": "Organization", "text": "Dx\nPPD forms Strategic Alliance"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.509417, "arguments": [{"text": "Unilabs\nQIAGEN Teams Up", "location": [5430, 5453], "entities": [{"type": "Organization", "text": "Unilabs\nQIAGEN Teams Up"}]}, {"text": "NeoGenomics\nLabCorp Collaborates", "location": [5392, 5424], "entities": [{"type": "Organization", "text": "NeoGenomics\nLabCorp Collaborates"}]}]}, {"type": "managerOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.420241, "arguments": [{"text": "Bliss", "location": [5492, 5497], "entities": [{"type": "Person", "text": "Bliss"}]}, {"text": "Biopharmaceutical\nFoundation Medicine", "location": [5498, 5535], "entities": [{"type": "Organization", "text": "Biopharmaceutical\nFoundation Medicine"}]}]}, {"type": "locatedAt", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.521136, "arguments": [{"text": "SA", "location": [715, 717], "entities": [{"type": "GeopoliticalEntity", "text": "SA"}]}, {"text": "France", "location": [719, 725], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.482372, "arguments": [{"text": "Join Thermo Fisher", "location": [5690, 5708], "entities": [{"type": "Person", "text": "Join Thermo Fisher"}]}, {"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5711, 5788], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}]}, {"type": "locatedAt", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.480631, "arguments": [{"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5711, 5788], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}, {"text": "North Carolina", "location": [5792, 5806], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.538313, "arguments": [{"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5711, 5788], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}, {"text": "Bristol-Myers Squibb Joins Hands", "location": [5807, 5839], "entities": [{"type": "Organization", "text": "Acquire Foundation Medicine\nThermo Fisher Scientific Joins Hands"}]}]}, {"type": "basedIn", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.834266, "arguments": [{"text": "Bristol-Myers Squibb Joins Hands", "location": [5807, 5839], "entities": [{"type": "Organization", "text": "Acquire Foundation Medicine\nThermo Fisher Scientific Joins Hands"}]}, {"text": "North Carolina", "location": [5792, 5806], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.574315, "arguments": [{"text": "Diagnostic Capabilities\nGrowing Cancer Incidence - An Opportunity Indicator", "location": [6100, 6175], "entities": [{"type": "Organization", "text": "Diagnostic Capabilities\nGrowing Cancer Incidence - An Opportunity Indicator"}]}, {"text": "Pharmaceutical Companies", "location": [6070, 6094], "entities": [{"type": "Organization", "text": "Pharmaceutical Companies"}]}]}, {"type": "authorOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.542309, "arguments": [{"text": "Companion Diagnostics\nList", "location": [6330, 6356], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Novel Paradigm", "location": [6312, 6326], "entities": [{"type": "TitleWork", "text": "Novel Paradigm"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.579496, "arguments": [{"text": "Companion Diagnostics\nList", "location": [6330, 6356], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "US", "location": [6360, 6362], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.638922, "arguments": [{"text": "FDA", "location": [6363, 6366], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [6360, 6362], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.509984, "arguments": [{"text": "Drug Development Fuel Demand\nList of FDA", "location": [6500, 6540], "entities": [{"type": "Organization", "text": "Drug Development Fuel Demand\nList of FDA"}]}, {"text": "Key Market Driver\nCompetitive Scenario\nRegulatory Overview\nFDA Requirements", "location": [6421, 6496], "entities": [{"type": "Organization", "text": "Key Market Driver\nCompetitive Scenario\nRegulatory Overview\nFDA Requirements"}]}]}, {"type": "managerOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.225958, "arguments": [{"text": "Higher R&D Spending", "location": [6598, 6617], "entities": [{"type": "Person", "text": "Higher R&D Spending"}]}, {"text": "Canada", "location": [6591, 6597], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.492357, "arguments": [{"text": "Danaher Corporation", "location": [741, 760], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [736, 739], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.614724, "arguments": [{"text": "Underpin CDx Revenues\nCancer Incidence", "location": [6621, 6659], "entities": [{"type": "Organization", "text": "Underpin CDx Revenues\nCancer Incidence"}]}, {"text": "Canada", "location": [6663, 6669], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.683166, "arguments": [{"text": "Companion Diagnostics\nRegulatory Scenario", "location": [6697, 6738], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Indicator for", "location": [6683, 6696], "entities": [{"type": "Organization", "text": "Indicator for"}]}]}, {"type": "residesIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.432518, "arguments": [{"text": "Companion Diagnostics\nRegulatory Scenario", "location": [6697, 6738], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Japan", "location": [6743, 6748], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.694495, "arguments": [{"text": "Growth", "location": [6774, 6780], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Spurs", "location": [6768, 6773], "entities": [{"type": "Organization", "text": "Spurs", "disambiguation": {"subtype": ["Sports"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.537173, "arguments": [{"text": "CDx\nCancer Incidence", "location": [6925, 6945], "entities": [{"type": "Organization", "text": "CDx\nCancer Incidence"}]}, {"text": "Europe", "location": [6949, 6955], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.317603, "arguments": [{"text": "Asia-Pacific", "location": [7048, 7060], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "Growing Market\nUptrend", "location": [7071, 7093], "entities": [{"type": "Organization", "text": "Growing Market\nUptrend"}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.833383, "arguments": [{"text": "Breast Cancer CDx", "location": [7149, 7166], "entities": [{"type": "Organization", "text": "Breast Cancer CDx"}]}, {"text": "China", "location": [7143, 7148], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.572924, "arguments": [{"text": "Dominant Category\nLaboratory Equipment & Supplies Sector", "location": [7168, 7224], "entities": [{"type": "Organization", "text": "Dominant Category\nLaboratory Equipment & Supplies Sector"}]}, {"text": "China", "location": [7228, 7233], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "COMPANY PROFILES For more information about this report visit https://www.researchandmarkets.com/research/wq6mtw/companion?w=4 P Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Diagnostics , In Vitro Diagnostics", "score": 0.604352, "arguments": [{"text": "Laura Wood", "location": [7447, 7457], "entities": [{"type": "Person", "text": "Laura Wood"}]}, {"text": "P\nContacts ResearchAndMarkets.com", "location": [7413, 7446], "entities": [{"type": "Organization", "text": "P\nContacts ResearchAndMarkets.com", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.473406, "arguments": [{"text": "F. Hoffmann-La Roche Ltd.", "location": [767, 792], "entities": [{"type": "Organization", "text": "F. Hoffmann-La Roche Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [762, 765], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.522437, "arguments": [{"text": "QIAGEN N.V.", "location": [1004, 1015], "entities": [{"type": "Person", "text": "QIAGEN N.V."}]}, {"text": "Netherlands", "location": [1017, 1028], "entities": [{"type": "Organization", "text": "Netherlands"}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.789002, "arguments": [{"text": "Scope", "location": [1354, 1359], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Wield Great Promise for Streamlined Drug Discovery & Development\nBroader", "location": [1281, 1353], "entities": [{"type": "Organization", "text": "Wield Great Promise for Streamlined Drug Discovery & Development\nBroader"}]}]}], "keywords": [{"text": "Companion Diagnostics", "sentiment": {"score": 0.926751, "label": "positive"}, "relevance": 0.665296, "count": 10}, {"text": "USA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593555, "count": 11}, {"text": "Agilent Bags FDA Approval", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.575514, "count": 1}, {"text": "Global Strategic Business Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572164, "count": 1}, {"text": "Foundation Medicine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56506, "count": 1}, {"text": "Agilent Technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563415, "count": 1}, {"text": "Thermo Fisher Scientific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562367, "count": 1}, {"text": "Abbott Molecular", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562063, "count": 1}, {"text": "Myriad Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5534, "count": 1}, {"text": "F. Hoffmann-La Roche Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550573, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549973, "count": 6}, {"text": "QIAGEN N.V.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543213, "count": 1}, {"text": "markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541783, "count": 1}, {"text": "Personalized Medicine", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.541665, "count": 1}, {"text": "report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54059, "count": 4}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537016, "count": 1}, {"text": "Leica Biosystems Nussloch GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536064, "count": 1}, {"text": "US", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.534933, "count": 3}, {"text": "Latin America", "sentiment": {"score": 0.977743, "label": "positive"}, "relevance": 0.533862, "count": 2}, {"text": "Broader Scope", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.533058, "count": 1}, {"text": "Laboratory Corporation of America Holdings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532797, "count": 1}, {"text": "Significant Cost Reductions", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.53185, "count": 1}, {"text": "Product Approvals", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.531837, "count": 1}, {"text": "Incidence of Cancer", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.531367, "count": 1}, {"text": "United States", "sentiment": {"score": 0.899854, "label": "positive"}, "relevance": 0.531051, "count": 2}, {"text": "Quest Diagnostics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530429, "count": 1}, {"text": "six-year", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525307, "count": 1}, {"text": "CDx", "sentiment": {"score": 0.913859, "label": "positive"}, "relevance": 0.523246, "count": 5}, {"text": "US FDA Approval", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.523026, "count": 2}, {"text": "Danaher Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522882, "count": 1}, {"text": "Market data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5204, "count": 1}, {"text": "Myriad Bags Manufacturing", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.520166, "count": 1}, {"text": "Merck", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.519972, "count": 2}, {"text": "Strategic Alliance", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.519158, "count": 1}, {"text": "Breast Cancer", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.518434, "count": 1}, {"text": "Pharmaceutical Company", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.51791, "count": 1}, {"text": "Thermo Fisher's CDx Center", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.517183, "count": 1}, {"text": "Biomarkers", "sentiment": {"score": 0.916223, "label": "positive"}, "relevance": 0.51702, "count": 2}, {"text": "EGFRx Assay", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.516487, "count": 1}, {"text": "Recent Past", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.516421, "count": 1}, {"text": "Switzerland", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516404, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515008, "count": 1}, {"text": "Drug Discovery", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.514821, "count": 1}, {"text": "Generation", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.514754, "count": 1}, {"text": "Great Promise", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.514461, "count": 1}, {"text": "Germany", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513928, "count": 1}, {"text": "PCR CDx Vertical", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.513842, "count": 1}, {"text": "Medicine", "sentiment": {"score": 0.96173, "label": "positive"}, "relevance": 0.513778, "count": 2}, {"text": "Cancer Treatment", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.513582, "count": 1}, {"text": "Role", "sentiment": {"score": 0.977743, "label": "positive"}, "relevance": 0.513008, "count": 1}]}, "extracted_metadata": {"sha1": "3e7732a32f0cadf81a241e9a2c9140a16e7abbc9", "filename": "1542422099708.zip-31ab5124a4fdfea85063241dddf6f200.xml", "file_type": "json"}, "external_links": ["https://www.researchandmarkets.com/research/wq6mtw/companion?w=4", "https://www.researchandmarkets.com/categories.asp?cat_id=237&campaign_id=wq6mtw", "https://www.researchandmarkets.com/categories.asp?cat_id=59&campaign_id=wq6mtw"], "title": "Companion Diagnostics Markets, 2015-2022: Oncology, Neurology & Others - Global Strategic Business Report 2018 - ResearchAndMarkets.com", "forum_title": "All News | Business Wire"}, {"id": "piVfNnOKghYPvHKfoZtR9PFpqe2XP8ptL7YhruRigwIez1IuyJ73Tq3EU7OGgIXI", "result_metadata": {"score": 28.73877}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Aventis", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Insomnia Therapeutics Market", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Sanofi-Aventis", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}, {"text": "Hoechst AG", "relevance": 0.891859, "dbpedia_resource": "http://dbpedia.org/resource/Hoechst_AG"}, {"text": "Aventis", "relevance": 0.863519, "dbpedia_resource": "http://dbpedia.org/resource/Aventis"}, {"text": "InnoMed PredTox", "relevance": 0.846036, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}, {"text": "Rh\u00f4ne-Poulenc", "relevance": 0.834539, "dbpedia_resource": "http://dbpedia.org/resource/Rh\u00f4ne-Poulenc"}, {"text": "Zolpidem", "relevance": 0.736978, "dbpedia_resource": "http://dbpedia.org/resource/Zolpidem"}, {"text": "Olanzapine", "relevance": 0.650827, "dbpedia_resource": "http://dbpedia.org/resource/Olanzapine"}, {"text": "Eli Lilly and Company", "relevance": 0.627417, "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}, {"text": "Lilly Endowment", "relevance": 0.615825, "dbpedia_resource": "http://dbpedia.org/resource/Lilly_Endowment"}, {"text": "Eli Lilly", "relevance": 0.602605, "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}, {"text": "Sanofi Pasteur", "relevance": 0.598437, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi_Pasteur"}], "categories": [{"score": 0.772239, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.754713, "label": "/health and fitness/disorders/sleep disorders"}, {"score": 0.663507, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "employedBy", "sentence": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis", "score": 0.504709, "arguments": [{"text": "players", "location": [29, 36], "entities": [{"type": "Person", "text": "players"}]}, {"text": "Insomnia Therapeutics Market", "location": [0, 28], "entities": [{"type": "Organization", "text": "Insomnia Therapeutics Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis", "score": 0.962826, "arguments": [{"text": "Eli Lilly", "location": [37, 46], "entities": [{"type": "Person", "text": "Eli Lilly"}]}, {"text": "players", "location": [29, 36], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOfMany", "sentence": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis", "score": 0.961748, "arguments": [{"text": "Takeda", "location": [48, 54], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "players", "location": [29, 36], "entities": [{"type": "Person", "text": "players"}]}]}], "keywords": [{"text": "Sanofi Aventis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.885021, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.722022, "count": 1}, {"text": "Insomnia Therapeutics Market players Eli Lilly", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568395, "count": 1}]}, "crawl_date": "2018-11-16T15:31:21Z", "url": "https://industrytoday.co.uk/health_and_safety/insomnia-therapeutics-market-players-eli-lilly--takeda--sanofi-aventis/167415/167415", "host": "industrytoday.co.uk", "text": "Ltd.305 Broadway,7th Floor", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T09:35:00Z", "enriched_text": {"entities": [{"count": 13, "sentiment": {"score": -0.783728, "label": "negative"}, "text": "Insomnia", "relevance": 0.840849, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Insomnia Therapeutics Market", "relevance": 0.486959, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.272435, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Aventis", "relevance": 0.234346, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.212803, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Aventis", "relevance": 0.21233, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.887145, "label": "negative"}, "text": "Alzheimer", "relevance": 0.154566, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "OrganizationSector"], "name": "Alzheimer's disease", "dbpedia_resource": "http://dbpedia.org/resource/Alzheimer's_disease"}}, {"count": 1, "sentiment": {"score": -0.620788, "label": "negative"}, "text": "benzodiazepine", "relevance": 0.154049, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.274751, "label": "negative"}, "text": "Zolpidem", "relevance": 0.146078, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.14514, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Trazodone", "relevance": 0.143443, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.140611, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zaleplon", "relevance": 0.122215, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@IndustryToday", "relevance": 0.122215, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.902938, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Insomnia", "keywords": [{"text": "Insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "sentence": " Insomnia may be defined as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs.", "object": {"text": "as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs", "keywords": [{"text": "non-restorative sleep"}, {"text": "lack"}, {"text": "pharmaceuticals"}, {"text": "drugs"}]}, "action": {"verb": {"text": "define", "tense": "future"}, "text": "may be defined", "normalized": "may be define"}}, {"subject": {"text": "A long term insomnia", "keywords": [{"text": "long term insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "sentence": " A long term insomnia may be a result of primary sleep disorder or a psychiatric illness.", "object": {"text": "a result of primary sleep disorder or a psychiatric illness", "keywords": [{"text": "primary sleep disorder"}, {"text": "psychiatric illness"}, {"text": "result"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "may be", "normalized": "may be"}}, {"subject": {"text": "Insomnia", "keywords": [{"text": "Insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "sentence": " Insomnia is a major issue during day time since it hampers daily activities and may cause irritation, lack of alertness consequently leading to increased risk for accidents.", "object": {"text": "a major issue", "keywords": [{"text": "major issue"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Insomnia is a major issue during day time since it hampers daily activities and may cause irritation, lack of alertness consequently leading to increased risk for accidents.", "object": {"text": "daily activities", "keywords": [{"text": "daily activities"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hampers", "normalized": "hamper"}}, {"subject": {"text": "us"}, "sentence": " Follow us on Twitter @IndustryToday", "object": {"text": "on Twitter @IndustryToday", "keywords": [{"text": "Twitter"}], "entities": [{"type": "TwitterHandle", "text": "@IndustryToday"}]}, "action": {"verb": {"text": "Follow", "tense": "present"}, "text": "Follow", "normalized": "Follow"}}, {"subject": {"text": "Insomnia", "keywords": [{"text": "Insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "sentence": " Insomnia may be defined as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs.", "object": {"text": "as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs", "keywords": [{"text": "non-restorative sleep"}, {"text": "lack"}, {"text": "pharmaceuticals"}, {"text": "drugs"}]}, "action": {"verb": {"text": "define", "tense": "future"}, "text": "may be defined", "normalized": "may be define"}}, {"subject": {"text": "A long term insomnia", "keywords": [{"text": "long term insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "sentence": " A long term insomnia may be a result of primary sleep disorder or a psychiatric illness.", "object": {"text": "a result of primary sleep disorder or a psychiatric illness", "keywords": [{"text": "primary sleep disorder"}, {"text": "psychiatric illness"}, {"text": "result"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "may be", "normalized": "may be"}}, {"subject": {"text": "Insomnia", "keywords": [{"text": "Insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "sentence": " Insomnia is a major issue during day time since it hampers daily activities and may cause irritation, lack of alertness consequently leading to increased risk for accidents.", "object": {"text": "a major issue", "keywords": [{"text": "major issue"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Insomnia is a major issue during day time since it hampers daily activities and may cause irritation, lack of alertness consequently leading to increased risk for accidents.", "object": {"text": "daily activities", "keywords": [{"text": "daily activities"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hampers", "normalized": "hamper"}}, {"subject": {"text": "loss of a loved person", "keywords": [{"text": "loved person"}, {"text": "loss"}]}, "sentence": " Increased stress factors such as job loss, family disharmony and loss of a loved person may also be the causative factors for insomnia.", "object": {"text": "the causative factors for insomnia", "keywords": [{"text": "causative factors"}, {"text": "insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "may also be", "normalized": "may also be"}}, {"subject": {"text": "The geriatric population", "keywords": [{"text": "geriatric population"}]}, "sentence": " The geriatric population is more prone for insomnia as compared to young people this is due to drug side-effects arising from treatment of chronic diseases.", "object": {"text": "more prone for insomnia", "keywords": [{"text": "insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "insomnia", "keywords": [{"text": "insomnia"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "sentence": " The geriatric population is more prone for insomnia as compared to young people this is due to drug side-effects arising from treatment of chronic diseases.", "object": {"text": "to young people this is due to drug side-effects arising from treatment of chronic diseases", "keywords": [{"text": "drug side-effects"}, {"text": "chronic diseases"}, {"text": "young people"}, {"text": "treatment"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Request Report Sample@ https://www.persistencemarketresearch.com/samples/5555 There", "keywords": [{"text": "Request Report Sample"}]}, "sentence": " Request Report Sample@ https://www.persistencemarketresearch.com/samples/5555 There have been several drugs available for the treatment of short and chronic insomnia.", "object": {"text": "been several drugs available for the treatment of short and chronic insomnia", "keywords": [{"text": "chronic insomnia"}, {"text": "drugs"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Request Report Sample@ https://www.persistencemarketresearch.com/samples/5555 There", "keywords": [{"text": "Request Report Sample"}]}, "sentence": " Request Report Sample@ https://www.persistencemarketresearch.com/samples/5555 There have been several drugs available for the treatment of short and chronic insomnia.", "object": {"text": "several drugs available for the treatment of short and chronic insomnia", "keywords": [{"text": "chronic insomnia"}, {"text": "drugs"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "have been", "normalized": "have be"}}, {"subject": {"text": "The most common drugs", "keywords": [{"text": "common drugs"}]}, "sentence": " The most common drugs used for treatment include benzodiazepines, Zolpidem, Zaleplon, Tricyclic Antidepressants, Trazodone and several new generation antidepressants.", "object": {"text": "for treatment include benzodiazepines", "keywords": [{"text": "benzodiazepines"}, {"text": "treatment"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "benzodiazepines, Zolpidem, Zaleplon, Tricyclic Antidepressants, Trazodone and several new generation antidepressants", "keywords": [{"text": "Tricyclic Antidepressants"}, {"text": "new generation antidepressants"}, {"text": "Zolpidem"}, {"text": "benzodiazepines"}], "entities": [{"type": "Drug", "text": "Zolpidem"}, {"type": "Drug", "text": "Zaleplon"}, {"type": "Drug", "text": "Trazodone"}]}, "sentence": " The most common drugs used for treatment include benzodiazepines, Zolpidem, Zaleplon, Tricyclic Antidepressants, Trazodone and several new generation antidepressants.", "object": {"text": "The most common drugs used for treatment", "keywords": [{"text": "common drugs"}, {"text": "treatment"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The benzodiazepine class of drugs", "keywords": [{"text": "benzodiazepine class"}, {"text": "drugs"}], "entities": [{"type": "Drug", "text": "benzodiazepine"}]}, "sentence": " The benzodiazepine class of drugs are used especially for short term treatment option and is commonly recommended for active persons and the elderly as they are easily eliminated from the body.", "object": {"text": "commonly recommended for active persons and the elderly", "keywords": [{"text": "active persons"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "they"}, "sentence": " The benzodiazepine class of drugs are used especially for short term treatment option and is commonly recommended for active persons and the elderly as they are easily eliminated from the body.", "object": {"text": "from the body", "keywords": [{"text": "body"}]}, "action": {"verb": {"text": "eliminate", "tense": "past"}, "text": "eliminated", "normalized": "eliminate"}}, {"subject": {"text": "The other class of insomnia drugs", "keywords": [{"text": "insomnia drugs"}, {"text": "class"}]}, "sentence": " The other class of insomnia drugs are myorelaxant along with anxiolytic properties.", "object": {"text": "myorelaxant along"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Prolong use of these drugs", "keywords": [{"text": "Prolong"}, {"text": "drugs"}]}, "sentence": " Prolong use of these drugs may cause dependency and addiction.", "object": {"text": "dependency and addiction", "keywords": [{"text": "dependency"}, {"text": "addiction"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "may cause", "normalized": "may cause"}}, {"subject": {"text": "these drugs", "keywords": [{"text": "drugs"}]}, "sentence": " Hence, these drugs must be taken under medical supervision.", "action": {"verb": {"text": "be", "tense": "future"}, "text": "must be taken", "normalized": "must be take"}}, {"subject": {"text": "The major factors", "keywords": [{"text": "major factors"}]}, "sentence": " The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease that require sedatives as one of the drug needed to be administered.", "object": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "The major factors driving the growth of this market", "keywords": [{"text": "major factors"}, {"text": "growth"}, {"text": "market"}]}, "sentence": " The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease that require sedatives as one of the drug needed to be administered.", "object": {"text": "rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease", "keywords": [{"text": "long lasting diseases"}, {"text": "geriatric population"}, {"text": "younger generation"}, {"text": "stress levels"}], "entities": [{"type": "HealthCondition", "text": "Alzheimer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "OrganizationSector"], "name": "Alzheimer's disease", "dbpedia_resource": "http://dbpedia.org/resource/Alzheimer's_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The major factors driving the growth of this market", "keywords": [{"text": "major factors"}, {"text": "growth"}, {"text": "market"}]}, "sentence": " The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease that require sedatives as one of the drug needed to be administered.", "object": {"text": "in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease that require sedatives as one of the drug needed to be administered", "keywords": [{"text": "long lasting diseases"}, {"text": "geriatric population"}, {"text": "younger generation"}, {"text": "stress levels"}], "entities": [{"type": "HealthCondition", "text": "Alzheimer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "OrganizationSector"], "name": "Alzheimer's disease", "dbpedia_resource": "http://dbpedia.org/resource/Alzheimer's_disease"}}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "is rise", "normalized": "be rise"}}, {"subject": {"text": "The major factors driving the growth of this market", "keywords": [{"text": "major factors"}, {"text": "growth"}, {"text": "market"}]}, "sentence": " The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease that require sedatives as one of the drug needed to be administered.", "object": {"text": "in number of mental disorders", "keywords": [{"text": "mental disorders"}, {"text": "number"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "stress levels", "keywords": [{"text": "stress levels"}]}, "sentence": " The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease that require sedatives as one of the drug needed to be administered.", "object": {"text": "among the younger generation coupled with rise in chronic and long lasting diseases such as cancers", "keywords": [{"text": "long lasting diseases"}, {"text": "younger generation"}, {"text": "cancers"}, {"text": "rise"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "Alzheimer\u2019s and Parkinson\u2019s disease", "keywords": [{"text": "Parkinson"}, {"text": "Alzheimer"}, {"text": "disease"}], "entities": [{"type": "HealthCondition", "text": "Alzheimer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "OrganizationSector"], "name": "Alzheimer's disease", "dbpedia_resource": "http://dbpedia.org/resource/Alzheimer's_disease"}}]}, "sentence": " The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer\u2019s and Parkinson\u2019s disease that require sedatives as one of the drug needed to be administered.", "object": {"text": "as one of the drug needed to be administered", "keywords": [{"text": "drug"}]}, "action": {"verb": {"text": "require", "tense": "present"}, "text": "require", "normalized": "require"}}, {"subject": {"text": "by Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Geographically, the North America accounts for the largest market in terms of consumption followed by Europe.", "object": {"text": "the largest market in terms of consumption", "keywords": [{"text": "consumption"}, {"text": "largest market"}, {"text": "terms"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "rise in chronic diseases in the Asian region along with rising disposable income", "keywords": [{"text": "disposable income"}, {"text": "chronic diseases"}, {"text": "Asian region"}, {"text": "rise"}]}, "sentence": " However, rise in chronic diseases in the Asian region along with rising disposable income has boosted the market for insomnia therapeutics market.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "has boosted", "normalized": "have boost"}}, {"subject": {"text": "Eli Lilly, Takeda, Sanofi Aventis and others", "keywords": [{"text": "Sanofi Aventis"}, {"text": "Eli Lilly"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Takeda"}, {"type": "JobTitle", "text": "Sanofi Aventis"}]}, "sentence": " The significant players of this market include Eli Lilly, Takeda, Sanofi Aventis and others.", "object": {"text": "The significant players of this market", "keywords": [{"text": "significant players"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Benzodiazepine", "relevance": 0.946958, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine"}, {"text": "Insomnia", "relevance": 0.922787, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Medicine", "relevance": 0.795617, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Mental disorder", "relevance": 0.678808, "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}, {"text": "Zolpidem", "relevance": 0.653948, "dbpedia_resource": "http://dbpedia.org/resource/Zolpidem"}, {"text": "Nonbenzodiazepine", "relevance": 0.650456, "dbpedia_resource": "http://dbpedia.org/resource/Nonbenzodiazepine"}, {"text": "Hypnotic", "relevance": 0.643151, "dbpedia_resource": "http://dbpedia.org/resource/Hypnotic"}, {"text": "Sleep deprivation", "relevance": 0.635281, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_deprivation"}, {"text": "Economics", "relevance": 0.586812, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Zopiclone", "relevance": 0.584978, "dbpedia_resource": "http://dbpedia.org/resource/Zopiclone"}, {"text": "Drug", "relevance": 0.555759, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Antidepressant", "relevance": 0.551148, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Causality", "relevance": 0.528616, "dbpedia_resource": "http://dbpedia.org/resource/Causality"}, {"text": "Sanofi-Aventis", "relevance": 0.523206, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}, {"text": "Sleep disorder", "relevance": 0.492729, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_disorder"}, {"text": "Caffeine", "relevance": 0.491744, "dbpedia_resource": "http://dbpedia.org/resource/Caffeine"}, {"text": "Term", "relevance": 0.479113, "dbpedia_resource": "http://dbpedia.org/resource/Term_(time)"}, {"text": "Sleep medicine", "relevance": 0.46564, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_medicine"}, {"text": "Sleep disorders", "relevance": 0.463715, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_disorders"}, {"text": "Circadian rhythm", "relevance": 0.462765, "dbpedia_resource": "http://dbpedia.org/resource/Circadian_rhythm"}, {"text": "Time", "relevance": 0.455034, "dbpedia_resource": "http://dbpedia.org/resource/Time"}, {"text": "Selective serotonin reuptake inhibitor", "relevance": 0.439448, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Pharmacology", "relevance": 0.438264, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Trazodone", "relevance": 0.431372, "dbpedia_resource": "http://dbpedia.org/resource/Trazodone"}, {"text": "Tricyclic antidepressant", "relevance": 0.425784, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Mirtazapine", "relevance": 0.423412, "dbpedia_resource": "http://dbpedia.org/resource/Mirtazapine"}, {"text": "Hoechst AG", "relevance": 0.419727, "dbpedia_resource": "http://dbpedia.org/resource/Hoechst_AG"}, {"text": "Zaleplon", "relevance": 0.407435, "dbpedia_resource": "http://dbpedia.org/resource/Zaleplon"}, {"text": "Delayed sleep phase syndrome", "relevance": 0.400503, "dbpedia_resource": "http://dbpedia.org/resource/Delayed_sleep_phase_syndrome"}, {"text": "Aventis", "relevance": 0.391115, "dbpedia_resource": "http://dbpedia.org/resource/Aventis"}, {"text": "Rh\u00f4ne-Poulenc", "relevance": 0.377315, "dbpedia_resource": "http://dbpedia.org/resource/Rh\u00f4ne-Poulenc"}, {"text": "Olanzapine", "relevance": 0.369347, "dbpedia_resource": "http://dbpedia.org/resource/Olanzapine"}, {"text": "Triazolam", "relevance": 0.368301, "dbpedia_resource": "http://dbpedia.org/resource/Triazolam"}, {"text": "Diazepam", "relevance": 0.367119, "dbpedia_resource": "http://dbpedia.org/resource/Diazepam"}, {"text": "Amphetamine", "relevance": 0.363934, "dbpedia_resource": "http://dbpedia.org/resource/Amphetamine"}, {"text": "Bipolar disorder", "relevance": 0.363696, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Temazepam", "relevance": 0.358765, "dbpedia_resource": "http://dbpedia.org/resource/Temazepam"}, {"text": "Flunitrazepam", "relevance": 0.356778, "dbpedia_resource": "http://dbpedia.org/resource/Flunitrazepam"}, {"text": "InnoMed PredTox", "relevance": 0.351004, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}, {"text": "Short", "relevance": 0.349778, "dbpedia_resource": "http://dbpedia.org/resource/Short_(finance)"}, {"text": "Amitriptyline", "relevance": 0.349762, "dbpedia_resource": "http://dbpedia.org/resource/Amitriptyline"}, {"text": "Psychiatry", "relevance": 0.346613, "dbpedia_resource": "http://dbpedia.org/resource/Psychiatry"}, {"text": "Benzodiazepine withdrawal syndrome", "relevance": 0.346346, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine_withdrawal_syndrome"}, {"text": "Narcolepsy", "relevance": 0.338927, "dbpedia_resource": "http://dbpedia.org/resource/Narcolepsy"}, {"text": "Nitrazepam", "relevance": 0.336816, "dbpedia_resource": "http://dbpedia.org/resource/Nitrazepam"}, {"text": "Antidepressants", "relevance": 0.334585, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressants"}, {"text": "Recreational drug use", "relevance": 0.331291, "dbpedia_resource": "http://dbpedia.org/resource/Recreational_drug_use"}, {"text": "Opioid", "relevance": 0.330108, "dbpedia_resource": "http://dbpedia.org/resource/Opioid"}, {"text": "Rebound effect", "relevance": 0.326102, "dbpedia_resource": "http://dbpedia.org/resource/Rebound_effect"}, {"text": "Drug addiction", "relevance": 0.319572, "dbpedia_resource": "http://dbpedia.org/resource/Drug_addiction"}], "categories": [{"score": 0.994693, "label": "/health and fitness"}, {"score": 0.972071, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}, {"score": 0.937327, "label": "/health and fitness/disorders/sleep disorders"}], "relations": [{"type": "employedBy", "sentence": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis Insomnia may be defined as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs.", "score": 0.467879, "arguments": [{"text": "players", "location": [29, 36], "entities": [{"type": "Person", "text": "players"}]}, {"text": "Insomnia Therapeutics Market", "location": [0, 28], "entities": [{"type": "Organization", "text": "Insomnia Therapeutics Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "The most common drugs used for treatment include benzodiazepines, Zolpidem, Zaleplon, Tricyclic Antidepressants, Trazodone and several new generation antidepressants.", "score": 0.640886, "arguments": [{"text": "Zolpidem", "location": [1471, 1479], "entities": [{"type": "GeopoliticalEntity", "text": "Zolpidem"}]}, {"text": "Zaleplon", "location": [1481, 1489], "entities": [{"type": "GeopoliticalEntity", "text": "Zaleplon"}]}]}, {"type": "affectedBy", "sentence": "The benzodiazepine class of drugs are used especially for short term treatment option and is commonly recommended for active persons and the elderly as they are easily eliminated from the body.", "score": 0.726287, "arguments": [{"text": "they", "location": [1724, 1728], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "eliminated", "location": [1740, 1750], "entities": [{"type": "EventPersonnel", "text": "eliminated"}]}]}, {"type": "agentOf", "sentence": "The benzodiazepine class of drugs are used especially for short term treatment option and is commonly recommended for active persons and the elderly as they are easily eliminated from the body.", "score": 0.639893, "arguments": [{"text": "body", "location": [1760, 1764], "entities": [{"type": "Person", "text": "Report Sample@"}]}, {"text": "eliminated", "location": [1740, 1750], "entities": [{"type": "EventPersonnel", "text": "eliminated"}]}]}, {"type": "hasAttribute", "sentence": "Visit For TOC@ https://www.persistencemarketresearch.com/toc/5555 The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer's and Parkinson's disease that require sedatives as one of the drug needed to be administered.", "score": 0.54803, "arguments": [{"text": "TOC@", "location": [1983, 1987], "entities": [{"type": "Organization", "text": "TOC@"}]}, {"text": "https://www.persistencemarketresearch.com/toc/", "location": [1988, 2034], "entities": [{"type": "Web", "text": "https://www.persistencemarketresearch.com/toc/"}]}]}, {"type": "partOfMany", "sentence": "Visit For TOC@ https://www.persistencemarketresearch.com/toc/5555 The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer's and Parkinson's disease that require sedatives as one of the drug needed to be administered.", "score": 0.747846, "arguments": [{"text": "cancers", "location": [2274, 2281], "entities": [{"type": "HealthCondition", "text": "mental disorders"}]}, {"text": "diseases", "location": [2257, 2265], "entities": [{"type": "HealthCondition", "text": "chronic diseases"}]}]}, {"type": "hasAttribute", "sentence": "Visit For TOC@ https://www.persistencemarketresearch.com/toc/5555 The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer's and Parkinson's disease that require sedatives as one of the drug needed to be administered.", "score": 0.633869, "arguments": [{"text": "Alzheimer", "location": [2283, 2292], "entities": [{"type": "Person", "text": "Alzheimer"}]}, {"text": "diseases", "location": [2257, 2265], "entities": [{"type": "HealthCondition", "text": "chronic diseases"}]}]}, {"type": "partOfMany", "sentence": "Visit For TOC@ https://www.persistencemarketresearch.com/toc/5555 The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer's and Parkinson's disease that require sedatives as one of the drug needed to be administered.", "score": 0.505392, "arguments": [{"text": "Parkinson\u2019s disease", "location": [2299, 2318], "entities": [{"type": "HealthCondition", "text": "Parkinson\u2019s disease"}]}, {"text": "diseases", "location": [2257, 2265], "entities": [{"type": "HealthCondition", "text": "chronic diseases"}]}]}, {"type": "hasAttribute", "sentence": "Visit For TOC@ https://www.persistencemarketresearch.com/toc/5555 The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer's and Parkinson's disease that require sedatives as one of the drug needed to be administered.", "score": 0.516021, "arguments": [{"text": "Alzheimer", "location": [2283, 2292], "entities": [{"type": "Person", "text": "Alzheimer"}]}, {"text": "cancers", "location": [2274, 2281], "entities": [{"type": "HealthCondition", "text": "mental disorders"}]}]}, {"type": "hasAttribute", "sentence": "Visit For TOC@ https://www.persistencemarketresearch.com/toc/5555 The major factors driving the growth of this market is rise in geriatric population, rise in number of mental disorders, growing stress levels among the younger generation coupled with rise in chronic and long lasting diseases such as cancers, Alzheimer's and Parkinson's disease that require sedatives as one of the drug needed to be administered.", "score": 0.507821, "arguments": [{"text": "Alzheimer", "location": [2283, 2292], "entities": [{"type": "Person", "text": "Alzheimer"}]}, {"text": "Parkinson\u2019s disease", "location": [2299, 2318], "entities": [{"type": "HealthCondition", "text": "Parkinson\u2019s disease"}]}]}, {"type": "partOfMany", "sentence": "The significant players of this market include Eli Lilly, Takeda, Sanofi Aventis and others.", "score": 0.671783, "arguments": [{"text": "Eli Lilly", "location": [2692, 2701], "entities": [{"type": "Person", "text": "Eli Lilly"}]}, {"text": "others", "location": [2730, 2736], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis Insomnia may be defined as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs.", "score": 0.913064, "arguments": [{"text": "Eli Lilly", "location": [37, 46], "entities": [{"type": "Person", "text": "Eli Lilly"}]}, {"text": "players", "location": [29, 36], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOfMany", "sentence": "The significant players of this market include Eli Lilly, Takeda, Sanofi Aventis and others.", "score": 0.959862, "arguments": [{"text": "Takeda", "location": [2703, 2709], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "others", "location": [2730, 2736], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "The significant players of this market include Eli Lilly, Takeda, Sanofi Aventis and others.", "score": 0.636196, "arguments": [{"text": "Sanofi Aventis", "location": [2711, 2725], "entities": [{"type": "Person", "text": "Sanofi Aventis\nInsomnia"}]}, {"text": "others", "location": [2730, 2736], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis Insomnia may be defined as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs.", "score": 0.867201, "arguments": [{"text": "Takeda", "location": [48, 54], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "players", "location": [29, 36], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOfMany", "sentence": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis Insomnia may be defined as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs.", "score": 0.492924, "arguments": [{"text": "Sanofi Aventis\nInsomnia", "location": [56, 79], "entities": [{"type": "Person", "text": "Sanofi Aventis\nInsomnia"}]}, {"text": "players", "location": [29, 36], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOf", "sentence": "Follow us on Twitter @IndustryToday Insomnia may be defined as lack of sleep or non-restorative sleep, which may be caused due to stress or use of some pharmaceuticals or drugs.", "score": 0.605842, "arguments": [{"text": "Insomnia", "location": [540, 548], "entities": [{"type": "Organization", "text": "Insomnia Therapeutics Market", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Twitter", "location": [517, 524], "entities": [{"type": "Organization", "text": "Twitter"}]}]}, {"type": "hasAttribute", "sentence": "Increased stress factors such as job loss, family disharmony and loss of a loved person may also be the causative factors for insomnia.", "score": 0.539294, "arguments": [{"text": "person", "location": [1026, 1032], "entities": [{"type": "Person", "text": "person"}]}, {"text": "insomnia", "location": [1071, 1079], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "hasAttribute", "sentence": "The geriatric population is more prone for insomnia as compared to young people this is due to drug side-effects arising from treatment of chronic diseases.", "score": 0.817009, "arguments": [{"text": "people", "location": [1154, 1160], "entities": [{"type": "Person", "text": "people"}]}, {"text": "insomnia", "location": [1124, 1132], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "agentOf", "sentence": "Request Report Sample@ https://www.persistencemarketresearch.com/samples/5555 There have been several drugs available for the treatment of short and chronic insomnia.", "score": 0.726093, "arguments": [{"text": "Report Sample@", "location": [1246, 1260], "entities": [{"type": "Person", "text": "Report Sample@"}]}, {"text": "Request", "location": [1238, 1245], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "hasAttribute", "sentence": "Request Report Sample@ https://www.persistencemarketresearch.com/samples/5555 There have been several drugs available for the treatment of short and chronic insomnia.", "score": 0.557711, "arguments": [{"text": "Report Sample@", "location": [1246, 1260], "entities": [{"type": "Person", "text": "Report Sample@"}]}, {"text": "chronic insomnia", "location": [1387, 1403], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}], "keywords": [{"text": "long term insomnia", "sentiment": {"score": -0.862806, "label": "negative"}, "relevance": 0.676685, "count": 2}, {"text": "major issue", "sentiment": {"score": -0.976992, "label": "negative"}, "relevance": 0.66441, "count": 2}, {"text": "treatment of chronic diseases", "sentiment": {"score": -0.9405, "label": "negative"}, "relevance": 0.645863, "count": 1}, {"text": "Insomnia", "sentiment": {"score": -0.94149, "label": "negative"}, "relevance": 0.633891, "count": 3}, {"text": "geriatric population", "sentiment": {"score": -0.953234, "label": "negative"}, "relevance": 0.600235, "count": 2}, {"text": "drugs", "sentiment": {"score": -0.876671, "label": "negative"}, "relevance": 0.598784, "count": 4}, {"text": "stress factors", "sentiment": {"score": -0.942932, "label": "negative"}, "relevance": 0.592272, "count": 1}, {"text": "young people", "sentiment": {"score": -0.917718, "label": "negative"}, "relevance": 0.590468, "count": 1}, {"text": "Asian region", "sentiment": {"score": -0.944492, "label": "negative"}, "relevance": 0.583615, "count": 1}, {"text": "lack of sleep", "sentiment": {"score": -0.834635, "label": "negative"}, "relevance": 0.581645, "count": 2}, {"text": "disposable income", "sentiment": {"score": -0.944492, "label": "negative"}, "relevance": 0.579512, "count": 1}, {"text": "daily activities", "sentiment": {"score": -0.976992, "label": "negative"}, "relevance": 0.57452, "count": 2}, {"text": "largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573176, "count": 1}, {"text": "major factors", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.572308, "count": 1}, {"text": "stress", "sentiment": {"score": -0.834635, "label": "negative"}, "relevance": 0.565019, "count": 2}, {"text": "treatment", "sentiment": {"score": -0.87596, "label": "negative"}, "relevance": 0.563104, "count": 2}, {"text": "diseases", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.560009, "count": 1}, {"text": "growth of this market", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.558877, "count": 1}, {"text": "job loss", "sentiment": {"score": -0.942932, "label": "negative"}, "relevance": 0.558764, "count": 1}, {"text": "insomnia", "sentiment": {"score": -0.926176, "label": "negative"}, "relevance": 0.558546, "count": 2}, {"text": "North America accounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55791, "count": 1}, {"text": "use of some pharmaceuticals", "sentiment": {"score": -0.834635, "label": "negative"}, "relevance": 0.556757, "count": 2}, {"text": "Request Report Sample", "sentiment": {"score": -0.961944, "label": "negative"}, "relevance": 0.556293, "count": 1}, {"text": "Parkinson\u2019s disease", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.553533, "count": 1}, {"text": "rise", "sentiment": {"score": -0.976334, "label": "negative"}, "relevance": 0.553504, "count": 4}, {"text": "chronic diseases", "sentiment": {"score": -0.944492, "label": "negative"}, "relevance": 0.550265, "count": 1}, {"text": "younger generation", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.548967, "count": 1}, {"text": "market", "sentiment": {"score": -0.944492, "label": "negative"}, "relevance": 0.547401, "count": 1}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.770481, "label": "negative"}, "relevance": 0.547196, "count": 1}, {"text": "benzodiazepines", "sentiment": {"score": -0.770481, "label": "negative"}, "relevance": 0.543519, "count": 1}, {"text": "loss of a loved person", "sentiment": {"score": -0.942932, "label": "negative"}, "relevance": 0.542589, "count": 1}, {"text": "Sanofi Aventis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540559, "count": 1}, {"text": "others", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533807, "count": 1}, {"text": "benzodiazepine class of drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52652, "count": 1}, {"text": "drug side-effects", "sentiment": {"score": -0.917718, "label": "negative"}, "relevance": 0.526419, "count": 1}, {"text": "short term treatment option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526419, "count": 1}, {"text": "irritation", "sentiment": {"score": -0.976992, "label": "negative"}, "relevance": 0.526005, "count": 2}, {"text": "causative factors", "sentiment": {"score": -0.942932, "label": "negative"}, "relevance": 0.525337, "count": 1}, {"text": "restorative sleep", "sentiment": {"score": -0.834635, "label": "negative"}, "relevance": 0.522443, "count": 2}, {"text": "result of primary sleep disorder", "sentiment": {"score": -0.862806, "label": "negative"}, "relevance": 0.521366, "count": 2}, {"text": "cancers", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.520083, "count": 1}, {"text": "drug", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.520009, "count": 1}, {"text": "Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519399, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.808654, "label": "negative"}, "relevance": 0.519003, "count": 2}, {"text": "medical supervision", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.518657, "count": 1}, {"text": "day time", "sentiment": {"score": -0.976992, "label": "negative"}, "relevance": 0.516426, "count": 2}, {"text": "Insomnia Therapeutics Market players Eli Lilly", "sentiment": {"score": -0.808654, "label": "negative"}, "relevance": 0.514467, "count": 1}, {"text": "family disharmony", "sentiment": {"score": -0.942932, "label": "negative"}, "relevance": 0.51332, "count": 1}, {"text": "chronic insomnia", "sentiment": {"score": -0.87596, "label": "negative"}, "relevance": 0.513217, "count": 1}, {"text": "sedatives", "sentiment": {"score": -0.985788, "label": "negative"}, "relevance": 0.511471, "count": 1}]}, "extracted_metadata": {"sha1": "f1133903e867494e338f34b7dcf7a1d740cbda07", "filename": "1542382281882.zip-e5627c06374d2ac5cb800c72eb38c6ac.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/insomnia-therapeutics-market.asp", "https://www.persistencemarketresearch.com/samples/5555", "http://twitter.com/IndustryToday", "https://www.persistencemarketresearch.com/toc/5555"], "title": "Insomnia Therapeutics Market players Eli Lilly, Takeda, Sanofi Aventis", "forum_title": "Industry Today"}, {"id": "fAB4028M5LRoao4S4D8ndCvcM8kiHIMSKW2Am8CRGpPw-4t5cwXcQB0KzChBF1Oa", "result_metadata": {"score": 28.666231}, "author": "mylubbocktv.com", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Trade", "relevance": 0.838718, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Capitalism", "relevance": 0.751422, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}], "categories": [{"score": 0.785651, "label": "/science/weather"}, {"score": 0.666068, "label": "/finance/financial news"}, {"score": 0.622531, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "Global Companion Diagnostics Market Estimates & Forecasts 2015-2", "score": 0.676359, "arguments": [{"text": "Global Companion Diagnostics Market Estimates & Forecasts", "location": [0, 57], "entities": [{"type": "Organization", "text": "Global Companion Diagnostics Market Estimates & Forecasts"}]}, {"text": "-2", "location": [62, 64], "entities": [{"type": "Phone", "text": "-2"}]}]}], "keywords": [{"text": "Global Companion Diagnostics Market Estimates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998407, "count": 1}, {"text": "Forecasts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759902, "count": 1}]}, "crawl_date": "2018-11-16T16:55:13Z", "url": "http://www.mylubbocktv.com/story/39495264/global-companion-diagnostics-market-estimates-forecasts-2015-2018-2022-quashing-the-one-size-fits-all-approach-cdx-wield-great-promise", "host": "mylubbocktv.com", "text": "Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T00:00:00-05:00", "enriched_text": {"entities": [{"count": 22, "sentiment": {"score": -0.315031, "label": "negative"}, "text": "Companion Diagnostics", "relevance": 0.882836, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.643894, "label": "negative"}, "text": "CDx Market", "relevance": 0.423671, "type": "Company"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "B. Market Analytics", "relevance": 0.35318, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics in Oncology", "relevance": 0.346579, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics in Clinical Trials", "relevance": 0.331051, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oncology CDx Testing", "relevance": 0.325625, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": -0.464862, "label": "negative"}, "text": "Europe", "relevance": 0.293522, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 5, "sentiment": {"score": 0.601571, "label": "positive"}, "text": "Thermo Fisher Scientific", "relevance": 0.286046, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}, {"count": 7, "sentiment": {"score": 0.452379, "label": "positive"}, "text": "US", "relevance": 0.25564, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership", "relevance": 0.246492, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quest Diagnostics, Inc.", "relevance": 0.238928, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.609676, "label": "negative"}, "text": "Cancer", "relevance": 0.234665, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 4, "sentiment": {"score": -0.651164, "label": "negative"}, "text": "Canada", "relevance": 0.224383, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 4, "sentiment": {"score": 0.0904137, "label": "positive"}, "text": "Personalized Medicine", "relevance": 0.220913, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": -0.317013, "label": "negative"}, "text": "Major Market Driver", "relevance": 0.218543, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Simcere Diagnostics", "relevance": 0.214724, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostic Manufacturer", "relevance": 0.21324, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": 0.633936, "label": "positive"}, "text": "FDA", "relevance": 0.211764, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 1, "sentiment": {"score": 0.488, "label": "positive"}, "text": "Thermo Fisher Scientific Inks New Oncology", "relevance": 0.21144, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.208864, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.205345, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 3, "sentiment": {"score": -0.351021, "label": "negative"}, "text": "Japan", "relevance": 0.203017, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.193933, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": -0.411196, "label": "negative"}, "text": "Foundation Medicine", "relevance": 0.187676, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.329022, "label": "positive"}, "text": "Thermo Fisher Scientific, Inc.", "relevance": 0.183641, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.740065, "label": "negative"}, "text": "Breast Cancer", "relevance": 0.181089, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Breast cancer", "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.18085, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": -0.411196, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.179864, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laboratory Corporation of America Holdings", "relevance": 0.179142, "type": "Company", "disambiguation": {"subtype": [], "name": "LabCorp", "dbpedia_resource": "http://dbpedia.org/resource/LabCorp"}}, {"count": 1, "sentiment": {"score": 0.256271, "label": "positive"}, "text": "Streamlined Drug Discovery & Development", "relevance": 0.177037, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Thermo Fisher Scientific Partners", "relevance": 0.176046, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aid Cancer Treatment", "relevance": 0.175241, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Kingdom", "relevance": 0.168471, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ResearchAndMarkets.com", "relevance": 0.165175, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Foundation Medicine Inks", "relevance": 0.165054, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.162927, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Danaher Corporation", "relevance": 0.162196, "type": "Company", "disambiguation": {"subtype": [], "name": "Danaher Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Danaher_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "DUBLIN", "relevance": 0.161838, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Foundation Medicine, Inc.", "relevance": 0.160977, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.160134, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clovis Oncology", "relevance": 0.159309, "type": "Facility"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.158561, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Agilent Technologies, Inc.", "relevance": 0.157557, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.157362, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": -0.734861, "label": "negative"}, "text": "Irritable Bowel Disease", "relevance": 0.15724, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Irritable bowel syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}}, {"count": 2, "sentiment": {"score": 0.601571, "label": "positive"}, "text": "Center of Excellence Program", "relevance": 0.156507, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.156295, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.673325, "label": "positive"}, "text": "Myriad Bags Manufacturing", "relevance": 0.156166, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck", "relevance": 0.155429, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck KGaA", "dbpedia_resource": "http://dbpedia.org/resource/Merck_KGaA"}}], "sentiment": {"document": {"score": 0.779987, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The \"Companion Diagnostics - Global Strategic Business Report\" report", "keywords": [{"text": "Global Strategic Business"}, {"text": "Companion Diagnostics"}, {"text": "report"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "sentence": " The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "added to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The \"Companion Diagnostics - Global Strategic Business Report\" report", "keywords": [{"text": "Global Strategic Business"}, {"text": "Companion Diagnostics"}, {"text": "report"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "sentence": " The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World.", "object": {"text": "separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World", "keywords": [{"text": "separate comprehensive analytics"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}, {"text": "Rest"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "object": {"text": "provided"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "are provided", "normalized": "be provide"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "provided for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "Market data and analytics", "keywords": [{"text": "analytics"}, {"text": "Market data"}]}, "sentence": " Market data and analytics are derived from primary and secondary research.", "object": {"text": "from primary and secondary research", "keywords": [{"text": "secondary research"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "are derived", "normalized": "be derive"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "object": {"text": "the worldwide markets for Companion Diagnostics in US$ Million", "keywords": [{"text": "Companion Diagnostics"}, {"text": "worldwide markets"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}, {"type": "Company", "text": "Companion Diagnostics"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies including many key and niche players", "keywords": [{"text": "niche players"}, {"text": "companies"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "many key and niche players such as", "keywords": [{"text": "niche players"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "CDx", "keywords": [{"text": "CDx"}]}, "sentence": " Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development", "object": {"text": "the One-Size-Fits-All Approach", "keywords": [{"text": "One-Size-Fits-All Approach"}]}, "action": {"verb": {"text": "Quashing", "tense": "present"}, "text": "Quashing", "normalized": "Quashing"}}, {"subject": {"text": "Healthy Growth", "keywords": [{"text": "Healthy Growth"}]}, "sentence": " Healthy Growth Projected over the Next Few Years", "action": {"verb": {"text": "Projected", "tense": "past"}, "text": "Projected", "normalized": "Projected"}}, {"subject": {"text": "Northbound Trajectory in R&D Spending", "keywords": [{"text": "Northbound Trajectory"}, {"text": "R&D Spending"}]}, "sentence": " Northbound Trajectory in R&D Spending Creates Conducive Environment", "object": {"text": "Conducive Environment", "keywords": [{"text": "Conducive Environment"}]}, "action": {"verb": {"text": "Creates", "tense": "present"}, "text": "Creates", "normalized": "Creates"}}, {"subject": {"text": "Prevailing Economic Scenario", "keywords": [{"text": "Economic Scenario"}]}, "sentence": " Prevailing Economic Scenario Favors Funding Pattern", "object": {"text": "Funding Pattern", "keywords": [{"text": "Funding Pattern"}]}, "action": {"verb": {"text": "Favors", "tense": "present"}, "text": "Favors", "normalized": "Favors"}}, {"subject": {"text": "Herceptin", "keywords": [{"text": "Herceptin"}]}, "sentence": " Herceptin Lays the Road for Companion Diagnostics", "object": {"text": "the Road", "keywords": [{"text": "Road"}]}, "action": {"verb": {"text": "Lays", "tense": "present"}, "text": "Lays", "normalized": "Lays"}}, {"subject": {"text": "Regulatory Scenario", "keywords": [{"text": "Regulatory Scenario"}]}, "sentence": " Regulatory Scenario Favors CDx Market", "object": {"text": "CDx Market", "keywords": [{"text": "CDx Market"}], "entities": [{"type": "Company", "text": "CDx Market"}]}, "action": {"verb": {"text": "Favors", "tense": "present"}, "text": "Favors", "normalized": "Favors"}}, {"subject": {"text": "them"}, "sentence": " Companion Diagnostics: What Makes them Work", "object": {"text": "Work", "keywords": [{"text": "Work"}]}, "action": {"verb": {"text": "Makes", "tense": "present"}, "text": "Makes", "normalized": "Makes"}}, {"subject": {"text": "Techniques", "keywords": [{"text": "Techniques"}]}, "sentence": " Techniques Used in Companion Diagnostics", "action": {"verb": {"text": "Used", "tense": "past"}, "text": "Used", "normalized": "Used"}}, {"subject": {"text": "Companion Diagnostics", "keywords": [{"text": "Companion Diagnostics"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "sentence": " Select Companion Diagnostics in Cancer", "object": {"text": "in Cancer", "keywords": [{"text": "Cancer"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "Select", "tense": "present"}, "text": "Select", "normalized": "Select"}}, {"subject": {"text": "Assay", "keywords": [{"text": "Assay"}]}, "sentence": " Trofile Assay to Aid in HIV Treatment", "object": {"text": "to Aid in HIV Treatment", "keywords": [{"text": "HIV Treatment"}, {"text": "Aid"}], "entities": [{"type": "HealthCondition", "text": "HIV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}]}, "action": {"verb": {"text": "Trofile", "tense": "present"}, "text": "Trofile", "normalized": "Trofile"}}, {"subject": {"text": "Players", "keywords": [{"text": "Players"}]}, "sentence": " Leading Players in the World Companion Diagnostics Market", "action": {"verb": {"text": "Leading", "tense": "present"}, "text": "Leading", "normalized": "Leading"}}, {"subject": {"text": "Vendors", "keywords": [{"text": "Vendors"}]}, "sentence": " Vendors Rely on Collaborations to Widen Market Footprint", "object": {"text": "on Collaborations", "keywords": [{"text": "Collaborations"}]}, "action": {"verb": {"text": "Rely", "tense": "present"}, "text": "Rely", "normalized": "Rely"}}, {"subject": {"text": "Foundation Medicine", "keywords": [{"text": "Foundation Medicine"}], "entities": [{"type": "Company", "text": "Foundation Medicine"}]}, "sentence": " Foundation Medicine Unveils FoundationOne CDx", "object": {"text": "FoundationOne CDx", "keywords": [{"text": "FoundationOne CDx"}]}, "action": {"verb": {"text": "Unveils", "tense": "present"}, "text": "Unveils", "normalized": "Unveils"}}, {"subject": {"text": "Roche", "keywords": [{"text": "Roche"}], "entities": [{"type": "Person", "text": "Roche"}]}, "sentence": " Roche to Fully Acquire Foundation Medicine", "object": {"text": "Foundation Medicine", "keywords": [{"text": "Foundation Medicine"}]}, "action": {"verb": {"text": "Acquire", "tense": "present"}, "text": "to Fully Acquire", "normalized": "to Fully Acquire"}}, {"subject": {"text": "Qiagen and Freenome", "keywords": [{"text": "Qiagen"}, {"text": "Freenome"}], "entities": [{"type": "Person", "text": "Qiagen"}]}, "sentence": " Qiagen and Freenome to Develop NGS-based Companion Diagnostics", "object": {"text": "NGS-based Companion Diagnostics", "keywords": [{"text": "NGS-based Companion Diagnostics"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "action": {"verb": {"text": "Develop", "tense": "future"}, "text": "to Develop", "normalized": "to Develop"}}, {"subject": {"text": "Merck KGaA and ArcherDX", "keywords": [{"text": "Merck KGaA"}, {"text": "ArcherDX"}], "entities": [{"type": "Company", "text": "Merck", "disambiguation": {"subtype": ["Company"], "name": "Merck KGaA", "dbpedia_resource": "http://dbpedia.org/resource/Merck_KGaA"}}]}, "sentence": " Merck KGaA and ArcherDX to Develop NGS-based CDx Assay", "object": {"text": "NGS-based CDx Assay", "keywords": [{"text": "NGS-based CDx Assay"}]}, "action": {"verb": {"text": "Develop", "tense": "future"}, "text": "to Develop", "normalized": "to Develop"}}, {"subject": {"text": "Foundation Medicine and Merck", "keywords": [{"text": "Merck"}, {"text": "Foundation Medicine"}], "entities": [{"type": "Company", "text": "Foundation Medicine"}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " Foundation Medicine and Merck to Develop CDx Tests", "object": {"text": "CDx Tests", "keywords": [{"text": "CDx Tests"}]}, "action": {"verb": {"text": "Develop", "tense": "future"}, "text": "to Develop", "normalized": "to Develop"}}, {"subject": {"text": "NeoGenomics", "keywords": [{"text": "NeoGenomics"}], "entities": [{"type": "Company", "text": "NeoGenomics"}]}, "sentence": " NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program", "object": {"text": "Thermo Fisher's CDx Center of Excellence Program", "keywords": [{"text": "Thermo Fisher"}, {"text": "CDx Center"}, {"text": "Excellence"}, {"text": "Program"}], "entities": [{"type": "Company", "text": "Thermo Fisher Scientific", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}, {"type": "Organization", "text": "Center of Excellence Program"}]}, "action": {"verb": {"text": "Join", "tense": "future"}, "text": "to Join", "normalized": "to Join"}}, {"subject": {"text": "Robust Personalized Medicine Market", "keywords": [{"text": "Robust Personalized Medicine"}, {"text": "Market"}]}, "sentence": " Robust Personalized Medicine Market Offers Potential", "object": {"text": "Potential"}, "action": {"verb": {"text": "Offers", "tense": "present"}, "text": "Offers", "normalized": "Offers"}}, {"subject": {"text": "you"}, "sentence": " Did you know that we also offer Custom Research?", "object": {"text": "that we also offer Custom Research", "keywords": [{"text": "Custom Research"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we"}, "sentence": " Did you know that we also offer Custom Research?", "object": {"text": "Custom Research", "keywords": [{"text": "Custom Research"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offer", "normalized": "offer"}}, {"subject": {"text": "a meeting", "keywords": [{"text": "meeting"}]}, "sentence": " Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.", "object": {"text": "with our Custom Research Manager", "keywords": [{"text": "Custom Research Manager"}], "entities": [{"type": "JobTitle", "text": "Custom Research Manager"}]}, "action": {"verb": {"text": "schedule", "tense": "present"}, "text": "schedule", "normalized": "schedule"}}], "concepts": [{"text": "Hoffmann\u2013La Roche", "relevance": 0.972254, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Pharmaceutical industry", "relevance": 0.6993, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Thermo Fisher Scientific", "relevance": 0.580041, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}, {"text": "Thermo Electron", "relevance": 0.547759, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Electron"}, {"text": "Cancer", "relevance": 0.541053, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Fisher Scientific", "relevance": 0.52643, "dbpedia_resource": "http://dbpedia.org/resource/Fisher_Scientific"}, {"text": "Food and Drug Administration", "relevance": 0.51676, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Breast cancer", "relevance": 0.515356, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Genentech", "relevance": 0.48738, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Bristol-Myers Squibb", "relevance": 0.466509, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Research support companies", "relevance": 0.454362, "dbpedia_resource": "http://dbpedia.org/resource/Research_support_companies"}, {"text": "Drug development", "relevance": 0.440049, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Financial markets", "relevance": 0.408067, "dbpedia_resource": "http://dbpedia.org/resource/Financial_markets"}, {"text": "Hoffmann-La Roche", "relevance": 0.407398, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}, {"text": "Pharmacology", "relevance": 0.388893, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Medicine", "relevance": 0.388291, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Laboratory equipment", "relevance": 0.388237, "dbpedia_resource": "http://dbpedia.org/resource/Laboratory_equipment"}, {"text": "Oncology", "relevance": 0.387234, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Economics", "relevance": 0.37478, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Drug discovery", "relevance": 0.37382, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Biotechnology companies", "relevance": 0.372096, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "United States", "relevance": 0.366184, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Assay", "relevance": 0.347282, "dbpedia_resource": "http://dbpedia.org/resource/Assay"}], "categories": [{"score": 0.895024, "label": "/health and fitness/disease/cancer"}, {"score": 0.756219, "label": "/science/medicine/oncology"}, {"score": 0.714505, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "timeOf", "sentence": "Research and Markets DUBLIN , Nov. 16, 2018 /PRNewswire/ -- The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.", "score": 0.533171, "arguments": [{"text": "Nov. 16, 2018 /PRNewswire/", "location": [30, 56], "entities": [{"type": "Date", "text": "Nov. 16, 2018 /PRNewswire/"}]}, {"text": "Companion Diagnostics", "location": [65, 86], "entities": [{"type": "TitleWork", "text": "Companion Diagnostics"}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.39781, "arguments": [{"text": "Witnesses", "location": [1541, 1550], "entities": [{"type": "Person", "text": "Witnesses"}]}, {"text": "Key Revenue Contributors\nMarket", "location": [1509, 1540], "entities": [{"type": "Organization", "text": "Key Revenue Contributors\nMarket", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.981572, "arguments": [{"text": "Fast Paced Growth", "location": [1551, 1568], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Witnesses", "location": [1541, 1550], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.618396, "arguments": [{"text": "Economic Scenario Favors Funding Pattern\n3", "location": [1670, 1712], "entities": [{"type": "Person", "text": "Economic Scenario Favors Funding Pattern\n3"}]}, {"text": "Witnesses", "location": [1541, 1550], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.515846, "arguments": [{"text": "Fast Paced Growth", "location": [1551, 1568], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Northbound Trajectory", "location": [1591, 1612], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.951464, "arguments": [{"text": "Northbound Trajectory", "location": [1591, 1612], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}, {"text": "Developing Regions", "location": [1572, 1590], "entities": [{"type": "GeopoliticalEntity", "text": "Developing Regions"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.564321, "arguments": [{"text": "CDx\nEmphasis", "location": [1965, 1977], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "CDx Tests Steers Momentum\nHerceptin Lays", "location": [2015, 2055], "entities": [{"type": "Organization", "text": "CDx Tests Steers Momentum\nHerceptin Lays", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.434281, "arguments": [{"text": "CDx\nEmphasis", "location": [1965, 1977], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "Road", "location": [2060, 2064], "entities": [{"type": "Facility", "text": "Road"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.419741, "arguments": [{"text": "Companion Diagnostics", "location": [2463, 2484], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx", "location": [2485, 2627], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx"}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.707006, "arguments": [{"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx", "location": [2485, 2627], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx"}]}, {"text": "US", "location": [2631, 2633], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Critical for Future Growth of CDx Market Key Issues in a Nutshell 4.", "score": 0.544116, "arguments": [{"text": "Critical for Future Growth of CDx Market\nKey Issues", "location": [2686, 2737], "entities": [{"type": "Organization", "text": "Critical for Future Growth of CDx Market\nKey Issues"}]}, {"text": "Nutshell\n4", "location": [2743, 2753], "entities": [{"type": "GeopoliticalEntity", "text": "Nutshell\n4"}]}]}, {"type": "residesIn", "sentence": "The report provides separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World.", "score": 0.824729, "arguments": [{"text": "Asia-Pacific", "location": [274, 286], "entities": [{"type": "Person", "text": "Asia-Pacific\nA. Market"}]}, {"text": "Latin America", "location": [289, 302], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.742631, "arguments": [{"text": "Companion Diagnostics\nCompanion Diagnostics", "location": [2823, 2866], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Personalized Medicine\nGenetic Tests", "location": [2787, 2822], "entities": [{"type": "Organization", "text": "Personalized Medicine\nGenetic Tests"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.744955, "arguments": [{"text": "Companion Diagnostics", "location": [3078, 3099], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Drug Development Process", "location": [3053, 3077], "entities": [{"type": "Organization", "text": "Drug Development Process"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.627167, "arguments": [{"text": "Companion Diagnostics", "location": [3119, 3140], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Clinical Trials", "location": [3103, 3118], "entities": [{"type": "Organization", "text": "Clinical Trials", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.314304, "arguments": [{"text": "Select Therapeutic", "location": [3144, 3162], "entities": [{"type": "Organization", "text": "Select Therapeutic"}]}, {"text": "Areas", "location": [3163, 3168], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.374683, "arguments": [{"text": "Companion Diagnostics", "location": [3169, 3190], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Areas", "location": [3163, 3168], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.701942, "arguments": [{"text": "Companion Diagnostics", "location": [3210, 3231], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Oncology\nSelect", "location": [3194, 3209], "entities": [{"type": "Organization", "text": "Oncology\nSelect", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.415113, "arguments": [{"text": "Oncotype DX\nQuantitative Recurrence Score\nOncotype DX Test", "location": [3242, 3300], "entities": [{"type": "Person", "text": "Oncotype DX\nQuantitative Recurrence Score\nOncotype DX Test"}]}, {"text": "Cancer", "location": [3235, 3241], "entities": [{"type": "GeopoliticalEntity", "text": "Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.624131, "arguments": [{"text": "IndexSM", "location": [3460, 3467], "entities": [{"type": "Person", "text": "IndexSM"}]}, {"text": "Breast Cancer", "location": [3446, 3459], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.699588, "arguments": [{"text": "Assays", "location": [3553, 3559], "entities": [{"type": "Person", "text": "Assays"}]}, {"text": "Breast Cancer", "location": [3539, 3552], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.570184, "arguments": [{"text": "Companion Diagnostics", "location": [3694, 3715], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Inflammatory Diseases\nPROMETHEUS IBD Serology 7", "location": [3719, 3766], "entities": [{"type": "Organization", "text": "Inflammatory Diseases\nPROMETHEUS IBD Serology 7"}]}]}, {"type": "residesIn", "sentence": "The report provides separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World.", "score": 0.388752, "arguments": [{"text": "Rest", "location": [309, 313], "entities": [{"type": "Cardinal", "text": "Rest"}]}, {"text": "World", "location": [317, 322], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.905081, "arguments": [{"text": "Companion Diagnostics", "location": [3795, 3816], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Bowel Disease", "location": [3781, 3794], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.392566, "arguments": [{"text": "Companion Diagnostics", "location": [3795, 3816], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Infectious Diseases\nTrofile Assay", "location": [3820, 3853], "entities": [{"type": "Organization", "text": "Infectious Diseases\nTrofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.386574, "arguments": [{"text": "Aid", "location": [3857, 3860], "entities": [{"type": "Organization", "text": "Aid Cancer Treatment\nc-Kit pharmDx Assay"}]}, {"text": "Infectious Diseases\nTrofile Assay", "location": [3820, 3853], "entities": [{"type": "Organization", "text": "Infectious Diseases\nTrofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.852005, "arguments": [{"text": "CYP450 Test\nHILOmet PhyzioType System", "location": [3929, 3966], "entities": [{"type": "Organization", "text": "CYP450 Test\nHILOmet PhyzioType System"}]}, {"text": "Drug Metabolism\nAmpliChip", "location": [3903, 3928], "entities": [{"type": "Organization", "text": "Drug Metabolism\nAmpliChip"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.570465, "arguments": [{"text": "Companion Diagnostic Manufacturer", "location": [4118, 4151], "entities": [{"type": "Person", "text": "Companion Diagnostic Manufacturer"}]}, {"text": "Diagnostic Company", "location": [4098, 4116], "entities": [{"type": "Organization", "text": "Diagnostic Company"}]}]}, {"type": "partOfMany", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.530278, "arguments": [{"text": "Companion Diagnostics Market\nVendors Rely", "location": [4256, 4297], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Players", "location": [4235, 4242], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "participantIn", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.860623, "arguments": [{"text": "Companion Diagnostics Market\nVendors Rely", "location": [4256, 4297], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "World", "location": [4250, 4255], "entities": [{"type": "SportingEvent", "text": "World"}]}]}, {"type": "agentOf", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.935809, "arguments": [{"text": "Widen Market Footprint\nSelect CDx Collaborative Deals", "location": [4319, 4372], "entities": [{"type": "Organization", "text": "Widen Market Footprint\nSelect CDx Collaborative Deals"}]}, {"text": "Announced", "location": [4373, 4382], "entities": [{"type": "EventCommunication", "text": "Announced"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.735672, "arguments": [{"text": "Dako PD-L1 IHC 22C3 pharmDx Assay", "location": [4545, 4578], "entities": [{"type": "Person", "text": "Dako PD-L1 IHC 22C3 pharmDx Assay"}]}, {"text": "Launches\nFoundation Medicine Unveils FoundationOne CDx\nAgilent Bags FDA Approval for", "location": [4460, 4544], "entities": [{"type": "Organization", "text": "Launches\nFoundation Medicine Unveils FoundationOne CDx\nAgilent Bags FDA Approval for"}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.52738, "arguments": [{"text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "location": [4702, 4783], "entities": [{"type": "Organization", "text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Urothelial Carcinoma\nRoche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test", "location": [4599, 4698], "entities": [{"type": "Organization", "text": "Urothelial Carcinoma\nRoche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test"}]}]}, {"type": "residesIn", "sentence": "This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "score": 0.589667, "arguments": [{"text": "Companion Diagnostics", "location": [590, 611], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "US$ Million", "location": [615, 626], "entities": [{"type": "GeopoliticalEntity", "text": "US$ Million"}]}]}, {"type": "basedIn", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.91448, "arguments": [{"text": "Roche Wins US", "location": [4793, 4806], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [4787, 4792], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.712751, "arguments": [{"text": "FDA", "location": [4807, 4810], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Roche Wins US", "location": [4793, 4806], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.534595, "arguments": [{"text": "Roche Wins US", "location": [4793, 4806], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Approval", "location": [4811, 4819], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.9814, "arguments": [{"text": "FDA", "location": [4807, 4810], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Approval", "location": [4811, 4819], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.625668, "arguments": [{"text": "Test v2", "location": [4844, 4851], "entities": [{"type": "Person", "text": "Test v2"}]}, {"text": "Approval", "location": [4811, 4819], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.427874, "arguments": [{"text": "CDx", "location": [4857, 4860], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "IRESSA\nMyriad Genetics Bags US FDA Approval for BRACAnalysis CDx\nMolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug\nThermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments", "location": [4866, 5102], "entities": [{"type": "Organization", "text": "IRESSA\nMyriad Genetics Bags US FDA Approval for BRACAnalysis CDx\nMolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug\nThermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.744249, "arguments": [{"text": "Companion Diagnostic Partnership", "location": [5292, 5324], "entities": [{"type": "Person", "text": "Companion Diagnostic Partnership"}]}, {"text": "Daiichi Sankyo\nSpectrum Pharmaceuticals Inks NGS", "location": [5243, 5291], "entities": [{"type": "Organization", "text": "Daiichi Sankyo\nSpectrum Pharmaceuticals Inks NGS"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.834622, "arguments": [{"text": "Companion Diagnostic Partnership", "location": [5292, 5324], "entities": [{"type": "Person", "text": "Companion Diagnostic Partnership"}]}, {"text": "Thermo Fisher Scientific\nQiagen", "location": [5330, 5361], "entities": [{"type": "Organization", "text": "Thermo Fisher Scientific\nQiagen", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.885545, "arguments": [{"text": "Companion Diagnostic Partnership", "location": [5292, 5324], "entities": [{"type": "Person", "text": "Companion Diagnostic Partnership"}]}, {"text": "Freenome", "location": [5366, 5374], "entities": [{"type": "Organization", "text": "Freenome", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs Merck KGaA and ArcherDX to Develop NGS-", "score": 0.277623, "arguments": [{"text": "Companion Diagnostics\nBristol-Myers Squibb", "location": [5396, 5438], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Hands", "location": [5445, 5450], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nBristol-Myers Squibb Joins Hands"}]}]}, {"type": "locatedAt", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.521136, "arguments": [{"text": "SA", "location": [776, 778], "entities": [{"type": "GeopoliticalEntity", "text": "SA"}]}, {"text": "France", "location": [781, 787], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs Merck KGaA and ArcherDX to Develop NGS-", "score": 0.482453, "arguments": [{"text": "NeoGenomics\nLabCorp Collaborates", "location": [5525, 5557], "entities": [{"type": "Organization", "text": "NeoGenomics\nLabCorp Collaborates"}]}, {"text": "Dx\nPPD forms Strategic Alliance", "location": [5488, 5519], "entities": [{"type": "Organization", "text": "Dx\nPPD forms Strategic Alliance"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs Merck KGaA and ArcherDX to Develop NGS-", "score": 0.385156, "arguments": [{"text": "NeoGenomics\nLabCorp Collaborates", "location": [5525, 5557], "entities": [{"type": "Organization", "text": "NeoGenomics\nLabCorp Collaborates"}]}, {"text": "Unilabs\nMerck KGaA", "location": [5563, 5581], "entities": [{"type": "Organization", "text": "Unilabs\nMerck KGaA", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.450598, "arguments": [{"text": "Bliss", "location": [5680, 5685], "entities": [{"type": "Person", "text": "Bliss"}]}, {"text": "Biopharmaceutical\nFoundation Medicine", "location": [5686, 5723], "entities": [{"type": "Organization", "text": "Biopharmaceutical\nFoundation Medicine"}]}]}, {"type": "partOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.319216, "arguments": [{"text": "Roche\nAgena Bioscience Inks CDx Collaboration Deal", "location": [5799, 5849], "entities": [{"type": "Organization", "text": "Roche\nAgena Bioscience Inks CDx Collaboration Deal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Simcere Diagnostics", "location": [5855, 5874], "entities": [{"type": "Organization", "text": "Simcere Diagnostics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.904323, "arguments": [{"text": "Foundation Medicine Inks CDx Partnership Deal", "location": [5884, 5929], "entities": [{"type": "Organization", "text": "Foundation Medicine Inks CDx Partnership Deal"}]}, {"text": "China", "location": [5878, 5883], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.590364, "arguments": [{"text": "Join Thermo Fisher", "location": [5957, 5975], "entities": [{"type": "Person", "text": "Join Thermo Fisher"}]}, {"text": "Pfizer\nNeoGenomics", "location": [5935, 5953], "entities": [{"type": "Organization", "text": "Pfizer\nNeoGenomics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.456132, "arguments": [{"text": "Join Thermo Fisher", "location": [5957, 5975], "entities": [{"type": "Person", "text": "Join Thermo Fisher"}]}, {"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5978, 6055], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}]}, {"type": "locatedAt", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.472206, "arguments": [{"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5978, 6055], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}, {"text": "North Carolina", "location": [6059, 6073], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "basedIn", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.825443, "arguments": [{"text": "Myriad Genetics Signs CDx Development Collaboration Deal", "location": [6074, 6130], "entities": [{"type": "Organization", "text": "Myriad Genetics Signs CDx Development Collaboration Deal"}]}, {"text": "North Carolina", "location": [6059, 6073], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "partOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.64948, "arguments": [{"text": "Ventana Medical Systems\nThermo Fisher Scientific Inks New Oncology CDx Development Agreement", "location": [6255, 6347], "entities": [{"type": "Organization", "text": "Ventana Medical Systems\nThermo Fisher Scientific Inks New Oncology CDx Development Agreement"}]}, {"text": "Blueprint Medicines\nThermo Fisher Scientific Partners", "location": [6353, 6406], "entities": [{"type": "Organization", "text": "Blueprint Medicines\nThermo Fisher Scientific Partners"}]}]}, {"type": "basedIn", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.492357, "arguments": [{"text": "Danaher Corporation", "location": [806, 825], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [800, 803], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.876218, "arguments": [{"text": "CDx Center of Excellence Program\nBristol-Myers Squibb Joins Hands", "location": [6483, 6548], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nBristol-Myers Squibb Joins Hands"}]}, {"text": "LabCorp Join Thermo Fisher", "location": [6454, 6480], "entities": [{"type": "Organization", "text": "LabCorp Join Thermo Fisher"}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.574315, "arguments": [{"text": "Diagnostic Capabilities\nGrowing Cancer Incidence - An Opportunity Indicator", "location": [6844, 6919], "entities": [{"type": "Organization", "text": "Diagnostic Capabilities\nGrowing Cancer Incidence - An Opportunity Indicator"}]}, {"text": "Pharmaceutical Companies", "location": [6814, 6838], "entities": [{"type": "Organization", "text": "Pharmaceutical Companies"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.601196, "arguments": [{"text": "Companion Diagnostics\nPioneering", "location": [6924, 6956], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Oncology CDx Testing\nRobust Personalized Medicine Market Offers Potential\nBiomarkers", "location": [6968, 7052], "entities": [{"type": "Organization", "text": "Oncology CDx Testing\nRobust Personalized Medicine Market Offers Potential\nBiomarkers"}]}]}, {"type": "authorOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.504892, "arguments": [{"text": "Companion Diagnostics\nList", "location": [7074, 7100], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Novel Paradigm", "location": [7056, 7070], "entities": [{"type": "TitleWork", "text": "Novel Paradigm"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.558135, "arguments": [{"text": "Companion Diagnostics\nList", "location": [7074, 7100], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "US", "location": [7104, 7106], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.638922, "arguments": [{"text": "FDA", "location": [7107, 7110], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [7104, 7106], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.509984, "arguments": [{"text": "Drug Development Fuel Demand\nList of FDA", "location": [7244, 7284], "entities": [{"type": "Organization", "text": "Drug Development Fuel Demand\nList of FDA"}]}, {"text": "Key Market Driver\nCompetitive Scenario\nRegulatory Overview\nFDA Requirements", "location": [7165, 7240], "entities": [{"type": "Organization", "text": "Key Market Driver\nCompetitive Scenario\nRegulatory Overview\nFDA Requirements"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.317117, "arguments": [{"text": "H1", "location": [7323, 7325], "entities": [{"type": "Person", "text": "H1"}]}, {"text": "A. Market Analysis\nHigher R&D Spending", "location": [7362, 7400], "entities": [{"type": "Organization", "text": "A. Market Analysis\nHigher R&D Spending"}]}]}, {"type": "basedIn", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.878606, "arguments": [{"text": "A. Market Analysis\nHigher R&D Spending", "location": [7362, 7400], "entities": [{"type": "Organization", "text": "A. Market Analysis\nHigher R&D Spending"}]}, {"text": "Canada", "location": [7355, 7361], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.558111, "arguments": [{"text": "Underpin CDx Revenues\nCancer Incidence", "location": [7404, 7442], "entities": [{"type": "Organization", "text": "Underpin CDx Revenues\nCancer Incidence"}]}, {"text": "Canada", "location": [7446, 7452], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.473406, "arguments": [{"text": "F. Hoffmann-La Roche Ltd.", "location": [834, 859], "entities": [{"type": "Organization", "text": "F. Hoffmann-La Roche Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [828, 831], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.881792, "arguments": [{"text": "A. Market Analysis\nGraying Population Spurs Growth\nB. Market Analytics", "location": [7553, 7623], "entities": [{"type": "Organization", "text": "Indicator for Companion Diagnostics\nRegulatory Scenario\nB. Market Analytics"}]}, {"text": "Japan", "location": [7547, 7552], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.461615, "arguments": [{"text": "A. Market Analysis", "location": [7635, 7653], "entities": [{"type": "Organization", "text": "A. Market Analysis\nHigher R&D Spending"}]}, {"text": "Europe", "location": [7628, 7634], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.530036, "arguments": [{"text": "CDx\nCancer Incidence", "location": [7787, 7807], "entities": [{"type": "Organization", "text": "CDx\nCancer Incidence"}]}, {"text": "Europe", "location": [7811, 7817], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.394609, "arguments": [{"text": "B. Market Analytics", "location": [7907, 7926], "entities": [{"type": "Organization", "text": "Indicator for Companion Diagnostics\nRegulatory Scenario\nB. Market Analytics"}]}, {"text": "Europe", "location": [7900, 7906], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.389677, "arguments": [{"text": "Market Analysis", "location": [7940, 7955], "entities": [{"type": "Organization", "text": "A. Market Analysis\nHigher R&D Spending"}]}, {"text": "France", "location": [7933, 7939], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.913914, "arguments": [{"text": "Market Analysis", "location": [7970, 7985], "entities": [{"type": "Organization", "text": "The United Kingdom\nMarket Analysis"}]}, {"text": "Germany", "location": [7962, 7969], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.749187, "arguments": [{"text": "Market Analysis", "location": [7998, 8013], "entities": [{"type": "Organization", "text": "The United Kingdom\nMarket Analysis"}]}, {"text": "Italy", "location": [7992, 7997], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.944249, "arguments": [{"text": "Market Analysis", "location": [8067, 8082], "entities": [{"type": "Organization", "text": "The United Kingdom\nMarket Analysis"}]}, {"text": "Spain", "location": [8061, 8066], "entities": [{"type": "GeopoliticalEntity", "text": "Spain", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.663945, "arguments": [{"text": "Rest", "location": [8089, 8093], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Market Analysis", "location": [8067, 8082], "entities": [{"type": "Organization", "text": "The United Kingdom\nMarket Analysis"}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.404087, "arguments": [{"text": "Rest", "location": [8089, 8093], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Europe", "location": [8097, 8103], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.522437, "arguments": [{"text": "QIAGEN N.V.", "location": [1085, 1096], "entities": [{"type": "Person", "text": "QIAGEN N.V."}]}, {"text": "Netherlands", "location": [1099, 1110], "entities": [{"type": "Organization", "text": "Netherlands"}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.332681, "arguments": [{"text": "Market Analysis", "location": [8104, 8119], "entities": [{"type": "Organization", "text": "The United Kingdom\nMarket Analysis"}]}, {"text": "Europe", "location": [8097, 8103], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.464374, "arguments": [{"text": "Asia-Pacific\nA. Market", "location": [8124, 8146], "entities": [{"type": "Person", "text": "Asia-Pacific\nA. Market"}]}, {"text": "Growing Market\nUptrend", "location": [8166, 8188], "entities": [{"type": "Organization", "text": "Growing Market\nUptrend"}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.979801, "arguments": [{"text": "A. Market Analysis\nBreast Cancer CDx", "location": [8264, 8300], "entities": [{"type": "Organization", "text": "A. Market Analysis\nHigher R&D Spending"}]}, {"text": "China", "location": [8258, 8263], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.725957, "arguments": [{"text": "Dominant Category\nLaboratory Equipment & Supplies Sector", "location": [8302, 8358], "entities": [{"type": "Organization", "text": "Dominant Category\nLaboratory Equipment & Supplies Sector"}]}, {"text": "China", "location": [8362, 8367], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "An Overview B. Market Analytics 7.5.2 Rest of Asia-Pacific Market Analysis 7.6 Latin America Market Analysis 7.7 Rest of World Market Analysis 8.", "score": 0.639055, "arguments": [{"text": "Market", "location": [8463, 8469], "entities": [{"type": "Facility", "text": "Market"}]}, {"text": "Latin America", "location": [8449, 8462], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "COMPANY PROFILES Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) France (5) Germany (4) The United Kingdom (9) Spain (1) Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5 Did you know that we also offer Custom Research?", "score": 0.619481, "arguments": [{"text": "Subsidiaries", "location": [8583, 8595], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "Divisions", "location": [8573, 8582], "entities": [{"type": "Organization", "text": "Divisions"}]}]}, {"type": "residesIn", "sentence": "COMPANY PROFILES Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) France (5) Germany (4) The United Kingdom (9) Spain (1) Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5 Did you know that we also offer Custom Research?", "score": 0.424349, "arguments": [{"text": "Rest", "location": [8704, 8708], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Europe", "location": [8712, 8718], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "COMPANY PROFILES Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) France (5) Germany (4) The United Kingdom (9) Spain (1) Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5 Did you know that we also offer Custom Research?", "score": 0.694324, "arguments": [{"text": "Asia-Pacific", "location": [8723, 8735], "entities": [{"type": "Person", "text": "Asia-Pacific\nA. Market"}]}, {"text": "we", "location": [8909, 8911], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "participantIn", "sentence": "Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.", "score": 0.927497, "arguments": [{"text": "Manager", "location": [9033, 9040], "entities": [{"type": "Person", "text": "Laura Wood"}]}, {"text": "meeting", "location": [9000, 9007], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "employedBy", "sentence": "Media Contact: Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 View original content: http://www.prnewswire.com/news-releases/global-companion-diagnostics-market-estimates--forecasts-2015-2018--2022---quashing-the-one-size-fits-all-approach-cdx-wield-great-promise-300752012.html", "score": 0.684702, "arguments": [{"text": "press@researchandmarkets.com", "location": [9085, 9113], "entities": [{"type": "Person", "text": "press@researchandmarkets.com"}]}, {"text": "E.S.T Office Hours Call +", "location": [9118, 9143], "entities": [{"type": "Organization", "text": "E.S.T Office Hours Call +"}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.789002, "arguments": [{"text": "Scope", "location": [1390, 1395], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Wield Great Promise for Streamlined Drug Discovery & Development\nBroader", "location": [1317, 1389], "entities": [{"type": "Organization", "text": "Wield Great Promise for Streamlined Drug Discovery & Development\nBroader"}]}]}, {"type": "locatedAt", "sentence": "Media Contact: Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 View original content: http://www.prnewswire.com/news-releases/global-companion-diagnostics-market-estimates--forecasts-2015-2018--2022---quashing-the-one-size-fits-all-approach-cdx-wield-great-promise-300752012.html", "score": 0.415646, "arguments": [{"text": "GMT Office Hours Call +", "location": [9206, 9229], "entities": [{"type": "Organization", "text": "GMT Office Hours Call +"}]}, {"text": "Fax", "location": [9249, 9252], "entities": [{"type": "Facility", "text": "Fax"}]}]}, {"type": "ownerOf", "sentence": "Media Contact: Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 View original content: http://www.prnewswire.com/news-releases/global-companion-diagnostics-market-estimates--forecasts-2015-2018--2022---quashing-the-one-size-fits-all-approach-cdx-wield-great-promise-300752012.html", "score": 0.501062, "arguments": [{"text": "U.S.", "location": [9244, 9248], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Fax", "location": [9249, 9252], "entities": [{"type": "Facility", "text": "Fax"}]}]}], "keywords": [{"text": "Companion Diagnostics", "sentiment": {"score": 0.827845, "mixed": "1", "label": "positive"}, "relevance": 0.651112, "count": 10}, {"text": "Myriad Genetics", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.585325, "count": 2}, {"text": "USA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580414, "count": 11}, {"text": "Thermo Fisher Scientific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575751, "count": 1}, {"text": "Agilent Bags FDA Approval", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.56541, "count": 1}, {"text": "Foundation Medicine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556997, "count": 1}, {"text": "U.S. Fax", "sentiment": {"score": 0.485368, "label": "positive"}, "relevance": 0.556307, "count": 1}, {"text": "Incidence of Cancer", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.556055, "count": 1}, {"text": "United States", "sentiment": {"score": 0.907686, "label": "positive"}, "relevance": 0.554977, "count": 2}, {"text": "Agilent Technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55463, "count": 1}, {"text": "Global Strategic Business Report", "sentiment": {"score": 0.59589, "label": "positive"}, "relevance": 0.554188, "count": 1}, {"text": "Abbott Molecular", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552055, "count": 1}, {"text": "F. Hoffmann-La Roche Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543225, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541016, "count": 6}, {"text": "markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540531, "count": 1}, {"text": "Leica Biosystems Nussloch GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537825, "count": 1}, {"text": "Personalized Medicine", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.53517, "count": 1}, {"text": "Fax", "sentiment": {"score": 0.485368, "label": "positive"}, "relevance": 0.534536, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534528, "count": 1}, {"text": "US", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.533114, "count": 3}, {"text": "report", "sentiment": {"score": 0.59589, "label": "positive"}, "relevance": 0.532717, "count": 4}, {"text": "QIAGEN N.V.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532112, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531896, "count": 1}, {"text": "Merck", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.530815, "count": 2}, {"text": "Laboratory Corporation of America Holdings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528578, "count": 1}, {"text": "CDx", "sentiment": {"score": 0.913859, "label": "positive"}, "relevance": 0.528119, "count": 5}, {"text": "Broader Scope", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.528086, "count": 1}, {"text": "Myriad Bags Manufacturing", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.526462, "count": 1}, {"text": "Breast Cancer", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.526348, "count": 1}, {"text": "Product Approvals", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.526005, "count": 1}, {"text": "Significant Cost Reductions", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.525374, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525296, "count": 1}, {"text": "Quest Diagnostics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524222, "count": 1}, {"text": "Thermo Fisher's CDx Center", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.524083, "count": 1}, {"text": "Germany", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521469, "count": 2}, {"text": "Europe", "sentiment": {"score": 0.884757, "label": "positive"}, "relevance": 0.520456, "count": 4}, {"text": "Breast Cancer IndexSM", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.520317, "count": 1}, {"text": "United Kingdom", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520184, "count": 1}, {"text": "Market data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52017, "count": 1}, {"text": "US FDA Approval", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.519755, "count": 2}, {"text": "Danaher Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519584, "count": 1}, {"text": "Cancer Treatment", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.519479, "count": 1}, {"text": "France", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51857, "count": 2}, {"text": "Canada", "sentiment": {"score": 0.488614, "mixed": "1", "label": "positive"}, "relevance": 0.518021, "count": 4}, {"text": "EGFRx Assay", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.517457, "count": 1}, {"text": "Pharmaceutical Company", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.517185, "count": 1}, {"text": "PCR CDx Vertical", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.515976, "count": 1}, {"text": "Biomarkers", "sentiment": {"score": 0.919916, "label": "positive"}, "relevance": 0.515425, "count": 2}, {"text": "NGS", "sentiment": {"score": 0.874365, "label": "positive"}, "relevance": 0.515249, "count": 3}, {"text": "six-year", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515177, "count": 1}]}, "extracted_metadata": {"sha1": "0d73a460ff19663611d7d10dfd94cc604219bbd9", "filename": "1542387313629.zip-ae6d4ba07d58660a4ee180260bbeb93f.xml", "file_type": "json"}, "external_links": ["https://www.researchandmarkets.com/info/custom-research", "http://www.prnewswire.com/news-releases/global-companion-diagnostics-market-estimates--forecasts-2015-2018--2022---quashing-the-one-size-fits-all-approach-cdx-wield-great-promise-300752012.html", "https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5", "http://www.xmlnews.org/ns/"], "title": "Global Companion Diagnostics Market Estimates & Forecasts 2015-2", "forum_title": "Health Care"}, {"id": "y_e1bMhRSZ0m1eHYdYKU46xfPao8U1W9j9YttjUrxZbV6I49YHv-SF8ES_07qXkE", "result_metadata": {"score": 28.568224}, "author": "Research and Markets", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.798188, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Trade", "relevance": 0.838718, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Capitalism", "relevance": 0.751422, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}], "categories": [{"score": 0.709573, "label": "/science/weather"}, {"score": 0.607472, "label": "/finance/financial news"}, {"score": 0.577668, "label": "/finance/investing"}], "relations": [], "keywords": [{"text": "Global Companion Diagnostics Market Estimates", "sentiment": {"score": 0.798188, "label": "positive"}, "relevance": 0.997169, "count": 1}, {"text": "Forecasts", "sentiment": {"score": 0.798188, "label": "positive"}, "relevance": 0.747574, "count": 1}, {"text": "Great Promise", "sentiment": {"score": 0.798188, "label": "positive"}, "relevance": 0.74673, "count": 1}, {"text": "Approach", "sentiment": {"score": 0.798188, "label": "positive"}, "relevance": 0.677754, "count": 1}, {"text": "One-Size-Fits", "sentiment": {"score": 0.798188, "label": "positive"}, "relevance": 0.524516, "count": 1}, {"text": "CDx", "sentiment": {"score": 0.798188, "label": "positive"}, "relevance": 0.146997, "count": 1}]}, "crawl_date": "2018-11-16T15:17:00Z", "url": "https://www.prnewswire.com:443/news-releases/global-companion-diagnostics-market-estimates--forecasts-2015-2018--2022---quashing-the-one-size-fits-all-approach-cdx-wield-great-promise-300752012.html", "host": "prnewswire.com", "text": "Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co.", "main_image_url": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T15:15:00Z", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.389003, "label": "negative"}, "text": "Companion Diagnostics", "relevance": 0.811985, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics Applications of Companion Diagnostics", "relevance": 0.673189, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer", "relevance": 0.559466, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.499317, "label": "positive"}, "text": "Companion Diagnostics Oncology", "relevance": 0.456953, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development", "relevance": 0.450378, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oncology Select Companion Diagnostics", "relevance": 0.438555, "type": "PrintMedia"}, {"count": 8, "sentiment": {"score": -0.0532092, "label": "negative"}, "text": "Europe", "relevance": 0.429291, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Companion Diagnostics Bristol-Myers Squibb", "relevance": 0.423644, "type": "Company"}, {"count": 6, "sentiment": {"score": 0.396734, "label": "positive"}, "text": "US", "relevance": 0.42225, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0.341089, "label": "positive"}, "text": "Companion Diagnostics Critical Healthcare", "relevance": 0.416209, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Trials Companion Diagnostics", "relevance": 0.410108, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics List", "relevance": 0.385551, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": 0.265824, "label": "positive"}, "text": "Japan", "relevance": 0.343429, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 4, "sentiment": {"score": -0.363255, "label": "negative"}, "text": "Canada", "relevance": 0.333576, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership", "relevance": 0.326144, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quest Diagnostics, Inc.", "relevance": 0.300211, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostic Manufacturer", "relevance": 0.286081, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Simcere Diagnostics", "relevance": 0.28157, "type": "Company"}, {"count": 5, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "FDA", "relevance": 0.281284, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Thermo Fisher Scientific Qiagen", "relevance": 0.266199, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Novartis CML Drug Thermo Fisher Scientific", "relevance": 0.258711, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Thermo Fisher", "relevance": 0.258598, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ResearchAndMarkets.com", "relevance": 0.248011, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Merck & Co. Inc.", "relevance": 0.245591, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.245529, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.237708, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Blueprint Medicines Thermo Fisher Scientific Partners", "relevance": 0.232392, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Clovis Oncology Loxo Oncology Inks Collaboration", "relevance": 0.231786, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aid Cancer Treatment", "relevance": 0.231441, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.329022, "label": "positive"}, "text": "Thermo Fisher Scientific, Inc.", "relevance": 0.229877, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.223999, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.330333, "label": "positive"}, "text": "DUBLIN", "relevance": 0.219223, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Bristol-Myers Squibb", "relevance": 0.214818, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.210209, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Roche Agena Bioscience Inks", "relevance": 0.210199, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Foundation Medicine", "relevance": 0.209947, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Fully Acquire Foundation Medicine", "relevance": 0.206033, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Danaher Corporation", "relevance": 0.204976, "type": "Company", "disambiguation": {"subtype": [], "name": "Danaher Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Danaher_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Foundation Medicine, Inc.", "relevance": 0.202027, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.201458, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SOURCE Research and Markets", "relevance": 0.200361, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.198827, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Agilent Technologies, Inc.", "relevance": 0.198675, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.389003, "label": "negative"}, "text": "Irritable Bowel Disease", "relevance": 0.19748, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Irritable bowel syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Urothelial Carcinoma Roche", "relevance": 0.197017, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "Takeda Pharmaceutical", "relevance": 0.196944, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "China Foundation Medicine Inks", "relevance": 0.194693, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.891656, "label": "positive"}, "text": "North Carolina", "relevance": 0.193439, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "North Carolina", "dbpedia_resource": "http://dbpedia.org/resource/North_Carolina"}}, {"count": 1, "sentiment": {"score": -0.389003, "label": "negative"}, "text": "HIV", "relevance": 0.191863, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}], "sentiment": {"document": {"score": 0.796358, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Global Strategic Business Report\" report", "keywords": [{"text": "Global Strategic Business"}]}, "sentence": "DUBLIN The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "added to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "DUBLINThe \"Companion Diagnostics - Global Strategic Business Report\" report", "keywords": [{"text": "Global Strategic Business"}, {"text": "Companion Diagnostics"}, {"text": "DUBLINThe"}, {"text": "report"}], "entities": [{"type": "Location", "text": "DUBLIN", "disambiguation": {"subtype": ["City"]}}, {"type": "PrintMedia", "text": "Oncology Select Companion Diagnostics"}]}, "sentence": "DUBLIN The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World.", "object": {"text": "separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World", "keywords": [{"text": "separate comprehensive analytics"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}, {"text": "Rest"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "object": {"text": "provided"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "are provided", "normalized": "be provide"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "provided for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "Market data and analytics", "keywords": [{"text": "analytics"}, {"text": "Market data"}]}, "sentence": " Market data and analytics are derived from primary and secondary research.", "object": {"text": "from primary and secondary research", "keywords": [{"text": "secondary research"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "are derived", "normalized": "be derive"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "object": {"text": "the worldwide markets for Companion Diagnostics in US$ Million", "keywords": [{"text": "Companion Diagnostics"}, {"text": "worldwide markets"}], "entities": [{"type": "Company", "text": "Oncology Select Companion Diagnostics"}, {"type": "PrintMedia", "text": "Oncology Select Companion Diagnostics"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies including many key and niche players", "keywords": [{"text": "niche players"}, {"text": "companies"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "many key and niche players such as", "keywords": [{"text": "niche players"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "you"}, "sentence": " Did you know that we also offer Custom Research?", "object": {"text": "that we also offer Custom Research", "keywords": [{"text": "Custom Research"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we"}, "sentence": " Did you know that we also offer Custom Research?", "object": {"text": "Custom Research", "keywords": [{"text": "Custom Research"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offer", "normalized": "offer"}}, {"subject": {"text": "a meeting", "keywords": [{"text": "meeting"}]}, "sentence": " Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.", "object": {"text": "with our Custom Research Manager", "keywords": [{"text": "Custom Research Manager"}], "entities": [{"type": "JobTitle", "text": "Custom Research Manager"}]}, "action": {"verb": {"text": "schedule", "tense": "present"}, "text": "schedule", "normalized": "schedule"}}], "concepts": [{"text": "Hoffmann\u2013La Roche", "relevance": 0.973628, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Pharmaceutical industry", "relevance": 0.703518, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Thermo Fisher Scientific", "relevance": 0.580381, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}, {"text": "Thermo Electron", "relevance": 0.548955, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Electron"}, {"text": "Cancer", "relevance": 0.54216, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Fisher Scientific", "relevance": 0.526438, "dbpedia_resource": "http://dbpedia.org/resource/Fisher_Scientific"}, {"text": "Food and Drug Administration", "relevance": 0.517646, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Breast cancer", "relevance": 0.516346, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Genentech", "relevance": 0.490037, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Bristol-Myers Squibb", "relevance": 0.468058, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Research support companies", "relevance": 0.455461, "dbpedia_resource": "http://dbpedia.org/resource/Research_support_companies"}, {"text": "Drug development", "relevance": 0.44289, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Hoffmann-La Roche", "relevance": 0.408598, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}, {"text": "Financial markets", "relevance": 0.408067, "dbpedia_resource": "http://dbpedia.org/resource/Financial_markets"}, {"text": "Pharmacology", "relevance": 0.391321, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Medicine", "relevance": 0.389506, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Laboratory equipment", "relevance": 0.388504, "dbpedia_resource": "http://dbpedia.org/resource/Laboratory_equipment"}, {"text": "Oncology", "relevance": 0.388474, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Economics", "relevance": 0.375135, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Drug discovery", "relevance": 0.375102, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Biotechnology companies", "relevance": 0.372736, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "United States", "relevance": 0.368889, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Assay", "relevance": 0.348163, "dbpedia_resource": "http://dbpedia.org/resource/Assay"}], "categories": [{"score": 0.894919, "label": "/health and fitness/disease/cancer"}, {"score": 0.756207, "label": "/science/medicine/oncology"}, {"score": 0.714947, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "residesIn", "sentence": "The report provides separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World.", "score": 0.824729, "arguments": [{"text": "Asia-Pacific", "location": [221, 233], "entities": [{"type": "Person", "text": "Asia-Pacific A. Market"}]}, {"text": "Latin America", "location": [236, 249], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.981572, "arguments": [{"text": "Fast Paced Growth", "location": [1498, 1515], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Witnesses", "location": [1488, 1497], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.618396, "arguments": [{"text": "Economic Scenario Favors Funding Pattern 3", "location": [1617, 1659], "entities": [{"type": "Person", "text": "Economic Scenario Favors Funding Pattern 3"}]}, {"text": "Witnesses", "location": [1488, 1497], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.515846, "arguments": [{"text": "Fast Paced Growth", "location": [1498, 1515], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Northbound Trajectory", "location": [1538, 1559], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.951464, "arguments": [{"text": "Northbound Trajectory", "location": [1538, 1559], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}, {"text": "Developing Regions", "location": [1519, 1537], "entities": [{"type": "GeopoliticalEntity", "text": "Developing Regions"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.564321, "arguments": [{"text": "CDx Emphasis", "location": [1912, 1924], "entities": [{"type": "Person", "text": "CDx Emphasis"}]}, {"text": "CDx Tests Steers Momentum Herceptin Lays", "location": [1962, 2002], "entities": [{"type": "Organization", "text": "CDx Tests Steers Momentum Herceptin Lays", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.434281, "arguments": [{"text": "CDx Emphasis", "location": [1912, 1924], "entities": [{"type": "Person", "text": "CDx Emphasis"}]}, {"text": "Road", "location": [2007, 2011], "entities": [{"type": "Facility", "text": "Road"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.419741, "arguments": [{"text": "Companion Diagnostics", "location": [2410, 2431], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx", "location": [2432, 2574], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx"}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.707006, "arguments": [{"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx", "location": [2432, 2574], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx"}]}, {"text": "US", "location": [2578, 2580], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Critical for Future Growth of CDx Market Key Issues in a Nutshell 4.", "score": 0.544116, "arguments": [{"text": "Critical for Future Growth of CDx Market Key Issues", "location": [2633, 2684], "entities": [{"type": "Organization", "text": "Critical for Future Growth of CDx Market Key Issues"}]}, {"text": "Nutshell 4", "location": [2690, 2700], "entities": [{"type": "GeopoliticalEntity", "text": "Nutshell 4"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.742631, "arguments": [{"text": "Companion Diagnostics Companion Diagnostics", "location": [2770, 2813], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Personalized Medicine Genetic Tests", "location": [2734, 2769], "entities": [{"type": "Organization", "text": "Personalized Medicine Genetic Tests"}]}]}, {"type": "residesIn", "sentence": "The report provides separate comprehensive analytics for the US, Canada , Japan , Europe , Asia-Pacific , Latin America , and Rest of World.", "score": 0.388752, "arguments": [{"text": "Rest", "location": [256, 260], "entities": [{"type": "Cardinal", "text": "Rest"}]}, {"text": "World", "location": [264, 269], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.744955, "arguments": [{"text": "Companion Diagnostics", "location": [3025, 3046], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Drug Development Process", "location": [3000, 3024], "entities": [{"type": "Organization", "text": "Drug Development Process"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.627167, "arguments": [{"text": "Companion Diagnostics", "location": [3066, 3087], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Clinical Trials", "location": [3050, 3065], "entities": [{"type": "Organization", "text": "Clinical Trials", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.314304, "arguments": [{"text": "Select Therapeutic", "location": [3091, 3109], "entities": [{"type": "Organization", "text": "Select Therapeutic"}]}, {"text": "Areas", "location": [3110, 3115], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.374683, "arguments": [{"text": "Companion Diagnostics", "location": [3116, 3137], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Areas", "location": [3110, 3115], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.701942, "arguments": [{"text": "Companion Diagnostics", "location": [3157, 3178], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Oncology Select", "location": [3141, 3156], "entities": [{"type": "Organization", "text": "Oncology Select", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.415113, "arguments": [{"text": "Oncotype DX Quantitative Recurrence Score Oncotype DX Test", "location": [3189, 3247], "entities": [{"type": "Person", "text": "Oncotype DX Quantitative Recurrence Score Oncotype DX Test"}]}, {"text": "Cancer", "location": [3182, 3188], "entities": [{"type": "GeopoliticalEntity", "text": "Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.624131, "arguments": [{"text": "IndexSM", "location": [3407, 3414], "entities": [{"type": "Person", "text": "IndexSM"}]}, {"text": "Breast Cancer", "location": [3393, 3406], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.699588, "arguments": [{"text": "Assays", "location": [3500, 3506], "entities": [{"type": "Person", "text": "Assays"}]}, {"text": "Breast Cancer", "location": [3486, 3499], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.570184, "arguments": [{"text": "Companion Diagnostics", "location": [3641, 3662], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Inflammatory Diseases PROMETHEUS IBD Serology 7", "location": [3666, 3713], "entities": [{"type": "Organization", "text": "Inflammatory Diseases PROMETHEUS IBD Serology 7"}]}]}, {"type": "hasAttribute", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.905081, "arguments": [{"text": "Companion Diagnostics", "location": [3742, 3763], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Bowel Disease", "location": [3728, 3741], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "residesIn", "sentence": "This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "score": 0.589667, "arguments": [{"text": "Companion Diagnostics", "location": [537, 558], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "US$ Million", "location": [562, 573], "entities": [{"type": "GeopoliticalEntity", "text": "US$ Million"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.392566, "arguments": [{"text": "Companion Diagnostics", "location": [3742, 3763], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Infectious Diseases Trofile Assay", "location": [3767, 3800], "entities": [{"type": "Organization", "text": "Infectious Diseases Trofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.386574, "arguments": [{"text": "Aid", "location": [3804, 3807], "entities": [{"type": "Organization", "text": "Aid Cancer Treatment c-Kit pharmDx Assay"}]}, {"text": "Infectious Diseases Trofile Assay", "location": [3767, 3800], "entities": [{"type": "Organization", "text": "Infectious Diseases Trofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.852005, "arguments": [{"text": "CYP450 Test HILOmet PhyzioType System", "location": [3876, 3913], "entities": [{"type": "Organization", "text": "CYP450 Test HILOmet PhyzioType System"}]}, {"text": "Drug Metabolism AmpliChip", "location": [3850, 3875], "entities": [{"type": "Organization", "text": "Drug Metabolism AmpliChip"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.570465, "arguments": [{"text": "Companion Diagnostic Manufacturer", "location": [4065, 4098], "entities": [{"type": "Person", "text": "Companion Diagnostic Manufacturer"}]}, {"text": "Diagnostic Company", "location": [4045, 4063], "entities": [{"type": "Organization", "text": "Diagnostic Company"}]}]}, {"type": "partOfMany", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.530278, "arguments": [{"text": "Companion Diagnostics Market Vendors Rely", "location": [4203, 4244], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Players", "location": [4182, 4189], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "participantIn", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.860623, "arguments": [{"text": "Companion Diagnostics Market Vendors Rely", "location": [4203, 4244], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "World", "location": [4197, 4202], "entities": [{"type": "SportingEvent", "text": "World"}]}]}, {"type": "agentOf", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.935809, "arguments": [{"text": "Widen Market Footprint Select CDx Collaborative Deals", "location": [4266, 4319], "entities": [{"type": "Organization", "text": "Widen Market Footprint Select CDx Collaborative Deals"}]}, {"text": "Announced", "location": [4320, 4329], "entities": [{"type": "EventCommunication", "text": "Announced"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.735672, "arguments": [{"text": "Dako PD-L1 IHC 22C3 pharmDx Assay", "location": [4492, 4525], "entities": [{"type": "Person", "text": "Dako PD-L1 IHC 22C3 pharmDx Assay"}]}, {"text": "Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for", "location": [4407, 4491], "entities": [{"type": "Organization", "text": "Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for"}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.52738, "arguments": [{"text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "location": [4649, 4730], "entities": [{"type": "Organization", "text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test", "location": [4546, 4645], "entities": [{"type": "Organization", "text": "Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test"}]}]}, {"type": "basedIn", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.91448, "arguments": [{"text": "Roche Wins US", "location": [4740, 4753], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [4734, 4739], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.521136, "arguments": [{"text": "SA", "location": [723, 725], "entities": [{"type": "GeopoliticalEntity", "text": "SA"}]}, {"text": "France", "location": [728, 734], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.712751, "arguments": [{"text": "FDA", "location": [4754, 4757], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Roche Wins US", "location": [4740, 4753], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.534595, "arguments": [{"text": "Roche Wins US", "location": [4740, 4753], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Approval", "location": [4758, 4766], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.9814, "arguments": [{"text": "FDA", "location": [4754, 4757], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Approval", "location": [4758, 4766], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.625668, "arguments": [{"text": "Test v2", "location": [4791, 4798], "entities": [{"type": "Person", "text": "Test v2"}]}, {"text": "Approval", "location": [4758, 4766], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.427874, "arguments": [{"text": "CDx", "location": [4804, 4807], "entities": [{"type": "Person", "text": "CDx Emphasis"}]}, {"text": "IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments", "location": [4813, 5049], "entities": [{"type": "Organization", "text": "IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.744249, "arguments": [{"text": "Companion Diagnostic Partnership", "location": [5239, 5271], "entities": [{"type": "Person", "text": "Companion Diagnostic Partnership"}]}, {"text": "Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS", "location": [5190, 5238], "entities": [{"type": "Organization", "text": "Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.834622, "arguments": [{"text": "Companion Diagnostic Partnership", "location": [5239, 5271], "entities": [{"type": "Person", "text": "Companion Diagnostic Partnership"}]}, {"text": "Thermo Fisher Scientific Qiagen", "location": [5277, 5308], "entities": [{"type": "Organization", "text": "Thermo Fisher Scientific Qiagen", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-", "score": 0.885545, "arguments": [{"text": "Companion Diagnostic Partnership", "location": [5239, 5271], "entities": [{"type": "Person", "text": "Companion Diagnostic Partnership"}]}, {"text": "Freenome", "location": [5313, 5321], "entities": [{"type": "Organization", "text": "Freenome", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs Merck KGaA and ArcherDX to Develop NGS-", "score": 0.277623, "arguments": [{"text": "Companion Diagnostics Bristol-Myers Squibb", "location": [5343, 5385], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Hands", "location": [5392, 5397], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs Merck KGaA and ArcherDX to Develop NGS-", "score": 0.482453, "arguments": [{"text": "NeoGenomics LabCorp Collaborates", "location": [5472, 5504], "entities": [{"type": "Organization", "text": "NeoGenomics LabCorp Collaborates"}]}, {"text": "Dx PPD forms Strategic Alliance", "location": [5435, 5466], "entities": [{"type": "Organization", "text": "Dx PPD forms Strategic Alliance"}]}]}, {"type": "basedIn", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.492357, "arguments": [{"text": "Danaher Corporation", "location": [753, 772], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [747, 750], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs Merck KGaA and ArcherDX to Develop NGS-", "score": 0.385156, "arguments": [{"text": "NeoGenomics LabCorp Collaborates", "location": [5472, 5504], "entities": [{"type": "Organization", "text": "NeoGenomics LabCorp Collaborates"}]}, {"text": "Unilabs Merck KGaA", "location": [5510, 5528], "entities": [{"type": "Organization", "text": "Unilabs Merck KGaA", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.450598, "arguments": [{"text": "Bliss", "location": [5627, 5632], "entities": [{"type": "Person", "text": "Bliss"}]}, {"text": "Biopharmaceutical Foundation Medicine", "location": [5633, 5670], "entities": [{"type": "Organization", "text": "Biopharmaceutical Foundation Medicine"}]}]}, {"type": "partOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.319216, "arguments": [{"text": "Roche Agena Bioscience Inks CDx Collaboration Deal", "location": [5746, 5796], "entities": [{"type": "Organization", "text": "Roche Agena Bioscience Inks CDx Collaboration Deal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Simcere Diagnostics", "location": [5802, 5821], "entities": [{"type": "Organization", "text": "Simcere Diagnostics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.904323, "arguments": [{"text": "Foundation Medicine Inks CDx Partnership Deal", "location": [5831, 5876], "entities": [{"type": "Organization", "text": "Foundation Medicine Inks CDx Partnership Deal"}]}, {"text": "China", "location": [5825, 5830], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.590364, "arguments": [{"text": "Join Thermo Fisher", "location": [5904, 5922], "entities": [{"type": "Person", "text": "Join Thermo Fisher"}]}, {"text": "Pfizer NeoGenomics", "location": [5882, 5900], "entities": [{"type": "Organization", "text": "Pfizer NeoGenomics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.456132, "arguments": [{"text": "Join Thermo Fisher", "location": [5904, 5922], "entities": [{"type": "Person", "text": "Join Thermo Fisher"}]}, {"text": "CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility", "location": [5925, 6002], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility"}]}]}, {"type": "locatedAt", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.472206, "arguments": [{"text": "CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility", "location": [5925, 6002], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility"}]}, {"text": "North Carolina", "location": [6006, 6020], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "basedIn", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.825443, "arguments": [{"text": "Myriad Genetics Signs CDx Development Collaboration Deal", "location": [6021, 6077], "entities": [{"type": "Organization", "text": "Myriad Genetics Signs CDx Development Collaboration Deal"}]}, {"text": "North Carolina", "location": [6006, 6020], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "partOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.64948, "arguments": [{"text": "Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement", "location": [6202, 6294], "entities": [{"type": "Organization", "text": "Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement"}]}, {"text": "Blueprint Medicines Thermo Fisher Scientific Partners", "location": [6300, 6353], "entities": [{"type": "Organization", "text": "Blueprint Medicines Thermo Fisher Scientific Partners"}]}]}, {"type": "partOf", "sentence": "based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.876218, "arguments": [{"text": "CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands", "location": [6430, 6495], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands"}]}, {"text": "LabCorp Join Thermo Fisher", "location": [6401, 6427], "entities": [{"type": "Organization", "text": "LabCorp Join Thermo Fisher"}]}]}, {"type": "partOf", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.473406, "arguments": [{"text": "F. Hoffmann-La Roche Ltd.", "location": [781, 806], "entities": [{"type": "Organization", "text": "F. Hoffmann-La Roche Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [775, 778], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.574315, "arguments": [{"text": "Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator", "location": [6791, 6866], "entities": [{"type": "Organization", "text": "Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator"}]}, {"text": "Pharmaceutical Companies", "location": [6761, 6785], "entities": [{"type": "Organization", "text": "Pharmaceutical Companies"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.601196, "arguments": [{"text": "Companion Diagnostics Pioneering", "location": [6871, 6903], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers", "location": [6915, 6999], "entities": [{"type": "Organization", "text": "Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers"}]}]}, {"type": "authorOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.504892, "arguments": [{"text": "Companion Diagnostics List", "location": [7021, 7047], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "Novel Paradigm", "location": [7003, 7017], "entities": [{"type": "TitleWork", "text": "Novel Paradigm"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.558135, "arguments": [{"text": "Companion Diagnostics List", "location": [7021, 7047], "entities": [{"type": "Person", "text": "Companion Diagnostics Companion Diagnostics Augur"}]}, {"text": "US", "location": [7051, 7053], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.638922, "arguments": [{"text": "FDA", "location": [7054, 7057], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [7051, 7053], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.509984, "arguments": [{"text": "Drug Development Fuel Demand List of FDA", "location": [7191, 7231], "entities": [{"type": "Organization", "text": "Drug Development Fuel Demand List of FDA"}]}, {"text": "Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements", "location": [7112, 7187], "entities": [{"type": "Organization", "text": "Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.317117, "arguments": [{"text": "H1", "location": [7270, 7272], "entities": [{"type": "Person", "text": "H1"}]}, {"text": "A. Market Analysis Higher R&D Spending", "location": [7309, 7347], "entities": [{"type": "Organization", "text": "A. Market Analysis Higher R&D Spending"}]}]}, {"type": "basedIn", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.878606, "arguments": [{"text": "A. Market Analysis Higher R&D Spending", "location": [7309, 7347], "entities": [{"type": "Organization", "text": "A. Market Analysis Higher R&D Spending"}]}, {"text": "Canada", "location": [7302, 7308], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis The United States : Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 B. Market Analytics 7.2 Canada A. Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada :", "score": 0.558111, "arguments": [{"text": "Underpin CDx Revenues Cancer Incidence", "location": [7351, 7389], "entities": [{"type": "Organization", "text": "Underpin CDx Revenues Cancer Incidence"}]}, {"text": "Canada", "location": [7393, 7399], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.881792, "arguments": [{"text": "A. Market Analysis Graying Population Spurs Growth B. Market Analytics", "location": [7500, 7570], "entities": [{"type": "Organization", "text": "Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics"}]}, {"text": "Japan", "location": [7494, 7499], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular ( USA ) Agilent Technologies, Inc. ( USA ) bioMrieux SA ( France ) Cepheid ( USA ) Danaher Corporation ( USA ) F. Hoffmann-La Roche Ltd. ( Switzerland ) Foundation Medicine, Inc. ( USA ) Laboratory Corporation of America Holdings ( USA ) Leica Biosystems Nussloch GmbH ( Germany ) Merck & Co. Inc. ( USA ) Myriad Genetics, Inc. ( USA ) NeoGenomics, Inc. ( USA ) QIAGEN N.V. ( Netherlands ) Quest Diagnostics, Inc. ( USA ) Thermo Fisher Scientific, Inc. ( USA ) Key Topics Covered: 2.", "score": 0.522437, "arguments": [{"text": "QIAGEN N.V.", "location": [1032, 1043], "entities": [{"type": "Person", "text": "QIAGEN N.V."}]}, {"text": "Netherlands", "location": [1046, 1057], "entities": [{"type": "Organization", "text": "Netherlands"}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.461615, "arguments": [{"text": "A. Market Analysis", "location": [7582, 7600], "entities": [{"type": "Organization", "text": "A. Market Analysis Higher R&D Spending"}]}, {"text": "Europe", "location": [7575, 7581], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.530036, "arguments": [{"text": "CDx Cancer Incidence", "location": [7734, 7754], "entities": [{"type": "Organization", "text": "CDx Cancer Incidence"}]}, {"text": "Europe", "location": [7758, 7764], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.394609, "arguments": [{"text": "B. Market Analytics", "location": [7854, 7873], "entities": [{"type": "Organization", "text": "Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics"}]}, {"text": "Europe", "location": [7847, 7853], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.389677, "arguments": [{"text": "Market Analysis", "location": [7887, 7902], "entities": [{"type": "Organization", "text": "A. Market Analysis Higher R&D Spending"}]}, {"text": "France", "location": [7880, 7886], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.913914, "arguments": [{"text": "Market Analysis", "location": [7917, 7932], "entities": [{"type": "Organization", "text": "The United Kingdom Market Analysis"}]}, {"text": "Germany", "location": [7909, 7916], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.749187, "arguments": [{"text": "Market Analysis", "location": [7945, 7960], "entities": [{"type": "Organization", "text": "The United Kingdom Market Analysis"}]}, {"text": "Italy", "location": [7939, 7944], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.944249, "arguments": [{"text": "Market Analysis", "location": [8014, 8029], "entities": [{"type": "Organization", "text": "The United Kingdom Market Analysis"}]}, {"text": "Spain", "location": [8008, 8013], "entities": [{"type": "GeopoliticalEntity", "text": "Spain", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.663945, "arguments": [{"text": "Rest", "location": [8036, 8040], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Market Analysis", "location": [8014, 8029], "entities": [{"type": "Organization", "text": "The United Kingdom Market Analysis"}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.404087, "arguments": [{"text": "Rest", "location": [8036, 8040], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Europe", "location": [8044, 8050], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.332681, "arguments": [{"text": "Market Analysis", "location": [8051, 8066], "entities": [{"type": "Organization", "text": "The United Kingdom Market Analysis"}]}, {"text": "Europe", "location": [8044, 8050], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.789002, "arguments": [{"text": "Scope", "location": [1337, 1342], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Wield Great Promise for Streamlined Drug Discovery & Development Broader", "location": [1264, 1336], "entities": [{"type": "Organization", "text": "Wield Great Promise for Streamlined Drug Discovery & Development Broader"}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.464374, "arguments": [{"text": "Asia-Pacific A. Market", "location": [8071, 8093], "entities": [{"type": "Person", "text": "Asia-Pacific A. Market"}]}, {"text": "Growing Market Uptrend", "location": [8113, 8135], "entities": [{"type": "Organization", "text": "Growing Market Uptrend"}]}]}, {"type": "partOf", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.979801, "arguments": [{"text": "A. Market Analysis Breast Cancer CDx", "location": [8211, 8247], "entities": [{"type": "Organization", "text": "A. Market Analysis Higher R&D Spending"}]}, {"text": "China", "location": [8205, 8210], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario B. Market Analytics 7.3 Japan A. Market Analysis Graying Population Spurs Growth B. Market Analytics 7.4 Europe A. Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe : An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe B. Market Analytics 7.4.1 France Market Analysis 7.4.2 Germany Market Analysis 7.4.3 Italy Market Analysis 7.4.4 The United Kingdom Market Analysis 7.4.5 Spain Market Analysis 7.4.6 Rest of Europe Market Analysis 7.5 Asia-Pacific A. Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B. Market Analytics 7.5.1 China A. Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China :", "score": 0.725957, "arguments": [{"text": "Dominant Category Laboratory Equipment & Supplies Sector", "location": [8249, 8305], "entities": [{"type": "Organization", "text": "Dominant Category Laboratory Equipment & Supplies Sector"}]}, {"text": "China", "location": [8309, 8314], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "An Overview B. Market Analytics 7.5.2 Rest of Asia-Pacific Market Analysis 7.6 Latin America Market Analysis 7.7 Rest of World Market Analysis 8.", "score": 0.639055, "arguments": [{"text": "Market", "location": [8410, 8416], "entities": [{"type": "Facility", "text": "Market"}]}, {"text": "Latin America", "location": [8396, 8409], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "COMPANY PROFILES Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) France (5) Germany (4) The United Kingdom (9) Spain (1) Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5 Did you know that we also offer Custom Research?", "score": 0.619481, "arguments": [{"text": "Subsidiaries", "location": [8530, 8542], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "Divisions", "location": [8520, 8529], "entities": [{"type": "Organization", "text": "Divisions"}]}]}, {"type": "residesIn", "sentence": "COMPANY PROFILES Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) France (5) Germany (4) The United Kingdom (9) Spain (1) Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5 Did you know that we also offer Custom Research?", "score": 0.424349, "arguments": [{"text": "Rest", "location": [8651, 8655], "entities": [{"type": "Person", "text": "Rest"}]}, {"text": "Europe", "location": [8659, 8665], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "COMPANY PROFILES Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) France (5) Germany (4) The United Kingdom (9) Spain (1) Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5 Did you know that we also offer Custom Research?", "score": 0.694324, "arguments": [{"text": "Asia-Pacific", "location": [8670, 8682], "entities": [{"type": "Person", "text": "Asia-Pacific A. Market"}]}, {"text": "we", "location": [8856, 8858], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "participantIn", "sentence": "Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.", "score": 0.927497, "arguments": [{"text": "Manager", "location": [8980, 8987], "entities": [{"type": "Person", "text": "Laura Wood"}]}, {"text": "meeting", "location": [8947, 8954], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "employedBy", "sentence": "Media Contact: Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.684702, "arguments": [{"text": "press@researchandmarkets.com", "location": [9032, 9060], "entities": [{"type": "Person", "text": "press@researchandmarkets.com"}]}, {"text": "E.S.T Office Hours Call +", "location": [9065, 9090], "entities": [{"type": "Organization", "text": "E.S.T Office Hours Call +"}]}]}, {"type": "locatedAt", "sentence": "Media Contact: Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.415646, "arguments": [{"text": "GMT Office Hours Call +", "location": [9153, 9176], "entities": [{"type": "Organization", "text": "GMT Office Hours Call +"}]}, {"text": "Fax", "location": [9196, 9199], "entities": [{"type": "Facility", "text": "Fax"}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.39781, "arguments": [{"text": "Witnesses", "location": [1488, 1497], "entities": [{"type": "Person", "text": "Witnesses"}]}, {"text": "Key Revenue Contributors Market", "location": [1456, 1487], "entities": [{"type": "Organization", "text": "Key Revenue Contributors Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "ownerOf", "sentence": "Media Contact: Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.501062, "arguments": [{"text": "U.S.", "location": [9191, 9195], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Fax", "location": [9196, 9199], "entities": [{"type": "Facility", "text": "Fax"}]}]}, {"type": "hasAttribute", "sentence": "Media Contact: Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.639318, "arguments": [{"text": "SOURCE Research and Markets\nRelated Links", "location": [9250, 9291], "entities": [{"type": "Organization", "text": "SOURCE Research and Markets\nRelated Links"}]}, {"text": "http://www.researchandmarkets.com", "location": [9292, 9325], "entities": [{"type": "Web", "text": "http://www.researchandmarkets.com"}]}]}], "keywords": [{"text": "Companion Diagnostics", "sentiment": {"score": 0.920361, "label": "positive"}, "relevance": 0.797006, "count": 5}, {"text": "markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.600796, "count": 1}, {"text": "INDUSTRY OVERVIEW Companion Diagnostics", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.586385, "count": 1}, {"text": "CDx Rising Incidence of Cancer", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.576759, "count": 1}, {"text": "Market data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575008, "count": 1}, {"text": "Quest Diagnostics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566335, "count": 1}, {"text": "CDx Emphasis", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.559098, "count": 1}, {"text": "Foundation Medicine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558891, "count": 1}, {"text": "CDx", "sentiment": {"score": 0.909533, "label": "positive"}, "relevance": 0.558118, "count": 4}, {"text": "Companion Diagnostics Oncology", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.552475, "count": 1}, {"text": "Global Strategic Business Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551981, "count": 1}, {"text": "Growth Opportunities Healthy Growth", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.551548, "count": 1}, {"text": "Product Approvals", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.546474, "count": 1}, {"text": "CDx Testing QuantaLife ddPCR System", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.544744, "count": 1}, {"text": "Drug Discovery", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.543591, "count": 1}, {"text": "worldwide markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542013, "count": 1}, {"text": "United States A. Market Analysis", "sentiment": {"score": 0.907686, "label": "positive"}, "relevance": 0.539905, "count": 1}, {"text": "Thermo Fisher Scientific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539253, "count": 1}, {"text": "US", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.538838, "count": 3}, {"text": "Personalized Medicine Significant Cost Reductions", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.53871, "count": 1}, {"text": "Agilent Technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538567, "count": 1}, {"text": "Companion Diagnostics Critical Healthcare Needs", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.53432, "count": 1}, {"text": "Adjuvant Treatment Decision Eligibility", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.532311, "count": 1}, {"text": "report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532065, "count": 4}, {"text": "CDx Testing Significant Role of Biomarkers", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.531476, "count": 1}, {"text": "CDx Tests Technology Advancements", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.531368, "count": 1}, {"text": "CDx Use Case PCR", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.529179, "count": 1}, {"text": "US FDA Approval", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.52786, "count": 2}, {"text": "six-year", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527723, "count": 1}, {"text": "Market List of Key Market Requirements", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.526973, "count": 1}, {"text": "Select Therapeutic Areas Companion Diagnostics", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.526867, "count": 1}, {"text": "United States", "sentiment": {"score": 0.907686, "label": "positive"}, "relevance": 0.525613, "count": 2}, {"text": "Canada", "sentiment": {"score": 0.488614, "mixed": "1", "label": "positive"}, "relevance": 0.524117, "count": 4}, {"text": "Europe", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.52198, "count": 3}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52193, "count": 1}, {"text": "USA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520551, "count": 11}, {"text": "Use", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.520143, "count": 1}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520088, "count": 2}, {"text": "analytics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52008, "count": 1}, {"text": "Breast Cancer Assays", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.519953, "count": 1}, {"text": "Companion Diagnostics Applications of Companion Diagnostics", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.519921, "count": 1}, {"text": "Cancer Treatment", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.519914, "count": 1}, {"text": "Great Promise", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.519689, "count": 1}, {"text": "PRODUCT OVERVIEW Diagnostics", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.518965, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518933, "count": 1}, {"text": "Broader Scope", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.518676, "count": 1}, {"text": "Pharmaceutical Companies", "sentiment": {"score": 0.907686, "label": "positive"}, "relevance": 0.518513, "count": 1}, {"text": "cobas EGFR Mutation Test v2", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.518031, "count": 2}, {"text": "separate comprehensive analytics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516649, "count": 1}, {"text": "Development", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.516612, "count": 1}]}, "extracted_metadata": {"sha1": "3fa9c2c8ef1c9e738b832bba466021ee07f9039e", "filename": "1542381420149.zip-1acf7f085e444747759770a26183f3b6.xml", "file_type": "json"}, "external_links": ["https://www.researchandmarkets.com/info/custom-research", "https://www.researchandmarkets.com/research/n3jr8q/global_companion?w=5"], "title": "Global Companion Diagnostics Market Estimates & Forecasts 2015-2018 & 2022 - Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise", "forum_title": "PR Newswire:"}]}